document incorporate reference portion proxy statement registrant annual meeting stockholder hold incorporate reference iii annual report table content item business general bristolmyers squibb company refer bristolmyer squibb bms company incorporate law state delaware august bristolmyer company successor new york business start bristolmyer company change bristolmyer squibb company result merger engage discovery development licensing manufacturing marketing distribution sale biopharmaceutical product global basis year execute strategy transform generation biopharmaceutical company transformation encompass area business operation strategy divest nonpharmaceutical business implement acquisition licensing strategy know stringofpearl execute productivity transformation initiative pti respect divestiture sell medical imaging business january sell convatec business august divest mead johnson nutrition company mead johnson december period complete numerous acquisition licensing transaction kosan biosciences inc june medarex inc medarex september zymogenetics inc zymogenetics october execute pti announce december realize billion annual cost saving cost avoidance base previous strategic plan future year achieve reduce general administrative operation simplify standardize outsource certain process service rationalize mature brand portfolio consolidated global manufacturing network eliminate complexity enhance profitability simplify geographic footprint implement efficient gotomarket model meet goal billion cost saving cost avoidance annualize runrate basis billion annual cost saving avoidance base previous strategic plan future year progress measure annualize runrate basis cost saving avoidance correlate directly result operation approximately billion annual cost saving cost avoidance relate marketing sell administrative expense relate cost product sell relate research development expense addition pti continue review cost structure intent create modernize efficient robust balance build competitive advantage secure innovative product plan future report financial operating information segmentbiopharmaceutical additional information business segment item financial statementsnote business segment information compete worldwide researchbase drug company small research company generic drug manufacturer product sell worldwide primarily wholesaler retail pharmacy hospital government entity medical profession manufacture product united states puerto rico foreign country net sale account total net sale respectively net sales europe account total net sale net sale japan account total net sale net sale canada account total net sale product pharmaceutical product include chemicallysynthesize drug small molecule increase portion product produce biological process typically involve recombinant dna technology call biologics small molecule drug typically administer orally eg form pill tablet drug delivery mechanism biologic typically administer patient injection infusion revenue come product follow therapeutic class cardiovascular virology include human immunodeficiency virus hiv infection oncology neuroscience immunoscience metabolic pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity business focus innovative biopharmaceutical product rely patent right form regulatory protection maintain market exclusivity product european union eu country patent right form exclusivity expire generic version medicine approve market substantial rapid decline sale original innovative product discussion patent right regulatory form exclusivity intellectual property product exclusivity discussion impact generic competition business generic competition table content chart show key product year early basic exclusivity loss patent right datum exclusivity occur currently estimate occur eu japan canada sell pharmaceutical product country datum provide country bycountry basis individual country sale significant outside eu japan canada instance basic exclusivity loss date list expiration date patent claim active ingredient drug method drug approve indication approve indication instance basic exclusivity loss date list chart expiration date datum exclusivity period situation datum exclusivity patent protection competitor seek regulatory approval submit clinical trial datum obtain marketing approval prior expiration datum exclusivity estimate market exclusivity period product casebycase basis purpose business planning length market exclusivity product impossible predict certainty complex interaction patent regulatory form exclusivity inherent uncertainty patent litigation assurance particular product enjoy market exclusivity period time appear estimate exclusivity limited estimate follow schedule present net sale key product estimate basic exclusivity loss eu japanese canadian market net sale product past currently estimate year basic exclusivity loss dollar million eu japan canada key product plavix b avaproavalide abilify h reyataz c sustiva franchise total revenue baraclude erbitux e l sprycel f ixempra g orencia j k n onglyzakombiglyze note currently estimate early year basic exclusivity loss include statutory extension exclusivity earn grant instance able obtain additional month exclusivity product base pediatric extension example certain instance laterexpire patent cover particular form composition drug method manufacturing method drug patent result favorable market position product product exclusivity predict assure new healthcare law enact qualifying biologic product receive year datum exclusivity biosimilar enter market describe detail intellectual property product exclusivity indicate brand name product trademark own bristolmyer squibb subsidiary specific trademark ownership information find currently market product country region indicate reference eu include member states members european union year end december basic patent application file current member state list product instance date basic exclusivity loss different eu member states instances early late date basic exclusivity loss list eu country basic patent obtain datum protection available b data exclusivity eu expire july major market europe product national patent expiring specifically claim bisulfate form clopidogrel generic alternate salt form clopidogrel bisulfate market compete plavix eu c data exclusivity eu expire exclusivity period relate sustiva brand include exclusivity relate combination therapy e biologic product approve bla datum exclusivity expire patent specifically claim composition matter cetuximab active ingredient erbitux right commercialize cetuximab terminate f pende application eu patent application file estonia latvia lithuania malta slovakia slovenia g ixabepilone approve market eu approve market switzerland composition matter patent expect expire h right commercialize aripiprazole terminate april rights commercialize aripiprazole eu terminate patent protection romania denmark expire j biologic product approve bla datum exclusivity expire k data exclusivity eu expire patent cover abatacept majority eu country expire l datum exclusivity japan expire exclusivity period base regulatory data protection n exclusivity period base regulatory datum protection data exclusivity canada expire table content summary indication intellectual property position product partner thirdparty manufacturing arrangement product applicable eu japan canada plavix plavix clopidogrel bisulfate platelet aggregation inhibitor approve protection fatal nonfatal heart attack stroke patient history heart attack stroke peripheral arterial disease acute coronary syndrome plavix label update new warning use drug strong moderate cyp c inhibitor prilosec omeprazole interfere plavix reduce effectiveness labeling update include warning variability response attribute cyp c genetic polymorphism label revise include box warning concern diminished effectiveness plavix patient genetic variation lead reduce formation active metabolite clopidogrel bisulfate codevelope jointly market sanofiaventis sanofi information alliance sanofi strategic alliance collaboration item financial statementsnote alliance collaboration composition matter patent expire november fda grant additional sixmonth period exclusivity market plavix exclusivity plavix expect expire plavix subject patent litigation apotex generic company court uphold validity composition matter patent enter judgment favor impose damage apotex infringe patent apotex appeal damage information litigation matter item financial statementsnote legal proceeding contingency eu regulatory datum exclusivity protection expire july major market europe plavix benefit national patent expire specifically claim bisulfate form clopidogrel generic alternative salt form clopidogrel bisulfate market compete eu obtain bulk requirement clopidogrel bisulfate sanofi thirdparty company sanofi finish product respective facility avaproavalide avaproavalide irbesartanirbesartanhydrochlorothiazide angiotensin ii receptor antagonist indicate treatment hypertension diabetic nephropathy irbesartan codevelope jointly market sanofi information alliance sanofi strategic alliance collaboration item financial statementsnote alliance collaboration basic composition matter patent expire march include pediatric extension country eu data exclusivity eu expire august avapro october avalide irbesartan manufacture company sanofi manufacture bulk requirement irbesartan finish avaproavalide facility avalide purchase bulk requirement hydrochlorothiazide thirdparty item risk factorswe experience difficulty delay manufacture distribution sale product information recent recall supply shortage abilify abilify aripiprazole atypical antipsychotic agent adult patient schizophrenia bipolar mania disorder major depressive disorder abilify pediatric use schizophrenia bipolar disorder global commercialization agreement otsuka pharmaceutical co ltd otsuka japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt information arrangement otsuka strategic alliance collaboration item financial statementsnote alliance collaboration basic composition matter patent abilify expire april include grant patent term extension month pediatric extension basic composition matter patent protect aripiprazole subject patent litigation otsuka sole right enforce patent information litigation matter item financial statement note legal proceeding contingency table content composition matter patent force germany united kingdom uk france italy netherlands romania sweden switzerland spain denmark original expiration date extend grant supplementary protection certificate country romania denmark datum exclusivity eu expire obtain bulk requirement aripiprazole otsuka company otsuka finish product respective facility reyataz reyataz atazanavir sulfate protease inhibitor treatment hiv reyataz launch july develop atazanavir worldwide license novartis pharmaceutical corporation novartis royalty pay base percentage net sale entitle promote reyataz use combination norvir ritonavir nonexclusive license agreement abbott laboratories amend royalty pay base percentage net sale market exclusivity reyataz expect expire major eu member country japan data exclusivity eu expire patent subject patent litigation information litigation matter item financial statementsnote legal proceeding contingency manufacture bulk requirement atazanavir finish product facility sustiva franchise sustiva efavirenz nonnucleoside reverse transcriptase inhibitor treatment hiv sustiva franchise include sustiva antiretroviral drug treatment hiv bulk efavirenz include combination therapy atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oncedaily single tablet drug regiman combine sustiva gilead sciences inc gilead truvada emtricitabine tenofovir disoproxil fumarate atripla complete highly active antiretroviral therapy treatment product hiv available fixeddose combination take daily fixeddose combination contain multiple medicine formulate help simplify hiv therapy patient provider information arrangement gilead strategic alliance collaboration item financial statementsnote alliance collaboration right market efavirenz canada united kingdom uk france germany ireland italy spain license merck co inc royalty base percentage net sale composition matter patent efavirenz expire method use patent treatment hiv infection expire possible month pediatric extension market exclusivity sustiva expect expire country eu company market efavirenz japan certain atripla patent subject patent litigation time patent cover efavirenz composition matter method use challenge information litigation matter item financial statementsnote legal proceeding contingency obtain bulk requirement efavirenz party produce finished good facility provide bulk efavirenz gilead responsible produce finished atripla product baraclude baraclude entecavir potent selective inhibitor hepatitis b virus approve fda march treatment chronic hepatitis b infection baraclude discover develop internally approve market country outside include china japan eu composition matter patent expire patent subject patent litigation information litigation matter item financial statementsnote legal proceeding contingency composition matter patent expire eu japan uncertainty chinas exclusivity law result generic competition china market manufacture bulk requirement entecavir finish product facility table content erbitux erbitux cetuximab igg monoclonal antibody design exclusively target block epidermal growth factor receptor egfr express surface certain cancer cell multiple tumor type normal cell erbitux biological product approve treatment combination irinotecan treatment patient egfrexpresse metastatic colorectal cancer mcrc fail irinotecanbase regimen monotherapy patient intolerant irinotecan fda approve erbitux use treatment squamous cell carcinoma head neck specifically erbitux approve use combination radiation therapy treatment locally regionally advanced squamous cell carcinoma head neck single agent treatment patient recurrent metastatic squamous cell carcinoma head neck prior platinumbase therapy fail october fda accept file supplemental biologic license application sbla firstline squamous cell carcinoma head neck grant priority review status fda request interim datum additional study complete review application continue work fda expect provide request information research development additional information erbitux market north america agreement imclone system incorporate imclone predecessor company imclone llc whollyowne subsidiary eli lilly company lilly share copromotion rights erbitux merck kgaa japan codevelopment cocommercialization agreement sign october imclone merck kgaa merck japan erbitux receive marketing approval japan july use treat patient advance recurrent colorectal cancer description alliance imclone strategic alliance collaboration item financial statementsnote alliance collaboration datum exclusivity expire patent specifically claim composition matter cetuximab active molecule erbitux erbitux approve fda health authority monotherapy use patent use erbitux combination antineoplastic agent approve fda combination use claim grant patent expire include grant patent term extension inventorship use patent challenge researcher yeda research development company ltd yeda pursuant settlement agreement execute announce december imclone sanofi yeda end worldwide litigation relate use patent sanofi yeda grant imclone worldwide license use patent yeda right license use patent yeda license patent party result product competition erbitux occur unable assess extent competitive impact occur quantify impact yeda grant amgen inc amgen license use patent amgen receive fda approval market egfrproduct compete erbitux obtain finish good requirement cetuximab use north america lilly lilly manufacture bulk requirement cetuximab facility finish perform thirdparty lilly description supply agreement lilly manufacture quality assurance sprycel sprycel dasatinib multitargete tyrosine kinase inhibitor approve treatment adult phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib mesylate treatment adult philadelphia chromosomepositive acute lymphoblastic leukemia resistance intolerance prior therapy fda approve sprycel treatment adult patient newly diagnose philadelphia chromosomepositive ph chronic myeloid leukemia cml chronic phase sprycel internally discover strategic alliance otsuka information alliance otsuka strategic alliance collaboration item financial statementsnote alliance collaboration patent term extension grant extend term basic composition matter patent cover dasatinib june dasatinib subject patent litigation information litigation matter item financial statementsnote legal proceeding contingency table content eu country patent pende grant expire april exclude term extension new chemical entity regulatory exclusivity protection expire orphan drug exclusivity expire protect product generic application currently approve orphan indication manufacture bulk requirement dasatinib finish product facility ixempra ixempra ixabepilone microtubule inhibitor belong class antineoplastic agent epothilone analogs fda approve ixabepilone combination capecitabine treatment patient metastatic locally advanced breast cancer resistant treatment anthracycline taxane cancer taxane resistant anthracycline therapy contraindicate monotherapy treatment metastatic locallyadvance breast cancer patient tumor resistant refractory anthracycline taxane capecitabine withdraw marketing authorization application eu march ixempra internally develop alliance otsuka information alliance otsuka strategic alliance collaboration item financial statementsnote alliance collaboration basic composition matter patent protect ixabepilone expire patent term extension request grant extend patent term september new chemical entity regulatory exclusivity protection expire ixabepilone subject license agreement helmholtz zentrum fur infektionsforschung gmbh hzi relate epothilone technology pay royalty base percentage net sale manufacture bulk requirement ixabepilone facility include manufacture active ingredient drug product comprise pharmaceutical kit finish baxter oncology gmbh orencia orencia abatacept biological product fusion protein novel immunosuppressive activity target initially adult patient moderate severe rheumatoid arthritis inadequate response certain currently available treatment abatacept approve fda december commercially available february orencia discover develop internally series patent cover abatacept method use patent term extension grant composition matter patent extend term patent majority eu country patent covering abatacept expire majority eu country apply supplementary protection certificate extend term patent grant datum exclusivity eu expire obtain bulk abatacept thirdparty finish product facility onglyza kombiglyze onglyza saxagliptin dipeptidyl peptidase inhibitor oral compound indicate treatment type diabete adjunct diet exercise kombiglyze saxagliptin metformin combination product indicate adjunct diet exercise improve glycemic control adult type diabete mellitus treatment saxagliptin metformin appropriate onglyza kombiglyze codevelope company astrazeneca plc astrazeneca worldwide japan codevelopment cocommercialization agreement astrazeneca saxagliptin information arrangement astrazeneca otsuka japan strategic alliance collaboration item financial statementsnote alliance collaboration patent cover saxagliptin composition matter expire manufacture bulk requirement saxagliptin facility include manufacture active ingredient obtain bulk metformin hcl kombiglyze party company thirdparty finish product facility table content emerge market refine focus emerge market represent significant opportunity growth market characterize strong economic development rise gross domestic product grow middle class increase wealth middle class demand quality healthcare emerge market provide growth opportunity pharmaceutical industry middle decade strategy capitalize growth opportunity innovationfocuse approach approach develop commercialize select innovative product key highgrowth market tailor approach market individually identify emerge market focus brazil russia india china turkey emerge public health interest country good align strategy current portfolio pipeline country identify improve intellectual property protection order capitalize growth opportunity emerge market balance relate risk develop innovative pricing access strategy product accessible patient provide reasonable return investment risk market include intellectual property protection currency volatility reimbursement issue government stability scale issue monitor mitigate risk extent possible research development invest heavily research development rd believe critical longterm competitiveness major rd facility princeton hopewell new brunswick new jersey wallingford connecticut pharmaceutical research development carry facility world include belgium uk india site supplement internal drug discovery development program alliance collaborative agreement agreement bring new product pipeline help remain cut edge technology search novel medicine drug development engage service physician hospital medical school research organization worldwide conduct clinical trial establish safety effectiveness new product management continue emphasize leadership innovation productivity quality strategy success research development activity concentrate biopharmaceutical research development effort follow disease area significant unmet medical need affective psychiatric disorder alzheimersdementia cardiovascular primarily atherosclerosisthrombosis diabete hepatitis hivaid obesity oncology rheumatoid arthritis relate disease solid organ transplant continue analyze selectively pursue promising lead area addition discover develop new molecular entity look way expand value exist product new indication formulation provide additional benefit patient order new drug reach market industry practice government regulation eu foreign country provide determination drug effectiveness safety preclinical test control clinical evaluation clinical development potential new drug include phase phase ii phase iii clinical trial design specifically support new drug application particular indication assume trial successful rd process typically take year long year spend phase iii latestage development consider rd program phase iii latestage development significant rd program program include investigational compound phase iii development initial indication market product phase iii development additional indication formulation drug development time consume expensive risky average chemical compound discover pharmaceutical industry researcher prove medically effective safe approve medicine drug candidate fail stage process latestage product candidate fail receive regulatory approval accord kmr group base industry success rate compound enter phase development fail achieve regulatory approval failure rate compound enter phase ii development approximately compound enter phase iii development approximately total research development expense include cost discovery research preclinical development early lateclinical development drug formulation clinical trial medical support market product proportionate allocation enterprisewide cost appropriate cost spend billion billion research development activity research development spending include payment party collaboration contract end employ approximately people rd activity include substantial number physician scientist hold graduate postgraduate degree higherskille technical personnel manage rd program portfolio basis invest resource stage research development early discovery latestage development continually evaluate portfolio rd asset ensure appropriate balance earlystage latestage program support future growth company spend latestage development table content program represent approximately annual rd expense individual investigational compound market product represent rd expense year list latestage investigational compound phase iii clinical trial potential indication investigational compound ultimately market product depend result clinical study competitive landscape potential product market manufacturing process necessary produce potential product commercial scale factor note assurance seek regulatory approval compound approval sought obtain assurance compound approve commercially successful stage development determine intellectual property issue patent protection available investigational compound patent coverage highlight include patent term extension grant include potential patent term extension eliquis eliquis apixaban oral factor xa inhibitor target prevention treatment venous thromboembolic vte disorder stroke prevention atrial fibrillation currently registrational process eu use vte prevention expect submit regulatory filing eu indication atrial fibrillation fourth quarter apixaban discover internally alliance pfizer inc pfizer patent cover apixaban composition matter expire nulojix nulojix belatacept biological product fusion protein novel immunosuppressive activity target prevention solid organ transplant rejection currently registrational process eu prophylaxis organ rejection kidney transplant patient patent cover belatacept composition matter expire brivanib brivanib oral small molecule dual kinase inhibitor blocks vegf receptor fgf receptor currently phase iii trial anticancer treatment potential use hepatocellular carcinoma colorectal cancer patent cover brivanib composition matter expire dapagliflozin dapagliflozin oral sglt inhibitor potential treatment diabete currently registrational process eu discover internally alliance astrazeneca patent cover dapagliflozin composition matter currently expire october yervoy yervoy ipilimumab biologic product monoclonal antibody currently registrational process treatment metastatic melanoma eu study lung cancer adjuvant melanoma hormone refractory prostate cancer novel class agent intend potentiate element immunologic response compound discover medarex subsidiary patent cover ipilimumab composition matter currently expire necitumumab imcf necitumumab fully human monoclonal antibody investigate anticancer treatment discover imclone alliance company lilly study outside lung cancer colorectal cancer phase iii trial non small cell lung cancer lilly own patent cover imcf composition matter expire terminate global codevelopment cocommercialization arrangement xl metvegret inhibitor oral anticancer compound phase iii clinical trial right return exelixis inc exelixis table content follow table list potential additional indication key marketed product phase iii development erbitux potential additional indication firstline nonsmall cell lung cancer firstline head neck cancer firstline colorectal cancer gastric cancer orencia potential subcutaneous formulation potential additional indication lupus nephritis plavix potential additional indication vascular event prevention atrial fibrillation sprycel potential additional indication prostate cancer ixempra potential additional indication endometrial cancer reyataz potential pediatric indication sustiva potential pediatric indication baraclude potential pediatric extension onglyza potential pediatric extension table present key development currently expect occur respect significant pipeline program outcome timing expect development dependent number factor include thing availability datum outcome certain clinical trial acceptance presentation certain medical meeting andor action health authority undertake obligation publicly update information result new information future event eliquis potential eu approval submission vte prevention aristotle trial result study apixaban versus warfarin expect mid potential eu submission stroke prevention atrial fibrillation dapagliflozin datum remain phase iii study potential approval treatment type diabetes nulojix potential eu approvals prevention organ rejection kidney transplant patient threeyear phase iii data potential presentation american transplant congress orencia potential approval eu submission subcutaneous formulation phase iiiii lupus nephritis data available yervoy datum available study combination dacarbazine dtic firstline metastatic melanoma potential eu approval second line metastatic melanoma plan phase iii start lung cancer brivanib phase iii study expect complete advanced unresectable hepatocellular carcinoma erbitux potential resubmission firstline nonsmall cell lung cancer firstline head neck cancer potential submission firstline colorectal cancer strategic alliance collaboration enter strategic alliance collaboration party right develop manufacture market andor sell pharmaceutical product own party party right develop manufacture market andor sell pharmaceutical product own alliance collaboration form include licensing arrangement codevelopment comarkete agreement copromotion arrangement joint venture alliance arrangement reduce risk incur research development expense compound lead revenuegenerate product profitability alliance product generally low substantially profitability product partner profit alliance product share alliance partner assurance new alliance form actively pursue arrangement view alliance important complement discovery development activity table content strategic alliance arrangement party right manufacture market andor sell pharmaceutical product contain customary early termination provision typically find agreement kind generally base party material breach bankruptcy voluntary involuntary product safety concern notice require early termination generally range immediately notice day receipt notice termination immediately notice generally available party file voluntary bankruptcy petition material safety issue arise product medical riskbenefit incompatible welfare patient continue develop commercialize product termination day notice generally available involuntary bankruptcy petition file dismiss material breach party occur cure number alliance agreement permit collaborator terminate cause typically exercisable substantial advance write notice exercisable specify period time elapse collaboration agreement sign strategic alliance arrangement typically contain provision provide party right terminate alliance short notice general retain right product bring alliance party party intellectual property alliance terminate loss right product market sell pursuant strategic alliance arrangement material result operation cash flow case plavix abilify material financial condition liquidity customary pharmaceutical industry term strategic alliance arrangement generally coextensive exclusivity period vary countrybycountry basis significant current alliance arrangement currently market product investigational compound describe current marketed productsinlicensed sanofi agreement sanofi codevelopment cocommercialization avaproavalide plavix avaproavalide copromote certain country outside tradename aprovelcoaprovel comarkete certain country outside tradename karveakarvezide plavix copromote certain country outside tradename plavix comarkete certain country outside tradename iscover worldwide alliance operate framework geographic territory cover certain european asian country refer territory cover puerto rico canada australia certain latin american country refer territory b territory b manage separate set agreement plavix puerto rico products australia mexico brazil colombia argentina separate set agreement avaproavalide puerto rico territory territory partnership exist supply finish product country territory manage contract certain central expense market research development royalty country territory b structured local affiliate sanofis local affiliate comarket separate brand ie affiliate operate independently compete sell product different trademark copromote single brand ie product trademark territory comarketing country include germany spain italy irbesartan greece china clopidogrel bisulfate sell iscover karveakarvezide sanofi sell plavix aprovelcoaprovel country china retain right currently comarket iscover company sanofi copromote plavix aprovelcoaprovel france uk belgium netherlands switzerland portugal addition company sanofi copromote plavix austria italy ireland denmark finland norway sweden taiwan south korea hong kong aprovelcoaprovel certain french export country prior company sanofi copromote plavix singapore sanofi act operating partner territory own financial control interest territory ownership interest territory account investment partnership entity territory equity method recognize share result equity net income affiliate share net income partnership entity tax million million million territory b company sanofi copromote plavix avaproavalide canada puerto rico territory b countries australia mexico brazil colombia clopidogrel bisulfate argentina comarketing country act operating partner territory b majority control interest territory consolidate partnership result territory b recognize sanofis share result net earning attributable noncontrolle interest net taxis million million million table content recognize net sale territory b territory comarkete country billion billion billion territory partnership govern series committee enumerate function power responsibilitie territory senior committee final decisionmake authority respect territory enumerate function power responsibility jurisdiction agreement sanofi expire later respect plavix respect avaproavalide americas australia europe asia ii expiration patent exclusivity right relate product applicable territory alliance arrangement terminate sanofi affected country territory depend circumstance event voluntary involuntary bankruptcy insolvency case involuntary bankruptcy continue day order decree approving continue unstayed effect day ii material breach obligation major alliance agreement remain uncured day follow notice breach commencement diligent prosecution cure occur day notice iii deadlock senior committee render continue commercialization product impossible give country territory iv increase combine cost good royalty exceed specify percentage net selling price product v good faith determination terminate party commercialization product terminate reason patient safety case termination right agreement include provision termination relevant alliance respect applicable product applicable country territory case termination bankruptcy insolvency material breach product applicable territory termination procedure slightly different event lose right product applicable relevant country territory case bankruptcy insolvency material breach default party discussion strategic alliance sanofi item financial statementsnote alliance collaboration otsuka maintain worldwide commercialization agreement otsuka codevelop copromote abilify abilify agreement japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt collaboration agreement otsuka relate certain oncology product oncology agreement fully describe current market productsinternally discover term abilify agreement amend purchase product otsuka perform finish manufacturing sale otsuka party customer abilify agreement expire april june eu countries country exclusive right sell abilify agreement expire later april loss exclusivity country germany france spain product invoice thirdparty customer behalf otsuka recognize alliance revenue contractual share thirdparty net sale contractual share net sale term agreement otsuka extend portion abilify agreement describe fully recognize expense relate product otsuka responsible commercialization expense relate product germany france spain contractual share net sale recognize expense relate product uk italy canada presently exclusive distributor product recognize net sale relate cost product sell expense begin january invoice thirdparty customer uk behalf otsuka company receive net sale expense reimbursement continue recognize net sale relate cost product sell expense italy canada exclusive right sell abilify country europe americas number countries asia country recognize net sale relate cost product sell april company otsuka extend portion abilify agreement expect loss product exclusivity april term extension pay otsuka million begin january share net sale recognize abilify change reduce january otsuka remain responsible expense relate commercialization abilify time table content begin january expect loss exclusivity april receive follow percentage annual net sale share net sale billion billion billion billion billion billion billion billion billion excess billion period otsuka responsible expense relate commercialization abilify portion abilify agreement oncology agreement describe include changeofcontrol provision acquire acquire company compete product abilify new company assume abilify agreement amend oncology agreement currently exist acquire company product compete abilify otsuka elect request acquire company choose div abilify compete product scenario abilify divest otsuka obligate acquire right abilify agreement amend price accord predetermine schedule agreement provide event generic competitor abilify january option terminate abilify april amendment agreement previously amend remain force exercise option receive payment otsuka accord predetermine schedule oncology agreement terminate time ii oncology agreement continue truncated period accord predetermine schedule early termination abilify agreement immediate notice case voluntary bankruptcy ii minimum payment otsuka iii commercial sale occur month receipt necessary approval day material breach occur cure commencement cure occur day notice material breach day case involuntary bankruptcy petition file dismiss addition termination available otsuka day notice event challenge otsuka patent right marketbymarket basis event market product direct competition abilify termination expiration abilify agreement retain right abilify recognize net sale abilify billion billion addition million extension payment total upfront licensing milestone payment otsuka abilify agreement million discussion oncology agreement otsuka current market productsinternally discover discussion strategic alliance otsuka item financial statementsnote alliance collaboration lilly egfr commercialization agreement lilly lillys subsidiary imclone codevelopment copromotion erbitux necitumumab imcf codevelopment copromotion right product canada japan information agreement respect necitumumab investigational compound developmentinlicense egfr agreement respect erbitux sale north america lilly receive distribution fee base flat rate net sale north america plus reimbursement certain royalty pay lilly company lilly share half profit loss evenly japan merck kgaa receive half profit loss japan party share royalty payable party pursuant formula set forth commercialization agreement purchase north american commercial requirement bulk erbitux lilly agreement expire erbitux north america september early termination available base material breach effective day notice material breach material breach cure commencement cure occur month notice exist significant concern regulatory patient safety issue seriously impact longterm viability product termination expiration alliance retain right erbitux share codevelopment copromotion right erbitux merck kgaa japan agreement sign october expire lilly merck kgaa merck japan lilly ability terminate agreement determine commercially unreasonable continue erbitux receive marketing approval japan july use erbitux treat patient advance recurrent colorectal cancer recognize net sale erbitux million million million table content discussion strategic alliance lilly item financial statementsnote alliance collaboration gilead joint venture gilead develop commercialize atripla canada europe company gilead share responsibility commercialize atripla canada eu certain european country provide fund fieldbased sale representative support promotional effort atripla gilead recognize atripla revenue canada countries europe revenue efavirenz component determine apply percentage atripla revenue approximate revenue sustiva brand recognize efavirenz revenue million million million relate atripla net sale joint venture company gilead continue terminate mutual agreement party describe event material breach party nonbreache party terminate joint venture party agree desirable practicable withdraw combination product market commercialize time generic version party component product appear market party right terminate joint venture acquire right combination product canada year terminate party continue receive percentage net sale base contribution bulk component atripla retain right product discussion strategic alliance gilead item financial statementsnote alliance collaboration current market productsinternally discover astrazeneca january enter worldwide japan codevelopment cocommercialization agreement astrazeneca onglyza saxagliptin agreement kombiglyze codevelope astrazeneca saxagliptin agreement exclusive right develop sell onglyza japan license otsuka december describe investigational compound developmentinternally discover company astrazeneca party worldwide codevelopment cocommercialization agreement dapagliflozin describe investigational compound developmentinternally discover manufacture onglyza kombiglyze certain limited exception recognize net sale key market receive million upfront licensing milestone payment astrazeneca meet certain development regulatory milestone onglyza kombiglyze receive additional million remain development regulatory milestone saxagliptin agreement meet additional million salesbased milestone meet majority cost initial development plan pay astrazeneca additional development cost generally share equally expense onglyza kombiglyze development cost net astrazenecas share research development company jointly develop clinical marketing strategy share commercialization expense profit loss equally global basis exclude japan discussion strategic alliance astrazeneca item financial statementsnote alliance collaboration otsuka simultaneously extension abilify agreement april company otsuka enter oncology agreement sprycel ixempra include japan eu market oncology territory begin collaboration fee pay otsuka annually follow percentage aggregate net sale sprycel ixempra oncology territory net sale million million million million million million billion excess billion period otsuka contribute million certain commercial operational expense relate oncology product oncology territory ii commercial operational expense relate product oncology territory excess million start otsuka right copromote sprycel japan eu market table content oncology agreement expire respect sprycel ixempra include changeofcontrol provision acquire abilify agreement describe discussion abilfy agreement otsuka current market productsinlicense discussion strategic alliance otsuka item financial statementsnote alliance collaboration investigational compound developmentinlicense exelixis october enter collaboration agreement exelixis license exelixis smallmolecule tgr agonist program include backup tgr agreement second collaborate discover optimize characterize smallmolecule ror antagonist ror agreement pay exelixis initial payment million pay additional development approval milestone million tgr agreement million ror agreement exelixis eligible receive sale performance milestone royalty net sale product tgr ror program receive exclusive worldwide license develop commercialize small molecule tgr agonist ror antagonist tgr agreement sole responsibility research development manufacturing commercialization ror agreement collaborate exelixis ror antagonist program preclinical transition point sole responsibility research development manufacture commercialization result product december company exelixis enter global codevelopment cocommercialization arrangement xl license xl utility ras raf mutant tumor development exelixis term arrangement pay exelixis million execution agreement additional million june company terminate development collaboration exelixis xl right return exelixis result million termination fee expense research development company pay exelixis development regulatory milestone million additional million salesbased milestone relate xl addition company exelixis history collaboration identify develop promote oncology target january company exelixis enter oncology collaboration license agreement exelixis pursue development small molecule ind codevelopment copromotion term agreement pay exelixis million upfront licensing milestone payment date pursuant amendment agreement execute october exelixis optedout codevelopment xl company payment exelixis million result company receive exclusive worldwide license develop commercialize xl sole responsibility development manufacture commercialization compound successful pay exelixis development regulatory milestone million additional million salesbased milestone royaltie royalty percentage rate tiere base net sale hold equity interest exelixis december represent outstanding share lilly january company lilly restructure egfr commercialization agreement provide codevelopment cocommercialization necitumumab imcf fully human antibody currently phase iii development nonsmall cell lung cancer item management discussion analysis financial condition result operationsproduct pipeline development update phase iii trial restructure company share cost develop share profit loss commercialize necitumumab canada japan lilly maintain exclusive right necitumumab market fund development cost study fund global study pay million lilly milestone payment approval grant canada recognize sale receive profit bear loss necitumumab lilly provide selling effort party general equally participate commercialization effort japan company lilly share commercial cost profit evenly agreement relate necitumumab continue patent expiration party agree terminate lilly manufacture bulk requirement assume responsibility fillfinish necitumumab begin alder november company alder biopharmaceuticals inc alder enter global agreement development commercialization ald novel biologic complete phase iia development treatment rheumatoid arthritis term collaboration agreement alder grant worldwide exclusive right develop commercialize ald potential indication cancer alder retain right grant option codevelop ald cancer exclusive right commercialize ald cancer outside united states pay alder million upfront licensing payment expense research development addition pay million developmentbase regulatorybase milestone payment potential salesbased milestone certain circumstance exceed million royalty net sale royalty percentage rate tiere base net sale choose option pursue cancer indication pay additional million developmentbased regulatorybase milestone payment aforementione salesbased milestone royalty net sale royalty percentage rate tiere base net sale table content investigational compound developmentinternally discover astrazeneca mention worldwide codevelopment cocommercialization agreement astrazeneca dapagliflozin sglt agreement dapagliflozin study potential treatment diabete discover sglt agreement receive million upfront licensing payment astrazeneca receive million development regulatory milestone meet dapagliflozin additional million salesbased milestone meet majority cost initial plan pay astrazeneca additional development cost generally share equally japan astrazeneca bear substantially development cost prior approval indication expense dapagliflozin development cost net alliance partner share research development sglt agreement like saxagliptin agreement company jointly develop clinical marketing strategy share commercialization expense profit loss dapagliflozin equally global basis manufacture dapagliflozin certain limited exception recognize net sale key market respect japan astrazeneca operational cost responsibility development regulatory activity behalf collaboration company jointly market product japan share commercialization expense activity split profit loss equally like rest world manufacture dapagliflozin recognize net sale japan like rest world dapagliflozin currently study phase ii clinical trial japan discussion strategic alliance astrazeneca item financial statementsnote alliance collaboration pfizer company pfizer party worldwide codevelopment cocommercialization agreement eliquis anticoagulant discover study prevention treatment broad range venous arterial thrombotic condition pfizer fund development cost january fund receive million upfront licensing milestone payment pfizer date include million milestone filing marketing authorization application eu receive additional million pfizer development regulatory milestone meet company jointly develop clinical marketing strategy eliquis share commercialization expense profit loss equally global basis discussion strategic alliance pfizer item financial statementsnote alliance collaboration otsuka january grant otsuka exclusive right japan develop commercialize onglyza entitle receive milestone payment base certain regulatory event salesbase payment follow regulatory approval onglyza japan retain right copromote onglyza otsuka japan otsuka responsible development cost japan royalty licensing arrangement addition strategic alliance describe inlicense outlicense arrangement respect inlicense agreement novartis reyataz hzi ixempra base current expectation respect expiration market exclusivity significant market license arrangement novartis reyataz expect expire eu japan arrangements hzi ixempra expect expire th anniversary commercial sale eu japan discussion market exclusivity protection include chart show net sale key product year basic exclusivity loss occur expect occur eu japan canada product result acquisition medarex august zymogenetics october certain compound outlicense party development commercialization expect receive milestone payment compound regulatory process royalty base product sale product commercialize intellectual property product exclusivity license number patent foreign country primarily cover product develop brand name trademark product consider overall protection patent trademark license intellectual property right material value act protect right infringement table content pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity product market exclusivity generally determine form intellectual property patent right hold innovator company regulatory form exclusivity innovative drug entitle patent key determinant market exclusivity brand pharmaceutical patent provide innovator right exclude practice invention relate medicine patent cover thing active ingredient use drug product pharmaceutical formulation drug delivery mechanism process intermediate useful manufacture product protection individual product extend vary period accordance expiration date patent country protection afford vary country country depend type patent scope coverage availability meaningful legal remedy country market exclusivity influence regulatory intellectual property right develop country provide certain nonpatent incentive development medicine example eu japan canada certain market regulatory intellectual property right offer incentive research medicine rare disease orphan drug medicine useful treat pediatric patient incentive extend market exclusivity period product patent term eu japan canada provide minimum period time approval new drug regulatory agency rely innovators data approve competitor generic copy datum protection certain market patent protection form market exclusivity expire datum protection particular importance regulatory form exclusivity prevent competitor gain regulatory approval prior expiration regulatory data exclusivity basis competitor safety efficacy datum drug drug identical market innovator specific aspect law govern market exclusivity datum protection pharmaceuticals vary country country follow summarize key exclusivity rule market represent significant sale united state key product protect patent vary term depend type patent filing date significant portion product patent life lose time take innovative company develop obtain regulatory approval new drug compensation lose patent term innovator depend number factor extend expiration date patent maximum term year provide extension cause patent effect year date drug approval company seek market innovative pharmaceutical submit complete set safety efficacy datum fda innovative pharmaceutical chemical company file new drug application nda medicine biological product biologic license application bla file type application file affect regulatory exclusivity right chemical product competitor seek launch generic substitute chemical innovative drug file abbreviate nda anda fda anda generic manufacturer need demonstrate bioequivalence generic substitute approve nda drug anda rely safety efficacy datum previously file innovator nda innovator company require list certain patent cover medicine fda commonly know orange book absent successful patent challenge fda approve anda innovators list patent expire innovator market product year generic manufacturer file anda allege patent list orange book innovators nda invalid infringe allegation commonly know paragraph iv certification innovator decide file patent infringement suit generic manufacturer time time anda include paragraph iv certification file respect certain product evaluate andas casebycase basis warrant file suit generic manufacturer protect patent right addition benefit patent protection certain innovative pharmaceutical product receive period regulatory exclusivity nda designate orphan drug receive seven year exclusivity orphan indication time period nda andas drug product approve orphan use company earn month additional exclusivity drug specific clinical trial conduct write request fda study use medicine treat pediatric patient submission fda prior loss basic exclusivity table content medicine approve nda receive type regulatory data protection innovative chemical pharmaceutical entitle year regulatory data protection competitor file fda approval generic substitutes innovators patent challenge describe generic manufacturer file anda fourth year fiveyear datum protection period pharmaceutical drug product contain active ingredient previously approve nda approve new formulation drug new indication basis new clinical trial receive year datum protection formulation indication biologic product new healthcare legislation enact abbreviate path regulatory approval biosimilar version biological product new path approval biosimilar product healthcare legislation significantly affect regulatory data exclusivity biological product new legislation provide regulatory mechanism allow fda approval biologic drug similar generic copy innovative drug basis extensive datum require bla legislation create approval pathway biosimilar version biological product previously exist innovative biological product long receive essentially unlimited regulatory data exclusivity exist prior creation regulatory path biosimilar version new law innovator market biological product year biosimilar manufacturer file application approval biosimilar version innovator product application approval biosimilar file year approval innovator product qualify innovative biological product receive year regulatory exclusivity mean fda approve biosimilar version year innovative biological product approve fda new law provide mechanism innovator enforce patent protect innovative biological product biosimilar applicant challenge patent patent litigation begin early year innovative biological product approve fda increase likelihood generic biosimilar challenge innovators intellectual property increase risk loss innovator market exclusivity generic company increasingly seek challenge innovator basic patent cover major pharmaceutical product second statutory regulatory provision limit ability innovator company prevent generic biosimilar drug approve launch patent litigation ongoing result development possible predict length market exclusivity particular product certainty base solely expiration relevant patent current form regulatory exclusivity european union patent pharmaceutical product generally enforceable eu extended compensate patent term lose regulatory review process extension grant countrybycountry basis primary route use obtain marketing authorization pharmaceutical product eu centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum marketing authorization application maa european medicine agency ema ema evaluates maa provide recommendation european commission ec ec approve deny maa possible new chemical product obtain marketing authorization eu mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state obtain marketing authorization approval company obtain pricing reimbursement pharmaceutical product typically subject member state law certain eu country process place simultaneously product market eu country process complete company market new product pricing reimbursement procedure month year complete eu product marketing authorization file octobernovember subject regime year innovator receive community authorization medicinal product generic company file marketing authorization application product health authority market authorization application approve generic company commercialize product year elapse initial marketing authorization grant innovator possible extension year available innovator year marketing authorization obtain additional indication significant clinical benefit comparison exist treatment product file prior octobernovember year period datum protection centralize procedure period year mutual recognition procedure depend member state table content contrast patent eu list regulatory authority generic version pharmaceutical product approve data protection expire regardless innovator hold patent cover drug possible innovator seek enforce patent generic competitor market product european patent system opposition procedure generic manufacturer challenge validity patent cover innovator product month grant general eu law treat chemicallysynthesize drug biologicallyderive drug respect intellectual property datum protection addition relevant legislation annexe relate biologic medicinal product ema issue guideline outline additional information provide biosimilar product know generic biologic order review application marketing approval japan japan medicines new chemical entity generally afford year datum exclusivity approve indication dosage patent pharmaceutical product enforceable generic copy receive regulatory approval datum exclusivity patent expiration patent japan extended compensate patent term lose regulatory review process general japanese law treat chemicallysynthesize biologicallyderive drug respect intellectual property market exclusivity canada canada medicines new chemical entity generally afford year datum exclusivity approve indication dosage patent pharmaceutical product enforceable generic copy receive regulatory approval datum exclusivity patent expiration currently unlike canada patent term restoration compensate patent term lose regulatory review process canada biologics generally treat chemicallysynthesized product respect patent right regulatory exclusivity health canada issue draft guidance outline additional information provide subsequent entry biologic know biosimilar product generic biologic order review application marketing approval rest world country outside eu japan canada wide variety legal system respect intellectual property market exclusivity pharmaceutical develop country utilize system similar eu eg switzerland develop country adopt patent law andor regulatory exclusivity law develop country formally adopt law order comply world trade organization wto commitment take step implement law meaningful way enforcement wto action long process government assurance outcome assess likely future market exclusivity innovative drug develop country account formal legal right political factor marketing distribution customer promote appropriate use product directly healthcare professional provider doctor nurse practitioner physician assistant pharmacist technologist hospital pharmacy benefit manager pbms manage care organization mcos provide information appropriate use product consumer directtoconsumer print radio television advertising addition sponsor general advertising educate public innovative medical research discussion regulation promotion marketing pharmaceutical government regulation price constraint sale marketing organization explain approve use risk benefit product medical professional work gain access health authority pbm mco formulary list recommend approve medicine product include medicare plan reimbursement list provide information clinical profile product marketing prescription pharmaceutical limit approve use particular product continue develop scientific datum information product provide information response unsolicite inquiry doctor medical professional manage care organization table content operation include marketing sale organization organization market distinct group product support sale force typically base particular therapeutic area physician group sale force focus sell new product introduce promotion physician increasingly target specialist key primary care physician product sell principally wholesaler less extent directly distributor retailer hospital clinic government agency pharmacie gross sale large pharmaceutical wholesaler percentage total gross sale follow mckesson corporation cardinal health inc amerisourcebergen corporation business inventory management agreement ima substantially direct wholesaler distributor customer allow monitor wholesaler inventory level require wholesaler maintain inventory level month demand ima year term december subject certain termination provision number small market outside eu move distributorbased model promotion distribution enter contract distributor market purchase product promote sell country sale distributorbase market represent company net sale competition market compete generally broad base highly competitive compete worldwide researchbase drug company small research company limit therapeutic focus generic drug manufacturer important competitive factor include product efficacy safety ease use price demonstrate costeffectiveness marketing effectiveness product label customer service research development new product process sale product impact new study indicate competitor product safe effective treat disease particular form disease product sale impact additional labeling requirement relate safety convenience impose product fda similar regulatory agency different country competitor introduce new product process therapeutic cost advantage product subject progressive price reduction decrease volume sale generic competition big competitive challenge face generic pharmaceutical manufacturer eu regulatory approval process exempt generic costly timeconsuming clinical trial demonstrate safety efficacy allow generic manufacturer rely safety efficacy innovator product result generic pharmaceutical manufacturer typically invest far research development researchbase pharmaceutical company price product significantly lower brand product accordingly brand product lose market exclusivity normally face intense price competition generic form product expiration loss market exclusivity product lose major portion sale product short period time rate sale decline product expiration exclusivity vary country general decline market rapid develop country observe rapid decline number eu country decline develop country tend rapid develop country rate sale decline expiration exclusivity historically influence product characteristic example drug large patient population eg prescribed key primary care physician tend experience rapid decline drug specialized area medicine eg oncology drug complex manufacture eg sterile injectable product usually experience slow decline simple manufacture certain country outside patent protection weak nonexistent compete generic version shortly launch innovative product addition generic pharmaceutical company introduce generic product exclusivity expire resolution relate patent litigation information market exclusivity intellectual property product exclusivity table content believe longterm competitive position depend success discover develop innovative costeffective product serve unmet medical need ability manufacture product efficiently market effectively highly competitive environment manage care organization growth mcos major factor healthcare marketplace half population participate version manage care mco include medical insurance company medical plan administrator healthmaintenance organization medicare prescription drug plan alliance hospital physician physician organization organization consolidate few large entity enhance purchasing strength importance successfully compete business mcos demonstrate product offer medical benefit cost advantage compare form care new product introduce compete product market product later develop competitor note generic drug exempt costly timeconsuming clinical trial demonstrate safety efficacy lower cost brandname drug mcos focus primarily immediate cost drug favor generic reason government encourage use generic alternative brandname drug healthcare program law generally allow case require pharmacist substitute generic drug rate government procedure essentially equivalent brandname drug substitution prescribe physician expressly forbid exclusion product formulary lead sharply reduce usage mco patient population consequently pharmaceutical company compete aggressively product include possible company compete inclusion base unique feature product great efficacy well patient ease use few effect low overall cost therapy important factor product demonstrate few therapeutic advantage compete inclusion base primarily price generally universally successful major product include mco formulary government regulation price constraint pharmaceutical industry subject extensive global regulation regional country state local agency federal food drug cosmetic act fdc act federal statute regulation state statute regulation law regulation foreign government govern vary degree test approval production labeling distribution postmarket surveillance advertising dissemination information promotion product lengthy process laboratory clinical testing datum analysis manufacture development regulatory review necessary require governmental approval extremely costly significantly delay product introduction give market promotion marketing manufacturing distribution pharmaceutical product extensively regulate major world market addition operation subject complex federal state local foreign environmental occupational safety law regulation anticipate law regulation affect manufacture sale current product introduction new product continue require substantial scientific technical effort time expense significant capital investment particular importance fda jurisdiction virtually activity impose requirement cover testing safety effectiveness manufacturing labeling marketing advertising postmarkete surveillance product case fda requirement increase time money necessary develop new product bring market fda mandate drug manufacture package label conformity current good manufacturing practice cgmp establish fda comply cgmp regulation manufacturer continue expend time money effort production recordkeeping quality control ensure product meet applicable specification requirement ensure product safety efficacy fda periodically inspect drug manufacturing facility ensure compliance applicable cgmp requirement failure comply statutory regulatory requirement subject possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experience use product report fda result imposition market restriction label change product removal product approval withdraw compliance regulatory requirement maintain problem concern safety efficacy occur follow approval federal government extensive enforcement power activitie pharmaceutical manufacturer include authority withdraw product approval commence action seize prohibit sale unapproved noncomplye product halt manufacture operation compliance cgmp impose seek injunction voluntary recall civil monetary criminal penalty restriction prohibition sale withdrawal approval product market materially adversely affect business financial condition result operation cash flow discussion warning letter receive relate manufacturing site manati puerto rico item risk factorswe experience difficulty delay manufacture distribution sale product item management discussion analysis financial condition result operation highlight table content marketing authorization product subject revocation applicable governmental agency addition modification enhancement approve product change manufacturing location circumstance subject additional fda approval receive subject lengthy application process distribution pharmaceutical product subject prescription drug marketing act pdma fdc act regulate activity federal state level pdma implement regulation state permit require registration manufacturer distributor provide pharmaceutical manufacturer distributor place business state state permit adopt regulation limit distribution product sample license practitioner pdma impose extensive licensing personnel recordkeeping packaging quantity labeling product handle facility storage security requirement intend prevent sale pharmaceutical product sample product diversion discussion recent settlement certain investigation drug pricing sale marketing activity item financial statementsnote legal proceeding contingency fda amendment act impose additional obligation pharmaceutical company delegate enforcement authority fda area drug safety key element legislation fda authority require company conduct postmarkete safety study drug impose certain drug labeling change relate safety mandate risk mitigation measure education healthcare provider restrict distribution medicine require company publicly disclose datum clinical trial prereview television advertisement marketing practice pharmaceutical manufacturer subject federal state healthcare law protect integrity government healthcare program office inspector general department health human service oig oversee compliance applicable federal law connection payment product government fund program primarily medicaid medicare law include federal antikickback statute criminalize offer value induce recommendation order purchase product service reimburse government healthcare program oig issue series guidance segment healthcare industry include compliance program guidance pharmaceutical manufacturer oig guidance include recommendation pharmaceutical manufacturer minimum adhere phrma code voluntary industry code marketing practice subscribe phrma code implement compliance program address requirement set forth oig guidance compliance healthcare law failure comply healthcare law subject administrative legal proceeding include action federal state government agency action result imposition civil criminal sanction include fine penalty injunctive remedy impact materially adversely affect business financial condition result operation cash flow subject jurisdiction federal state regulatory enforcement department agency federal trade commission department justice department health human service license drug enforcement agency procure produce control substance subject possible administrative legal proceeding action organization action result imposition civil criminal sanction include fine penalty injunctive administrative remedy activity outside subject regulatory requirement govern testing approval safety effectiveness manufacturing labeling marketing product regulatory requirement vary country country fda approval approval ema obtain product approval product comparable regulatory authority country outside eu case obtain prior marketing product country approval process rigorous country country time require approval long shorter require approval country assure product approve country market outside operate environment governmentmandate costcontainment program government place restriction physician prescription level patient reimbursement emphasize great use generic drug andor enact acrosstheboard price cut method cost control eu countries example government regulate price new product launch direct price control international price comparison control profit andor reference pricing market uk germany government set pricing restriction launch pricing freedom subsequently limited operation profit price control plan uk operation reference price system germany company face significant delay market access new product mainly france spain italy belgium year elapse new medicine available national market additionally member states eu regularly impose new additional cost containment measure pharmaceutical recent year italy example impose mandatory price decrease existence price differential eu different national pricing reimbursement law lead significant parallel trade flow table content internationally healthcare industry subject governmentimposed regulation authorize price price control continue impact net sale march government enact healthcare reform legislation sign law patient protection affordable care act hr reconciliation bill contain package change healthcare bill new legislation make extensive change current system healthcare insurance benefit intend broaden coverage reduce cost bill significantly change americans receive healthcare coverage pay significant impact company particular company pharmaceutical industry healthcare relate industry include bms experience continue experience additional financial cost certain change business new healthcare law implement example minimum rebate medicaid drug sale increase percent percent medicaid rebate extend drug riskbase medicaid manage care plan addition extend discount certain critical access hospital cancer hospital cover entity require expansion b drug pricing program public health service act provide percent discount brandname drug patient fall medicare coverage gap refer donut hole pay annual nontaxdeductible fee federal government base allocation market share brand prior year sale certain government program include medicare medicaid department veterans affairs department defense tricare fee classify financial reporting purpose operate expense estimate new discount new pharmaceutical company fee healthcare reform law include related regulation medicare coverage gap manage medicaid expansion public health service b program require additional assumption lack historical claim experience market outside operate environment governmentmandate costcontainment program regulatory body group exert downward pressure pricing pricing freedom limited uk instance operation profit control plan germany operation reference price system company face significant delay market access new product year elapse drug approval new medicine available country federal state government pursue direct method reduce cost drug pay participate state government medicaid program certain qualify federal state government program discount rebate provide participate state local government entity participate government program specify discount certain government entity significant department defense department veterans affair entity receive minimum discount base define nonfederal average manufacturer price purchase program participate provide discount outpatient medicine purchase certain specify entity section b public health service act discussion rebate program item management discussion analysis financial condition result operationsnet sale critical accounting policy source availability raw material general purchase raw material supply require production product open market product purchase raw material supply source source available single source approve source available require obtain raw material supply particular source attempt possible mitigate raw material supply risk inventory management alternative source strategy discussion source manufacture quality assurance discussion particular product manufacture quality assurance meet expect product demand operate manage manufacturing network include thirdparty contract manufacturer inventory relate thereto manner permit improve efficiency maintain flexibility reallocate manufacturing capacity pharmaceutical production process complex highly regulate vary widely product product give shift add manufacturing capacity lengthy process require significant capital outofpocket expenditure regulatory approval maintain operate flexible manufacturing network consist internal external resource minimize unnecessary product transfer inefficient use manufacturing capacity discussion regulatory impact manufacturing government regulation price constraint table content pharmaceutical manufacturing facility require significant ongoing capital investment maintenance compliance increase regulatory requirement addition product line change year expect modify exist manufacturing network meet complex processing standard require newly introduce product include biologic biologic manufacturing involve complex process traditional pharmaceutical operation february purchase acre site locate large scale multiproduct bulk biologic manufacturing facility deven massachusetts construction deven massachusetts facility begin early substantially complete expect submit site regulatory approval late rely party manufacture supply active ingredient necessary manufacture certain product include plavix baraclude avalide reyataz abilify erbitux sustiva franchise orencia onglyza kombiglyze maintain stable supply product variety action include inventory management maintenance additional quantity material possible design provide reasonable level ingredient hold thirdparty supplier manufacturing operation interrupt additional protection case step maintain approve backup source available example rely combine capacity deven massachusetts syracuse new york manati puerto rico facility capacity available thirdparty contract manufacturer manufacture orencia commercial quantity investigational biologic compound latestage development compound receive regulatory approval thirdparty manufacturer rely exist future product unable maintain stable supply product operate sufficient capacity meet order requirement comply government regulation manufacturing pharmaceutical meet heighten processing requirement biologic business performance prospect negatively impact additionally thirdparty supplier experience extend plant shutdown substantial unplanned increase demand suspension manufacture regulatory reason experience interruption supply certain product product shortage production resume expand connection divestiture license arrangement distribution agreement certain product certain circumstance enter agreement agree supply product party addition liability arise failure supply product agreement arrangement require invest facility production nonstrategic product result additional regulatory filing obligation cause interruption manufacturing product success depend great measure customer confidence quality product integrity datum support safety effectiveness product quality arise total commitment quality part operation include research development purchasing facility planning manufacturing distribution maintain qualityassurance procedure relate quality integrity technical information production process control production process involve detailed specification ingredient equipment facility manufacturing method process packaging material labeling perform test stage production process final product ensure product meet regulatory requirement standard test involve chemical physical chemical analyse microbiological testing combination analyse quality control provide business unitsite quality assurance group monitor exist manufacturing procedure system subsidiary thirdparty supplier environmental regulation facility operation subject extensive foreign law regulation relate environmental protection human health safety include govern discharge pollutant air water use management disposal hazardous radioactive biological material waste cleanup contamination pollution control permit require operation permit subject modification renewal revocation issue authority environment health safety group monitor operation world provide overview regulatory requirement oversee implementation standard compliance incur operating capital cost matter ongoing basis expend approximately million million million capital project undertake specifically meet environmental requirement believe substantial compliance applicable environmental health safety requirement permit require operation incur additional cost include civil criminal fine penalty cleanup cost thirdparty claim property damage personal injury violation liabilitie law table content current facility operation year time operator facility generate store dispose substance waste consider hazardous federal state andor foreign environmental law include comprehensive environmental response compensation liability act cercla result soil groundwater certain facility contaminate require significant expenditure investigate control remediate contamination case provide compensation andor restoration damage natural resource currently involve investigation remediation current facility identify potentially responsible party prp applicable law environmental condition approximately waste disposal reprocess facility operate party investigation andor remediation activity ongoing face liability cercla federal state foreign law entire cost investigation remediation contaminate site natural resource damage regardless fault ownership time disposal release addition certain site bear remediation responsibility pursuant contractual obligation generally thirdparty operator site involve multiple prps liability expect apportion base nature hazardous substance dispose party site number financially viable prps additional information matter item financial statementsnote legal proceeding contingency employee december employ approximately people continue implement comprehensive cost reduction program include work force reduction rationalization facility discussion pti restructuring activity item financial statementsnote restructure foreign operation significant operation outside conduct subsidiary distributor geographic breakdown net sale table caption geographic area item financial statementsnote business segment information discussion net sale geographic area item management discussion analysis financial condition result operation geographic area international operation subject certain risk inherent conduct business abroad include limited currency fluctuation possible nationalization expropriation price exchange control counterfeit product limitation foreign participation local enterprise restrictive governmental action international business subject governmentimpose constraint include law price reimbursement use product depend direction change relative dollar foreign currency value increase decrease report dollar value net asset result operation change foreign exchange rate net favorable impact growth rate revenue predict certainty future change foreign exchange rate effect attempt mitigate impact operational mean financial instrument discussion item quantitative qualitative disclosure market risk item financial statementsnote financial instrument bristolmyer squibb website internet website address wwwbmscom website available free charge annual quarterly current report include amendment report soon reasonably practicable electronically file material furnish material securities exchange commission sec information relate corporate governance bristolmyer squibb include standard business conduct ethic code ethic senior financial officer code business conduct ethic director collectively code corporate governance guideline information concern executive committee board director include board committee committee charter transaction bristolmyers squibb security director executive officer available website investorscorporate governance caption print stockholder request waiver code director executive officer material amendment code business conduct ethic director code ethic senior financial officer post promptly website information relate stockholder service include dividend reinvestment plan direct deposit dividend available website investorsstockholder service caption incorporate reference certain information part proxy statement annual meeting stockholder sec allow disclose important information refer manner refer information proxy statement annual meeting stockholder annual report available website investorssec filing caption march table content item risk factor factor describe significantly negatively affect business prospect financial condition operating result credit rating cause trading price common stock decline additional risk uncertainty presently know risk currently consider immaterial impair operation face intense competition pharmaceutical manufacturer include innovative medicine lowerprice generic product competition manufacturer compete product include lowerpriced generic version product major challenge internationally face patent expiration increasingly aggressive generic competition competition include new product develop competitor low price superior performance feature competitive current product ii technological advance patent attain competitor iii result clinical study relate product competitor product iv earlierthanexpecte competition generic company v business combination competitor major customer experience limited market access real perceive difference value proposition product compare compete product depend key product net sale cash flow earning derive majority revenue earning key product net sale plavix contribute approximately billion represent approximately total net sale net sale abilify contribute approximately billion represent approximately total net sale product avaproavalide reyataz sustiva franchise contribute billion net sale reduction sale key product significantly negatively impact net sale cash flow earning january partner sanofi voluntarily recall certain lot avalide puerto rican canadian mexican argentinean market supply avalide market affect indefinitely total avalide sale country million working partner sanofi identify possible solution issue include process adjustment alternate supply source unable resupply market timely manner negative impact net sale cash flow earning market exclusivity plavix avaproavalide expect expire march respectively plavix topselle product worldwide net sale approximately billion net sale approximately billion expect plavix lose exclusivity rapid precipitous material decline plavix net sale reduction net income operate cash flow avaproavalide lose patent protection march experience precipitous decline avaproavalide net sale unable support grow currently market product advance latestage pipeline manage cost effectively loss exclusivity plavix avaproavalide significant material negative impact result operation cash flow financial condition datum protection plavix expire eu plavix face competition european market datum protection plavix expire july eu plavix face competition generic alternate salt form clopidogrel bisulfate eu year plavix experience substantial market share erosion price discount plavix sales eu decrease international net sale plavix equity net income affiliate decrease respectively compare expect continue decline possible lose market exclusivity product early expect pharmaceutical biotechnology industry majority innovative product commercial value usually realize period market exclusivity country market exclusivity expire generic version product approve market usually substantial rapid decline product sale rate decline vary country therapeutic category market exclusivity product base patent right andor certain regulatory form exclusivity scope patent right vary country country dependent availability meaningful legal remedy country failure obtain patent intellectual property right limitation use loss right material country include certain eu member state basic patent protection product exist certain country historically offer right obtain certain type patent andor licensor file market absent relevant patent protection product datum exclusivity period expire generic version product approve market generic clopidogrel bisulfate certain eu markets addition prior expiration datum exclusivity competitor seek regulatory approval submit clinical trial datum obtain marketing approval table content manufacturer generic product increasingly seek challenge patent expire key patent cover key product abilify atripla baraclude reyataz sprycel currently subject patent litigation case generic manufacturer choose launch generic product risk expiration applicable patent andor final resolution relate patent litigation length market exclusivity product impossible predict certainty assurance particular product enjoy market exclusivity period time appear estimate disclose face increase pricing pressure restriction abroad manage care organization institutional purchaser government agency program negatively affect net sale profit margin pharmaceutical product subject increase price pressure restriction worldwide include rule practice manage care organization institutional governmental purchasers ii judicial decision governmental law regulation relate medicare medicaid healthcare reform include medicare prescription drug improvement modernization act patient protection affordable care act iii potential impact importation restriction legislative andor regulatory change pharmaceutical reimbursement medicare formularie product pricing general iv delay gain reimbursement andor reduction reimbursement amount country government mandate costcontainment program eg major european market japan canada v developments technology andor industry practice directly indirectly impact reimbursement policy practice thirdparty payer vi limited market access real perceive difference value proposition product compare compete product business result operation affect continue affect recent healthcare reform legislation describe item management discussion analysis financial condition result operationsexecutive summarybusiness environment patient protection affordable care act hr reconciliation bill contain package change healthcare bill sign law march bill include provision increase medicaid rebate expand medicaid program provide additional prescription drug discount certain patient medicare assess new nontaxdeductible annual fee pharmaceutical company thing experience continue experience significant financial cost certain change business new healthcare law implement high rebate medicaid medicaid manage care plan reduce net sale million pretax income million incremental yearoveryear basis expect healthcare reform negative impact earning share approximately estimate include expect reduction net sale approximately million new discount associate medicare donut hole coverage gap increase marketing sale administrative expense approximately million new annual nontaxdeductible pharmaceutical company fee law create regulatory mechanism allow approval biologic drug similar generic copy innovative drug basis extensive datum basis bla foreign law regulation negatively affect net sale profit margin subject new government law regulation additional healthcare reform initiative federal state level country include additional mandatory discount ii change fda foreign regulatory approval process cause delay approve prevent approval new product iii tax change phase tax benefit heretofore available certain foreign country change tax law recent amendment puerto rico internal revenue code impose excise tax certain transaction potentially negative impact result operation iv new law regulation judicial governmental decision affect pricing reimbursement marketing jurisdiction v change intellectual property law vi matter compulsory license alter protection afford product legal regulatory change negatively affect business andor operating result financial condition company change product label market product result certain study release product approve potentially negative impact sale product label pharmaceutical product change regulatory authority time include product market year change result additional datum postmarkete study headtohead trial spontaneous reporting adverse event patient healthcare professional study identify biomarker objective characteristic indicate particular response product therapy study produce important additional information product new information add product label affect safety risk andor efficacy benefit profile product additional information study identify portion patient population nonresponsive medicine change label base study limit patient population recent change label plavix erbitux study provide additional information sponsor sponsor competitor insurance company government institution manage care organization influential scientist investigator interested party additional safety efficacy information study assist healthcare provider identify good patient population product negative impact sale product extent patient population product labeling limited additionally certain study result especially headtohead trial affect product formulary listing adverse effect sale table content experience difficulty delay manufacture distribution sale product experience difficulty delay inherent manufacture distribution sale product seizure recall product force closing manufacture plant ii supply chain continuity include result natural man disaster facility critical supplier vendor failure failure vendor supplier comply current good manufacturing practice applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture iii manufacturing quality assurancequality control supply problem governmental approval delay consolidation rationalization manufacture facility sale closure certain site iv failure sole source single source supplier provide necessary raw material supply finish good extend period time impact continuous supply v failure thirdparty manufacturer supply finish product timely basis vi construction regulatory approval delay relate new facility expansion exist facility include intended support future demand biologic product vii manufacturing distribution problem include limit manufacturing capacity regulatory requirement change type product produce biologic physical limitation business interruption impact continuous supply receive warning letter fda manufacturing facility manati puerto rico warning letter focus certain gmp process practice fda identify inspection improve remediate provide response warning letter inform fda manati facility inspectionready unable timely adequately improve remediate gmp issue identify fda satisfaction subject additional inspectional observation fda require remediation observation face additional negative consequence include temporary delay production facility corrective action delay approval filing january partner sanofi voluntarily recall certain lot avalide puerto rican canadian mexican argentinean market working partner sanofi identify possible solution issue include process adjustment alternate supply source unable resupply market timely manner negative impact net sale cash flow earning resolution manufacture supply issue discuss potential impact issue revenue earning subject substantial risk uncertainty risk uncertainty include time scope duration resolving manufacturing supply issue experience difficulty delay development commercialization new product experience difficulty delay development commercialization new product include inherent risk uncertainty associate product development compound product appear promise development fail reach market expect optimal timeframe fail reach market approve product extension additional indication number reason include efficacy safety concern delay denial necessary regulatory approval delay difficulty produce product commercial scale level excessive cost manufacture product ii failure enter successfully implement optimal alliance appropriate discovery andor commercialization product iii failure maintain consistent scope variety promise latestage product iv failure product achieve maintain commercial viability addition observe recent trend fda delay approval decision new product announce action date month long regulatory approval delay especially common product expect risk evaluation mitigation strategy address significant riskbenefit issue inability bring product market significant delay expect approval relate launch date new product potentially negative impact net sale earning result significant impairment inprocess research development intangible asset finally natural man disaster sabotage research development lab loss key molecule intermediary negatively impact product development cycle legal matter adverse outcome negatively affect business currently involve future involved lawsuit claim proceeding government investigation preclude delay commercialization product adversely affect operation profitability liquidity financial condition possible insurance recovery available legal matter include intellectual property dispute ii sale marketing practice internationally iii adverse decision litigation include product liability commercial case iv recall withdrawal pharmaceutical product force closing manufacture plant v failure fulfill obligation supply contract government customer result liability vi product pricing promotional matter vii lawsuit claim assert violation security antitrust federal state pricing antibribery foreign corrupt practice act law viii environmental health safety matter ix tax liability assurance increase scope matter additional lawsuit claim proceeding investigation future assurance matter material adverse impact table content rely party meet contractual regulatory obligation rely supplier vendor partner include alliance pharmaceutical company manufacture development commercialization product party meet contractual regulatory obligation relation arrangement failure party meet obligation andor development significant disagreement factor materially disrupt ongoing commercial relationship prevent optimal alignment partner activity material adverse impact addition party violate allege violate law regulation performance obligation possible suffer financial reputational harm negative outcome include possible legal consequence increasingly dependent outsourcing arrangement increase dependence thirdparty provider certain outsource service include certain research development capabilitie certain financial outsource arrangement certain human resource function information technology activity system thirdparty provider locate market subject political risk corruption infrastructure problem natural disaster addition country specific privacy datum security risk give current legal regulatory environment failure service provider meet obligation adequately deploy business continuity plan event crisis andor development significant disagreement natural man disaster factor materially disrupt ongoing relationship provider negatively affect operation failure execute business strategy adversely impact growth profitability year transform diversified pharmaceutical relate healthcare product company biopharmaceutical company focus innovative product area high unmet medical need expect loss exclusivity large product plavix time expect rapid precipitous material decline plavix net sale reduction net income operate cash flow focus building foundation future plan achieve foundation continue support grow currently market product advance latestage pipeline manage cost maintain improve financial strength strong balance sheet risk associate strategy able consistently replenish innovative pipeline internal research development transaction party competition major pharmaceutical company acquisition product licensing opportunity intense eliminate opportunity make expensive able locate suitable acquisition target license partner reasonable price successfully execute transaction additionally change structure operation revenue cost efficiency result major transaction acquisition divestiture merger alliance restructuring strategic initiative result great expect cost long expect complete encounter difficulty include need regulatory approval appropriate inability expand product portfolio new product maintain competitive cost basis materially adversely affect future result operation unable support grow currently market product advance latestage pipeline manage cost effectively experience significant material negative impact result operation financial condition addition failure hire retain personnel right expertise experience operation critical business function adversely impact execution business strategy increasingly dependent information technology expand social medium vehicle present new risk increasingly dependent information technology system significant breakdown invasion destruction interruption system negatively impact operation addition risk business interruption reputational damage infiltration datum center datum leakage confidential information internally thirdparty provider inappropriate use certain medium vehicle cause brand damage information leakage lead legal implication improper collection personal information negative post comment social network web site seriously damage reputation addition disclosure nonpublic company sensitive information external medium channel lead information loss structured process place secure achieve information identify new point entry social medium continue expand present new challenge adverse change global regional economic condition continue adverse effect profitability business high government debt burden continue high unemployment rate rise price include related commodity energy low economic growth adversely affect commercial activity europe region world business government austerity measure decline economic activity market business adversely affect demand pricing product reduce revenue earning cash flow passthrough effect result significant financial instability customer distributor alliance partner supplier critical vendor service provider counterpartie certain financial instrument marketable security derivative future pension plan funding requirement continue sensitive global economic condition relate impact equity market table content change foreign currency exchange rate interest rate material adverse effect result operation significant operation outside revenue operation outside account revenue expose fluctuation foreign currency exchange rate significant borrowing expose change interest rate expose economic factor control illegal distribution sale party counterfeit version product steal product negative impact reputation business party illegally distribute sell counterfeit version product meet rigorous manufacturing testing standard product undergo patient receive counterfeit drug risk number dangerous health consequence reputation business suffer harm result counterfeit drug sell product addition theft inventory warehouse plant intransit properly store sell unauthorized channel adversely impact patient safety reputation business table content item b unresolved staff comment item property world headquarter locate park avenue new york ny lease approximately square foot floor space lease approximately propertie country manufacture product worldwide location own manufacturing location aggregate square foot floor space geographic area follow december number location square feet united states europe latin america middle east africa japan asia pacific canada emerge market total portion manufacturing location property own lease research development administration storage distribution information property item businessmanufacture quality assurance item legal proceeding information pertain legal proceeding find item financial statementsnote legal proceeding contingency incorporate reference item submission matter vote security holder matter submit vote security holder fourth quarter year end december table content ia executive officer registrant list information executive officer february executive officer elect board director initial term continue board meeting follow annual meeting stockholder elect oneyear term successor elect executive officer serve pleasure board director current position age employment history past year lamberto andreotti executive vice president president worldwide chief executive officer director pharmaceutical division company executive vice member senior management team president chief operating officer worldwide pharmaceutical division company executive vice president chief operating officer president chief operating officer director company present chief executive officer director company charle bancroft vice president finance worldwide pharmaceutical chief financial officer division company member senior management team present chief financial officer company joseph c caldarella vice president corporate controller present senior vice president corporate controller senior vice president corporate controller beatrice cazala president emea worldwide medicine international senior vice president commercial operation president emea asia pacific worldwide medicine president global commercialization europe international emerge market president global commercialization president europe member senior management team present senior vice president commercial operation president global commercialization europe emerge market john e celentano president health care group division company senior vice president human resource public senior vice president strategy productivity affairs philanthropy transformation member senior management team president emerge market asia pacific present senior vice president human resource public affair philanthropy francis cuss mb bchir frcp senior vice president discovery exploratory clinical senior vice president research development member senior management team present senior vice president research research development brian daniels md senior vice president global clinical development research senior vice president global development development division company medical affair present senior vice president global development medical member senior management team affair table content carlo de notaristefani president technical operation worldwide president technical operation global support pharmaceutical division company function present president technical operation global support member senior management team function anthony c hooper president pharmaceuticals worldwide pharmaceutical senior vice president commercial operation group division company president japan intercontinental president americas member senior management team present senior vice president commercial operation president japan intercontinental sandra leung vice president corporate secretary acting general general counsel corporate secretary counsel member senior management team present general counsel corporate secretary jeremy levin dphil mb bchir global head business development strategic alliance senior vice president strategy alliances member executive committee novartis institute biomedical transaction research member senior management team senior vice president external science technology license senior vice president strategic transaction present senior vice president strategy alliance transactions elliott sigal md phd present executive vice president chief scientific officer executive vice president chief scientific officer president research development president research development member senior management team table content ii item market registrant common stock stockholder matter market price bristolmyer squibb common preferred stock trade new york stock exchange nyse symbol bmy quarterly summary high low market price present high low high low common quarter second quarter quarter fourth quarter prefer quarter second quarter quarter fourth quarter quarter observable trade company prefer stock holder common stock number record holder common stock december number record holder base actual number holder register book date include holder share street name person partnership association corporation entity identify security position listing maintain depository trust company dividend board director declare follow dividend share pay quarter indicate common prefer quarter second quarter quarter fourth quarter december board director declare quarterly dividend share common stock pay february shareholders record january board director declare quarterly dividend share prefer stock payable march shareholders record february table content issuer purchase equity security follow table summarize surrender repurchase equity security month period end december total number share approximate dollar value average price purchase share total number pay publicly announce purchase period share purchaseda sharea plan programsb plan programsb dollar million share datum january february march month end march april june month end june july august september month end september october november december month end december month end december difference total number share purchase total number share purchase publicly announce program share common stock withhold employee restrict stock award order satisfy applicable tax withholding obligation b announce board director authorize purchase billion common stock repurchase program expiration date expect place year board director terminate program previously announce june pursuant billion common stock authorize purchase approximately billion remain repurchase table content item select financial datum year financial summary amount million share datum income statement dataa net sale earning continue operation income taxis net earning continue operation attributable bristolmyer squibb company net earning continue operation common share attributable bristolmyer squibb company basic diluted average common share outstanding basic dilute dividend pay bms common preferred stock dividend declare common share financial position datum december total asset cash cash equivalent marketable securitiesb longterm debt equity recognize item affect comparability result discussion item year item management discussion analysis financial condition result operationsexpense b marketable security include current noncurrent asset table content item management discussion analysis financial condition result operation executive summary bristolmyers squibb company refer bristolmyer squibb bms company global biopharmaceutical company consist global pharmaceuticalbiotechnology international consumer medicine business mission discover develop deliver innovative medicine help patient prevail disease license manufacture market distribute sell pharmaceutical product continue execute stringofpearl strategy acquisition zymogenetics inc zymogenetics october collaboration agreement enter year meet productivity transformation initiative pti objective implement strategic process design achieve culture continuous improvement launch kombiglyze saxagliptin metformin united states treatment type diabete adult key product pipeline advancement yervoy ipilimumab dapagliflozin eliquis apixaban baraclude entecavir sprycel dasatinib orencia abatacept receive warning letter manati puerto rico facility voluntarily recall certain lot avalide irbesartan hydrochlorothiazide puerto rican canadian mexican argentinean market repurchase million principal value high interest rate debt tender offer announce billion share repurchase program million share repurchase highlight follow table summary financial highlight year end december dollar million share datum net sale segment income net earning continue operation attributable bms net earning discontinue operation attributable bms net earning attributable bms dilute earning share continue operation attributable bms nongaap dilute earning share continue operation attributable bms cash cash equivalent marketable security net sale worldwide net sale increase primarily growth key product include plavix clopidogrel bisulfate virology portfolio include baraclude sustiva efavirenz franchise reyataz atazanavir sulfate orencia sprycel sale recently launch onglyza saxagliptin kombiglyze net sale increase prior year despite unfavorable impact increase medicaid rebate healthcare reform reduction contractual share abilify aripiprazole net sale extension commercialization manufacturing agreement otsuka pharmaceutical co ltd otsuka decline sale mature brand strategic divestiture generic competition avalide recall government austerity measure europe reduce health care cost segment income increase segment income attribute net sale growth key product efficient reduced spending marketing selling administrative reduce promotional spending certain key brand coincide product life cycle table content increase partially offset reduce equity income impact generic competition international plavix sale international partnership sanofi increase research development spending support mature pipeline possible launch new product net earning continue operation attributable bristolmyer squibb company decrease primarily attribute unfavorable impact specify item affect comparability result include million charge relate impairment loss sale manufacturing operation million tax charge attribute taxable income earning foreign subsidiary previously consider permanently reinveste offshore gain million prior year sale certain mature brand decrease partially offset reduced upfront licensing milestone payment million litigation settlement charge increase segment income net earning discontinue operation attributable bristolmyer squibb company complete splitoff mead johnson result aftertax gain approximately billion result mead johnson business relate gain include discontinue operation dilute earning share continue operation dilute earning share ep continue operation increase lower average outstanding common share attribute year impact million share reduction result december mead johnson splitoff common stock repurchase million share stock repurchase program announce nongaap financial measure include nongaap earning continue operation relate eps information adjust exclude certain cost expense gain loss specify item nongaap dilute ep continue operation increase adjust specify item million million detailed listing specify item information reconciliation nongaap financial measure specify item nongaap financial measure cash cash equivalent marketable security source cash cash equivalent marketable security include billion generate operating activity primary nonoperating use cash cash equivalent marketable security include dividend payment billion debt repurchase mean tender offer million acquisition zymogenetic million common stock repurchase million capital expenditure million business environment conduct business primarily pharmaceuticalbiotechnology industry highly competitive subject numerous government regulation competitive factor significantly affect sale product include product efficacy safety price costeffectiveness marketing effectiveness market access product label quality control quality assurance manufacturing operation research development new product successfully compete business healthcare industry demonstrate product offer medical benefit cost advantage new product introduction compete product market therapeutic category addition potential competition new product competitor introduce future manufacture brand product price high generic product generic competition lead challenge globally pharmaceuticalbiotechnology industry majority innovative product commercial value usually realize period product market exclusivity product lose exclusivity long protect patent subject new compete product form generic brand exclusivity loss lose major portion product sale table content short period time competitor seek approval biological product biologic license application bla file safety efficacy datum address challenge biologics manufacturing involve complex process costly traditional pharmaceutical operation new healthcare legislation enact describe fully abbreviate path regulatory approval generic version biological product new path approval biosimilar product healthcare legislation significantly affect regulatory data exclusivity biological product new legislation provide regulatory mechanism allow regulatory approval biologic drug similar generic copy innovative drug basis extensive datum require bla possible time reasonably assess impact new biosimilar legislation company globally healthcare industry subject governmentimposed regulation authorize price price control continue impact net sale march government enact healthcare reform legislation sign law patient protection affordable care act hr reconciliation bill contain package change healthcare bill new legislation make extensive change current system healthcare insurance benefit intend broaden coverage reduce cost bill significantly change americans receive healthcare coverage pay significant impact company particular company pharmaceutical industry healthcare relate industry include bms experience continue experience additional financial cost certain change business new healthcare law provision effective example minimum rebate medicaid drug sale increase percent percent medicaid rebate extend drug riskbase medicaid manage care plan addition extend discount certain critical access hospital cancer hospital cover entity require expansion b drug pricing program public health service act provide percent discount brandname drug patient medicare coverage gap refer donut hole pay annual nontaxdeductible fee federal government base allocation market share brand prior year sale certain government program include medicare medicaid department veterans affairs department defense tricare fee classify financial reporting purpose operate expense new discount new pharmaceutical company fee healthcare reform law include related regulation medicare coverage gap manage medicaid expansion public health service b program historical claim experience subject additional change estimate high rebate medicaid medicaid manage care plan reduce net sale million pretax income million year end december recognize onetime tax charge million quarter elimination tax deductibility portion retiree healthcare cost eps impact healthcare reform incremental yearoveryear basis expect healthcare reform additional negative impact earning share approximately estimate include expect reduction net sale approximately million new discount associate medicare donut hole coverage gap increase marketing sale administrative expense approximately million new annual nontaxdeductible pharmaceutical company fee aggregate financial impact healthcare reform year depend number factor include limited pende implementation guidance potential change sale volume eligible new rebate discount fee impact cost sharing arrangement certain alliance partner positive impact net sale expect increase number people healthcare coverage potentially occur future expect early market outside operate environment governmentmandate costcontainment program regulatory body group exert downward pressure pricing pricing freedom limited uk instance operation profit control plan germany operation reference price system company face significant delay market access new product year elapse drug approval new medicine available country growth manage care organization mcos play large role competition surround healthcare industry mco seek reduce healthcare expenditure participant make volume purchase enter longterm contract negotiate discount pharmaceutical provider market potential create large pool participant marketing prescription drug mcos important strategy company compete inclusion mco formulary generally successful major product include believe development manage care industry include continued consolidation continue downward pressure price pharmaceutical biotechnology production process complex highly regulate vary widely product product shift add manufacturing capacity lengthy process require significant capital expenditure regulatory approval biologic manufacturing involve complex process traditional pharmaceutical operation biologic large percentage product portfolio continue arrangement thirdparty manufacturer substantial investment increase internal capacity produce biologic commercial scale investment new stateoftheart manufacturing facility production biologic devens massachusetts expect submit site regulatory approval late table content maintain competitive position market strive uphold position dependent success discover develop deliver innovative costeffective product help patient prevail disease subject number significant pende lawsuit claim proceeding investigation possible time reasonably assess final outcome investigation litigation additional discussion legal matter item financial statementsnote legal proceeding contingency strategy past year transform company focus biopharmaceutical company transformation encompass area business operation focus portfolio product yielded continue yield substantial cost saving cost avoidance turn increase financial flexibility advantage attractive market opportunity arise expect loss exclusivity large product plavix time expect rapid precipitous material decline plavix net sale reduction net income operate cash flow event norm industry company experience loss exclusivity product recognize fact focus sustain business building robust foundation future plan achieve foundation continue support grow currently market product advance pipeline manage cost maintain improve financial strength strong balance sheet overall strategy build company strategy include focus emerge market stringofpearl optimize mature brand portfolio managing cost strategy emerge market develop commercialize innovative product key highgrowth market tailor approach market remain focused acquisition licensing strategy know stringofpearl transaction range collaboration license agreement acquisition company october complete acquisition zymogenetic enter restructure collaboration agreement company include eli lilly company lilly allergan inc exelixis inc exelixis oncolys biopharma inc continue core biopharmaceutical focus maximization value mature brand portfolio complete sale mature brand relate manufacturing facility country manage cost overall strategy execute pti realize billion annual cost saving cost avoidance base previous strategic plan future year meet goal billion cost saving cost avoidance annualize runrate basis achieve reduce general administrative operation simplify standardize outsource certain process service rationalize mature brand portfolio consolidated global manufacturing network eliminate complexity enhance profitability simplify geographic footprint implement efficient gotomarket model billion annual cost saving avoidance base previous strategic plan future year progress measure annualize runrate basis cost saving avoidance correlate directly result operation approximately billion annual cost saving cost avoidance relate marketing sell administrative expense relate cost product sell relate research development expense addition pti continue review cost structure intent create modernize efficient robust balance build competitive advantage secure innovative product plan future table content product pipeline development manage research development rd program portfolio basis invest resource stage research development early discovery latestage development continually evaluate portfolio rd asset ensure appropriate balance earlystage latestage program support future growth consider rd program enter phase iii development significant program constitute latestage development pipeline phase iii development program include investigational compound phase iii development initial indication market product phase iii development additional indication formulation spend program represent approximately annual rd expense individual investigational compound market product represent rd expense year expect latestage development program market latestage development program rd program potentially impact revenue earning year follow recent significant development market product latestage pipeline yervoy ipilimumab monoclonal antibody currently registrational process treatment metastatic melanoma study indication include lung cancer adjuvant melanoma hormonerefractory prostate cancer august food drug administration fda accept file review bla yervoy treatment adult patient advance melanoma previously treat application grant priority review designation fda fdas current state action date bla march yervoy marketing authorization application maa metastatic melanoma pretreate patient validate european medicine agency ema june company announce positive result phase iii randomize double blind study yervoy demonstrate overall survival significantly extend patient previouslytreate metastatic melanoma receive yervoy result statistically significant patient receive yervoy yervoy combination gp peptide vaccine compare patient receive control therapy gp fortyfour percent patient treat yervoy alive year compare percent patient treat control arm year percent patient treat yervoy alive compare percent patient treat control arm company announce positive result randomize phase ii study evaluate yervoy combination standard chemotherapy previously untreated patient advance nonsmall cell lung cancer study know meet predefine criterion significant improvement pvalue immunerelate progressionfree survival primary endpoint chemotherapy additional analysis progressionfree survival assess traditional modify world health organization criterion reach statistical significance dose schedule combine yervoy standard chemotherapy eliquis apixaban oral factor xa inhibitor phase iii development prevention treatment venous thromboembolic disorder stroke prevention atrial fibrillation strategic alliance pfizer inc pfizer base discussion fda agreement pfizer expect submit nda file include datum averroe trial aristotle trial assume positive outcome aristotle study indication stroke prevention atrial fibrillation cover broad spectrum patient single filing expect initial line result aristotle datum second quarter submit regulatory filing europe fourth quarter february company pfizer publish result averroe study eliquis new england journal medicine study demonstrate patient atrial fibrillation af expect demonstrate unsuitable vitamin k antagonist therapy warfarin eliquis statistically superior aspirin reduce composite stroke systematic embolism significant increase major bleed fatal bleed intracranial bleed significant difference risk hemorrhagic stroke eliquis aspirin study result show eliquis demonstrate superiority secondary efficacy endpoint reduce composite stroke systematic embolism mycordial infarction vascular death patient af compare aspirin december company pfizer publish result phase iii advance study eliquis new england journal medicine result show eliquis statistically superior mg oncedaily enoxaparin comparable rate bleed prevention venous thromboembolism follow total hip replacement surgery november company pfizer report phase iii appraise clinical trial patient recent acute coronary syndrome treat eliquis placebo addition mono dual antiplatelet therapy discontinue study stop early recommendation independent datum monitor committee clear evidence clinically important increase bleed patient randomize eliquis offset clinically meaningful reduction ischemic event table content august positive preliminary datum averroe trial present european society cardiology congress stockholm sweden preliminary datum demonstrate eliquis significantly reduce relative risk composite stroke systematic embolism percent significant increase major bleed fatal bleed intracranial bleed compare aspirin patient expect demonstrate unsuitable warfarin treatment minor bleed significantly increase june company pfizer announce phase iii averroes trial end early clear evidence efficacy interim analysis independent datum monitor committee show clinically important reduction stroke systematic embolism patient atrial fibrillation consider intolerant unsuitable warfarin therapy receive eliquis compare aspirin interim analysis demonstrate acceptable safety profile eliquis compare aspirin march result advance study publish lancet result present july show eliquis statistically superior mg daily enoxaparin reduce incidence venous thromboembolism patient undergo elective total knee replacement surgery accord advance study result study result show numerically low rate major clinically relevant nonmajor bleed patient treat eliquis compare treat enoxaparin result meet statistical significance march eliquis marketing authorization application prevention venous thromboembolic event adult patient undergo elective hip knee replacement validate european medicine agency nulojix belatacept fusion protein novel immunosuppressive activity target prevention solid organ transplant rejection fda issue complete response letter bla nulojix indication prophylaxis organ rejection preservation function allograft adult patient receive renal transplant use combination interleukin il receptor antagonist mycophenolic acid mpa corticosteroid december fda inform information submit nulojix complete response request additional information outline fda complete response letter prescription drug user fee act pdufa date fda action bla june fda advise resolve gmp issue raise fdas recent warning letter manufacturing facility manati puerto rico prior grant approval pende bla nulojix december notify fda manati facility inspectionready reinspection fda satisfied result delay approval nulojix filing item risk factorswe experience difficulty delay manufacture distribution sale product information nulojix subject clinical presentation relate kidney transplantation american transplant congress march fdas cardiovascular renal drug advisory committee vote recommend approval nulojix selective co simulation blocker prophylaxis acute rejection de novo kidney transplant patient fda bind recommendation advisory committee take advice consideration review new drug application february nulojix maa treatment prophylaxis organ rejection kidney transplant patient validate ema dapagliflozin oral sglt inhibitor phase iii development treatment diabete strategic alliance astrazeneca december company astrazeneca complete submission new drug application fda marketing authorization application european medicines agency dapagliflozin oncedaily oral therapy treatment adult patient type diabete maa validate european medicine agency january september company astrazeneca announce result randomize double blind phase iii clinical study dapagliflozin th european association study diabetes easd annual meeting demonstrate addition dapagliflozin glimepiride sulphonylurea therapy produce significant reduction glycosylate hemoglobin level hbac adult patient type diabete compare glimepiride study demonstrate dapagliflozin plus glimepiride achieve reduction secondary efficacy endpoint change total body weight oral glucose tolerance test ogtt fast plasma glucose fpg level baseline week compare placebo plus glimepiride people take dapagliflozin glimepiride able achieve target hbac compare patient take glimepiride drugrelate adverse affect report similar rate treatment group sign symptom report suggestive genital tract infection urinary tract infection frequently report dapagliflozin treat subject table content september company astrazeneca announce easd result randomize doubleblind phase iii clinical study adult type diabete inadequately control metformin therapy study demonstrate dapagliflozin noninferior compare glipizide improve hbac add exist metformin therapy week treatment period study demonstrate dapagliflozin plus metformin achieve significant reduction key efficacy secondary endpoint reduction total body weight baseline compare weight gain glipizide plus metformin therapy reduce number patient report hypoglycemic event frequencie adverse event adverse event study discontinuation comparable treatment group sign symptom report suggestive urinary tract genital infection common dapagliflozin treat subject june finding week phase iii clinical study publish demonstrate dapagliflozin administer monotherapy achieve statistically significant mean reduction mg mg dose daily primary endpoint glycosylate hemoglobin level treatmentnave adult patient newly diagnose type diabete compare placebo june result week phase iii clinical study present demonstrate addition dapagliflozin achieve reduction primary endpoint glycosylate hemoglobin level inadequately control type diabetes patient treat insulin oral antidiabete medication oad compare placebo plus insulin oad study demonstrate dapagliflozin achieve reduction secondary endpoint evaluate change total body weight baseline change baseline mean daily insulin dose change baseline fast plasma glucose plavix platelet aggregation inhibitor alliance sanofiaventis sanofi january company sanofi announce fda grant company additional sixmonth period exclusivity market plavix exclusivity plavix schedule expire march company sanofi announce revision prescribe information plavix include box warning box warning concern diminish effectiveness plavix patient genetic variation lead reduce formation active metabolite patient designate poor metabolizer represent accord prescribe information approximately white black chinese percentage poor metabolizer estimate approximately population base publish study revision addition update plavix labeling report november warning use prilosec omeprazole certain drug interfere plavix reduce effectiveness march company sanofi announce approval european commission dual antiplatelet combination tablet duoplavinduocover clopidogrel mg acetylsalicylic acid mg mg indicate prevention atherothrombotic event adult patient take clopidogrel acetylsalicylic acid asa avalide angiotensin ii receptor blocker treatment hypertension diabetic nephropathy sanofi alliance january bms partner sanofiaventis voluntarily recall certain lot avalide puerto rican canadian mexican argentinean market identification soluble form irbesartan find lot produce humacao puerto rico facility batch produce evansville indiana facility attribute manufacturing process change supply avalide market affect indefinitely total avalide sale country million working partner sanofiaventis identify possible solution issue include process adjustment alternate supply source abilify antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder strategic alliance otsuka february company otsuka announce fda approve abilify adjunct mood stabilizer lithium valproate maintenance treatment bipolar disorder reyataz protease inhibitor treatment hiv february fda approve update labeling reyataz include dose recommendation hivinfecte pregnant woman hiv combination therapy treatment recommend adult dose reyataz mg boost mg ritonavir achieve minimum plasma concentration hour postdose trimester pregnancy comparable observe historically hivinfecte adult post partum period atazanavir concentration increase dose adjustment necessary patient monitor month delivery table content baraclude oral antiviral agent treatment chronic hepatitis b october fda approve supplemental new drug application baraclude treatment chronic hepatitis b adult patient decompensate liver disease sprycel oral inhibitor multiple tyrosine kinase indicate treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib meslylate firstline treatment adult philadelphia chromosomepositive chronic myeloid leukemia chronic phase sprycel strategic alliance otsuka december company announce sprycel mg daily receive marketing authorization european commission treatment adult patient newly diagnose philadelphia chromosomepositive chronic myeloid leukemia chronic phase december company otsuka announce nd annual meeting american society hematology month followup result phase iii dasision study sprycel firstline treatment adult philadelphia chromosomepositive chronic phase chronic myeloid leukemia consistent month datum sprycel demonstrate high fast rate complete cytogenetic response major molecular response compare imatinib october company otsuka announce fda approve sprycel mg daily treatment adult patient newly diagnose philadelphia chromosomepositive chronic myeloid leukemia chronic phase july company submit review japan supplemental new drug application sprycel treatment adult patient newly diagnose chronic myeloid leukemia june company otsuka announce phase iii study result sprycel mg daily demonstrate superior rate confirm complete cytogenetic response compare gleevec study show percent sprycel patient versus percent gleevec patient achieve confirm complete cytogenetic response rate months june company otsuka announce year followup result phase iii randomize openlabel doseoptimization study sprycel chronicphase chronic myeloid leukemia patient resistant intolerant gleevec year patient administer sprycel mg daily overall survival ci progressionfree survival ci fouryear safety datum study consistent previously report safety profile sprycel mg daily orencia fusion protein indicate rheumatoid arthritis december fda accept review supplemental biologic license application subcutaneous formulation orencia treatment adult patient moderate severe rheumatoid arthritis administer injection skin pdufa date august november company announce new phase iii clinical datum show weekly subcutaneous injection investigational formulation orencia follow single intravenous iv loading dose provide improvement disease activity similar improvement see monthly iv administration orencia patient moderate severe rheumatoid arthritis july japanese ministry health labour welfare approve japanese new drug application orencia treatment adult rheumatoid arthritis inadequate response exist treatment july european commission approve new indication orencia combination methotrexate mtx treatment moderate severe rheumatoid arthritis adult patient respond inadequately previous therapy diseasemodifye anti rheumatic drug include mtx tnfalpha inhibitor january european commission approve orencia combination methotrexate treatment moderate severe active polyarticular juvenile idiopathic arthritis pediatric patient year age old insufficient response disease modify antirheumatic drug include tnf inhibitor table content onglyzakombiglyze treatment type diabete strategic alliance astrazeneca plc astrazeneca november fda approve kombiglyze xr saxagliptin metformin hcl extendedrelease treatment type diabete adult kombiglyze xr onceaday metformin extendedrelease xr plus dipeptidyl peptidase inhibitor combination tablet offer strong glycemic control glycosylate hemoglobin level fast plasma glucose postprandial glucose july marketing authorization application komgiblyze know kombiglyze fix dose combination onglyza metformin tablets treatment adult type diabete validate european medicine agency june company astrazeneca announce result week phase iiib study adult type diabete inadequate glycemic control metformin therapy plus diet exercise study find addition onglyza mg exist metformin therapy achieve primary objective demonstrate noninferiority compare addition titrate glipizide sulphonylurea exist metformin therapy reduce glycosylate hemoglobin level study find treatment onglyza mg plus metformin result statistically significant low proportion subject report hypoglycemic event statistically significant weight loss compare titrate glipizide plus metformin onglyza mg plus metformin result significantly small rise week hbac week week compare titrate glipizide plus metformin june company astrazeneca announce result week phase iii study onglyza initial combination therapy metformin produce longterm glycemic improvement measure hbac level treatmentnave adult type diabete mellitus inadequately control diet exercise compare treatment investigational mg dose onglyza metformin study demonstrate high number patient able achieve american diabetes association recommend glycosylate hemoglobin level target onglyza metformin initial combination therapy compare monotherapy treatment week march company astrazeneca announce commencement saxagliptin assessment vascular outcome record patient diabete mellitus trial savortimi multicenter randomize doubleblind placebocontrolle phase iv study evaluate treatment onglyza adult type diabete patient cardiovascular risk factor year study follow approximately patient type diabete history previous cardiovascular event multiple risk factor vascular disease include patient renal impairment necitumumab imcf investigational anticancer agent strategic alliance lilly january company lilly announce enrollment stop phase iii inspire study necitumumab firstline treatment advanced nonsmall cell lung cancer trial evaluate addition necitumumab combination alimta pemetrexed injection cisplatin decision stop enrollment follow independent datum monitor committee dmc recommendation new recently enrol patient continue treatment trial safety concern related thromboembolism experimental arm study dmc note patient receive cycle necitumumab appear low ongoing risk safety concern patient choose remain trial inform additional potential risk investigator continue assess patient cycle determine potential benefit treatment necitumumab continue study phase iii trial name squire study evaluating necitumumab potential treatment different type lung cancer call squamous nonsmall cell lung cancer combination gemzar gemcitibane hcl injection cisplatin independent dmc recommend trial continue safety concern observe xl june company terminate development collaboration exelixis experimental cancer drug xl right return exelixis table content result operation result continue operation exclude result relate mead johnson business prior splitoff december convatec business prior divestiture august medical imaging business prior divestiture january business segregate continue operation include discontinue operation year present discontinued operation result continue operation follow year end december change change dollar million vs vs net sale total expense earning continue operation income taxis net sale provision income taxis effective tax rate net earning continue operation net sale attributable noncontrolle interest net sale attributable bristolmyer squibb company net sale net sale composition change net sale follow year end december vs vs net sale analysis change analysis change total foreign total foreign dollar million change volume price exchange change volume price exchange nonus total net sale net sale growth attribute increase volume high average net selling price impact price increase take partially offset increase medicaid rebate attribute healthcare reform reduction contractual share abilify net sale effective january plavix abilify represent total net sale respectively plavix contribute total net sale growth drive primarily high average net selling price abilify net sale decrease change abilify collaboration agreement plavix abilify represent total net sale respectively plavix contribute total net sale growth drive high average net selling process increase demand abilify contribute total net sale growth drive increase demand key product contribute net sale growth international net sale international net sale remain relatively flat low average net selling price offset increase volume slight favorability foreign exchange low average net selling price primarily attribute government austerity measure europe reduce health care cost table content international sale volume reflect increase net sale baraclude hiv portfolio sprycel abilify orencia decrease net sale mature brand attribute divestiture generic competition decrease net sale plavix avaproirbesartanavalide attribute increase generic competition international net sale decrease include negative impact foreign exchange partially offset factor impact sale growth report international net sale include copromotion sale report alliance partner sanofi plavix avaproavalide decrease generic competition net sale mature brand business divest represent approximately total net sale year detail domestic international key product net sale discuss general business seasonal information pharmaceutical prescriber demand reference table estimated endus demand set forth comparison change net sale estimate total prescription growth retail mail order customer certain key pharmaceutical new product nonu net sale categorize base location customer recognize revenue net sale adjustment arrive net sale report consolidated statement earning adjustment refer grosstonet sale adjustment describe critical accounting policy reconciliation gross sale net sale significant category grosstonet sale adjustment follow year end december dollar millions gross sale grosstonet sale adjustment chargeback related government program cash discount manage healthcare rebate contract discount medicaid rebate sale return adjustment total grosstonet sale adjustment net sale activity end balance significant category grosstonet sale reserve adjustment follow manage healthcare rebate chargeback woman relate infant government cash contract medicaid sale child dollar million program discount discount rebate return adjustment wic rebate total balance january provision relate sale current period provision relate sale prior period return payment impact foreign currency translation discontinue operation balance december provision relate sale current period provision relate sale prior period return payment impact foreign currency translation balance december table content grosstonet sale adjustment percentage gross sale primarily function gross sale trend change sale mix contractual legislative discount rebate grosstonet sale adjustment increase overall primarily attribute enactment healthcare reform expect future increase grosstonet sale adjustment relate healthcare reform discuss executive summarybusiness environment specifically medicaid rebate increase change minimum rebate drug sale extension medicaid rebate rate drug sell riskbase medicaid manage care organization manage healthcare rebate contract discount increase mainly increase sale chargeback relate government program increase increase sale additional rebate require certain european country attribute government austerity measure sale return decrease primarily overall reduce provision mature brand partially offset million charge estimate return associate avalide recall adjustment increase overall additional rebate require certain product sell europe attribute government austerity measure high discount increase rebate coupon program grosstonet sale adjustment increase specifically manage healthcare rebate contract discount increase primarily high plavix medicare sale increase contractual discount rate sale return decrease primarily low provision pravachol zerit partially offset increase provision sprycel mature brand drive high anticipate sale return medicaid rebate include refund net overpayment medicaid rebate million year period center medicare medicaid services policy group approve revise calculation table content net sale key product represent total net sale follow table present international net sale key product percentage change prior period foreign exchange impact compare prior period commentary detail reason significant variance key product provide change attributable year end december change foreign exchange dollar million vs vs vs vs key product plavix clopidogrel bisulfate nonus total avaproavalide irbesartanirbesartanhydrochlorothiazide nonus total abilify aripiprazole nonus total reyataz atazanavir sulfate nonus total sustiva efavirenz franchise total revenue nonus total baraclude entecavir nonus total erbitux cetuximab nonus total sprycel dasatinib nonus total ixempra ixabepilone nonus na total orencia abatacept nonus total onglyzakombiglyze saxagliptinsaxagliptin metformin na na nonus na na total na na mature product nonu total change excess table content plavix platelet aggregation inhibitor alliance sanofi net sale increase primarily high average net selling price estimate total prescription demand decrease increase international net sale continue impact launch generic clopidogrel product eu country august negative impact net sale relate eu sale comarkete country equity net income affiliate relate share sale partnership sanofi europe asia expect continue erosion plavix net sale eu impact international net sale equity net income affiliate january company sanofi announce fda grant company additional sixmonth period exclusivity market plavix exclusivity plavix schedule expire item financial statementsnote legal proceeding contingenciesplavix litigation discussion plavix exclusivity litigation eu avaproavalide know eu aprovelkarvea angiotensin ii receptor blocker treatment hypertension diabetic nephropathy sanofi alliance international net sale decrease primarily decrease overall demand generic competition eu reduce supply avalide addition million sale return adjustment record result avalide recall estimate total prescription demand decrease net sale decrease primarily decrease overall demand estimate total prescription demand decrease international net sale increase primarily high average net selling price partially offset unfavorable foreign exchange impact abilify antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder strategic alliance otsuka net sale decrease primarily reduction contractual share net sale recognize increase medicaid rebate healthcare reform decrease partially offset high average net selling price increase overall demand net sale increase primarily increase overall demand new indication certain patient bipolar disorder major depressive disorder high average net selling price increase partially offset million amortization million extension payment otsuka april estimate total prescription demand increase international net sale increase increase prescription demand aid new bipolar indication second quarter eu offset unfavorable foreign exchange impact reyataz protease inhibitor treatment hiv net sale increase primarily higher estimate total prescription demand net sale increase higher estimate total prescription demand high average net selling price international net sale increase primarily high demand markets europe key driver june approval firstline treatment sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv include sustiva antiretroviral drug bulk efavirenz include combination therapy atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg product sell joint venture gilead net sale increase primarily higher estimate total prescription demand net sale increase primarily higher estimate total prescription demand high average net selling price international net sale increase primarily high demand partially offset unfavorable foreign exchange international net sale increase primarily continue demand generate launch atripla canada eu fourth quarter partially offset unfavorable foreign exchange impact baraclude oral antiviral agent treatment chronic hepatitis b worldwide net sale increase primarily continue strong demand international market continue implement global campaign raise awareness chronic hepatitis b overall market expansion effort table content erbitux monoclonal antibody design exclusively target block epidermal growth factor receptor express surface certain cancer cell multiple tumor type normal cell currently indicate use colorectal cancer head neck cancer erbitux strategic alliance lilly sell exclusively net sale continue decrease primarily low demand low average net selling price sprycel oral inhibitor multiple tyrosine kinase indicate treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib meslylate firstline treatment adult philadelphia chromosomepositive chronic myeloid leukemia chronic phase sprycel strategic alliance otsuka worldwide net sale increase primarily high demand previously launch market growth attribute recently launch market high average net selling price fourth quarter sprycel mg daily approve firstline treatment adult patient newly diagnose philadelphia chromosomepositive chronic myeloid leukemia chronic phase eu ixempra microtubule inhibitor treatment patient metastatic locally advanced breast cancer strategic alliance otsuka net sale continue remain flat orencia fusion protein indicate adult patient moderate severe rheumatoid arthritis inadequate response currently available treatment methotrexate antitumor necrosis factor therapy worldwide net sale increase primarily increase demand net sale impact high average selling price worldwide net sale increase primarily increase demand onglyzakombiglyze treatment type diabetes onglyza launch country quarter kombiglyze launch fourth quarter mature product include product lose exclusivity major market counter brand net sale remain relatively flat continued generic erosion certain product partially offset high average net selling price international net sale decrease continued generic erosion certain brand include taxol pravachol pravastatin sodium low average net selling price europe year year impact rationalization divestiture nonstrategic product portfolio low demand certain counter product net sale include million recothrom net sale product acquire zymogenetic acquisition october item financial statementsnote acquisition detail estimate prescription change datum provide report include information retail mail order channel reflect information channel hospital home healthcare clinic federal facility include va hospital longterm care quarter change service provider prescription data wolter kluwer health inc wk supplier market research audit datum pharmaceutical industry external reporting purpose internal demand product prior prescription datum base generation prescription service version national prescription audit provide ims health im continuously seek improve quality estimate prescription change amount ultimate patientconsumer demand reviewing estimate calculation methodology process analyze internal thirdparty datum expect continue review refine methodology process calculation estimate continue review analyze party datum calculation estimate prescription datum base source prescription audit provide supplier product respective recordkeeping projection processes datum subject inherent limitation estimate base sampling include margin error table content change sprycel demand calculate base tablet sell retail mail order channel base datum obtain ims health im national sale perspective audit product im recordkeeping projection process datum subject inherent limitation estimate base sampling include margin error calculate estimate total prescription change weightedaverage basis reflect fact mail order prescription include great volume product supply compare retail prescription mail order prescription typically reflect day prescription retail prescription typically reflect day prescription calculation derive multiply mail order prescription datum factor approximate add retail prescription believe calculation estimate total prescription change base weightedaverage approach provide superior estimate total prescription demand retail mail order channel use methodology internal demand report estimate endus demand follow table set forth key product sell year end december total net sales year ii change report net sale year iii estimate total prescription change retail mail order channel calculate base party datum weightedaverage basis iv month inventory hand wholesale distribution channel year end december december change change month total net sale net sale total prescription hand dollar million wk wk im plavix avaproavalide abilify reyataz sustiva franchisea baraclude erbituxb na na na sprycel ixemprab na na na orenciab na na na onglyza kombiglyzec na na na na sustiva franchise total revenue include sale sustiva revenue bulk efavirenz include combination therapy atripla month hand relate sustiva b erbitux ixempra orencia parenterally administer product prescriptionlevel datum physician write prescription product c onglyza launch august kombiglyze launch fourth quarter onglyza month inventory hand december kombiglyze month inventory hand december support initial product launch change excess pursuant securities exchange commission sec consent order describe sec consent order monitor level inventory hand wholesaler distribution channel outside direct customer distribution channel obligate disclose product level inventory excess month hand expect demand subject de minimis exception product estimate level inventory distribution channel excess month hand december international product estimate level inventory distribution channel excess month hand september kombiglyze month inventory hand support initial product launch inventory nominal expect work time demand new product increase post launch dafalgan analgesic product sell principally europe month inventory hand direct customer compare month inventory hand december level inventory hand primarily september launch new dosage france fervex cold flu product month inventory hand internationally direct customer compare month inventory hand december level inventory hand primarily lower expect demand table content videx antiviral product month inventory hand internationally direct customer compare month inventory hand december level inventory hand primarily government purchasing pattern brazil principen antibiotic product month inventory hand direct customer compare month inventory hand december increase level inventory low demand reenforcement antibiotic law mexico require prescription antibiotic product sell exclusively wholesaler distributor generally determine month hand estimate inventory level product hand outmovement provide large wholesaler account approximately total gross sale product provide distributor factor influence estimate include generic competition seasonality product wholesaler purchase light increase wholesaler list price new product launch new warehouse opening wholesaler new customer stocking wholesaler addition estimate calculate thirdparty datum impact recordkeeping process business outside significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely case direct customer product level inventory ultimate patientconsumer demand outmovement datum exist available develop variety methodology estimate datum include factor historical sale direct customer thirdparty market research datum relate prescription trend endus demand accordingly rely variety method estimate direct customer product level inventory calculate month hand factor affect estimate include generic competition seasonality product direct customer purchase light price increase new product launch new warehouse opening direct customer new customer stocking direct customer expect direct customer purchase governmental bidding situation information require estimate month hand direct customer distribution channel nonus business year end december available prior file annual report disclose product level inventory excess month hand expect demand subject de minimis exception quarterly report form q geographic area general product available country world large market france canada japan italy spain germany china united kingdom net sale geographic area base location end customer follow net sale change total net sale vs vs dollar millions united states europe japan asia pacific canada latin america middle east africa emerge market total net sale discussion net sale increase net sale europe decrease primarily unfavorable foreign exchange impact decrease net sale certain mature brand divestiture increase generic competition plavix avaproavalide partially offset sale growth major european market abilify hiv portfolio baraclude sprycel onglyza orencia sale growth previously mention product temper continue fiscal challenge european country healthcare payer include government agency reduce expect continue reduce cost healthcare action directly indirectly impose additional price reduction support expand use generic drug measure include limited mandatory discount rebate price reduction reflect net sale net sale decrease primarily unfavorable foreign exchange impact decrease net sale certain mature brand divestiture increase generic competition plavix partially offset sale growth major european market hiv portfolio abilify baraclude sprycel orencia net sale japan asia pacific canada increase primarily favorable foreign exchange impact increase net sale baraclude sprycel partially offset decrease net sale certain mature brand divestiture generic competition net sale remain relatively flat decrease net sale certain mature brand unfavorable foreign exchange impact offset increase net sale baraclude sprycel table content net sale latin america middle east africa increase primarily increase net sale sprycel reyataz baraclude orencia favorable foreign exchange impact partially offset decrease net sale mature brand net sale decrease primarily unfavorable foreign exchange impact decrease net sale certain mature brand partially offset increase net sale reyataz orencia plavix emerge market brazil russia india china turkey net sale emerge market increase primarily favorable foreign exchange impact increase net sale baraclude sprycel abilify reyataz net sale increase primarily increase net sale baraclude sprycel partially offset unfavorable foreign exchange impact consist primarily sale supply agreement active pharmaceutical ingredient include temporary supply agreement facilitate recent divestiture manufacture facility continue supply agreement alliance partner net sale decrease primarily winddown temporary supply agreement relate manufacturing facility divestiture elimination bulk sale pharmaceutical ingredient previously manufacture latina italy facility divest reduce sale irbesartan bulk pharmaceutical ingredient alliance partner decline worldwide avaproavalide sale net sale increase primarily temporary supply agreement enter facilitate divestiture certain manufacturing facility pakistan egypt australia single country outside contribute total net sale expense expense change net sale vs vs dollar million cost product sell marketing sell administrative advertising product promotion research development acquire inprocess research development provision restructure litigation expense net equity net income affiliate gain sale imclone share incomeexpense total expense change excess cost product sell cost product sell consist material cost internal labor overhead own manufacturing site thirdparty processing cost supply chain cost change foreign currency forward contract offset manufacture relate asset liability denominate foreign currency essentially cost manage primarily global manufacturing organization refer technical operation addition discovery royalty attribute license product connection alliance amortization milestone payment occur regulatory approval include cost percentage net sale vary period result product mix price inflation cost attribute rationalization manufacturing site result accelerated depreciation impairment charge strand cost addition change foreign currency provide volatility give high percentage total cost denominate foreign currency decrease cost product sell percentage net sale primarily attribute favorable product mix price increase favorable foreign exchange partially offset reduction share abilify sale relate extended commercialization manufacturing agreement abilifyand collaboration fee pay otsuka sprycel ixempra oncology collaboration begin additional medicare rebate grant healthcare reform international price decrease related government austerity measure european economic crisis improvement cost product sell percentage net sale drive favorable foreign exchange high average net selling price favorable product mix realize manufacturing efficiency pti offset high manufacturing cost attribute inflation cost include manufacture rationalization charge million primarily relate implementation pti compare million rationalization charge recognize table content marketing sell administrative marketing sell administrative expense consist employee salary benefit cost thirdparty professional marketing fee outsource fee shipping handling cost expense attribute product manufacturing cost research development expense expense manage regional commercialization function global function finance law information technology human resource decrease primarily attribute reduction sale relate activity certain key product coincide respective life cycle prior year impact million funding payment bms foundation reduction abilify sale force otsuka establish sale force promotion abilify sprycel ixempra reduce project standardization implementation cost role new accounting human resource relate system overall efficiency gain pti continuous improvement initiative decrease result favorable foreign exchange impact efficiency gain pti advertising product promotion advertising product promotion expense consist related media sample direct consumer program decrease primarily attribute reduced spending promotion certain key product coincide product life cycle otsukas reimbursement certain abilify sprycel ixempra advertising product promotion expense partially offset increase spend onglyza launch pipeline product decrease attribute reduced spending promotion product near patent expiration favorable foreign exchange impact partially offset increase spend onglyza launch pipeline product research development research development expense consist internal salary benefit cost thirdparty grant fee pay clinical research organization supply facility cost total research development expense include cost discovery research preclinical development early lateclinical development drug formulation clinical trial medical support market product proportionate allocation enterprisewide cost appropriate cost expense include thirdparty licensing fee typically pay upfront regulatory contractual milestone meet certain expense share alliance partner base contractual agreement approximately expense manage global research development organization approximately total spend attribute development activity remainder attribute preclinical research activity expense vary period number reason include time upfront license milestone payment decrease primarily attribute timing upfront license milestone payment partially offset additional spending support mature pipeline compound obtain stringofpearl strategy upfront license milestone payment expense research development million primarily attribute exelixis allergan pdl biopharma inc million primarily attribute zymogenetic alder nissan million primarily attribute exelixis pdl biopharma inc kai pharmaceuticals inc increase attribute additional spending support mature pipeline compound obtain stringofpearl strategy offset favorable foreign exchange impact acquire inprocess research development charge relate acquisition kosan biosciences inc kosan provision restructure change provision restructure primarily attributable timing implementation certain pti continuous improvement initiative litigation expense net include million insurance reimbursement prior litigation partially offset additional reserve establish certain average wholesale price awp litigation expense primarily million security litigation settlement information item financial statementsnote legal proceeding contingency equity net income affiliate equity net income affiliate primarily related international partnership sanofi vary base international plavix net sale include partnership decrease attribute impact alternative salt form clopidogrel generic clopidogrel competition international plavix net sale commence additional information item financial statementsnote alliance collaboration table content gain sale imclone share gain sale imclone share attribute receipt approximately billion cash tender investment imclone item financial statementsnote alliance collaboration detail incomeexpense incomeexpense include year end december dollar million interest expense interest income impairment loss sale manufacturing operation lossgain debt repurchase ar impairment net foreign exchange transaction gainslosse gain sale product line business asset acquisition relate item income alliance partner pension curtailment settlement charge incomeexpense interest expense decrease year year primarily lower overall interest rate float rate debt amortization result termination interest rate swap debt outstanding repurchase interest income increase primarily high average cash cash equivalent marketable security balance high return continue diversification investment portfolio interest income decrease primarily low interest rate compare partially offset high average cash cash equivalent marketable security balance impairment loss sale manufacturing operation primarily attribute disposal manufacturing operation latina italy item financial statementsnote restructuring auction rate security ar impairment charge recognize severity duration decline value future prospect issuer ability intent hold security recover value value ars december million impact foreign exchange mainly foreign exchange hedge discontinue qualify cash flow hedge net foreign exchange transaction loss include million charge remeasurement venezuelan monetary asset devaluation bolivar net foreign exchange gain primarily sudden dramatic strengthen dollar second half generate significant gain foreign currency denominate transaction item financial statementsnote financial instrument gain sale product line businesse asset primarily relate sale mature brand include business indonesia australia business egypt acquisition relate item attribute acquisition zymogenetic medarex item financial statementsnote acquisition income alliance partner include income earn sanofi partnership amortization certain upfront license milestone receipt relate alliance pension settlementscurtailment primarily attribute amendment eliminate credit future benefit relate service pension plan participant amendment result curtailment charge million million respectively remainder charge result lump sum payment certain plan exceed sum plan interest cost service cost result acceleration portion previously defer actuarial loss activity drive pti certain divestiture additional charge recognize future particularly pension plan low threshold result elimination service cost item financial statement note pension postretirement postemployment liability detail table content specify item follow specify item affect comparability result period present item exclude segment result marketing year end december cost sell research provision product litigation income dollar million sell administrative development restructure expense expense total restructuring activity downsize streamline worldwide operation impairment loss sale manufacturing operation accelerate depreciation asset impairment shutdown cost pension curtailment settlement charge process standardization implementation cost total restructuring litigation charge net upfront licensing milestone payment iprd impairment acquisition relate item product liability charge total income taxis item outofperiod tax adjustment specify tax charge decrease net earning continue operation year end december cost marketing research provision product sell litigation income dollar million sell administrative development restructure expense expense total restructuring activity downsize streamline worldwide operation accelerate depreciation asset impairment shutdown cost pension curtailment settlement charge process standardization implementation cost gain sale product line business asset total restructure litigation charge bms foundation funding initiative loss sale investment upfront license milestone payment acquisition relate item debt repurchase product liability chargesinsurance recovery total income taxis item decrease net earning continue operation table content acquire marketing inprocess gain year end december cost sell research research provision sale product litigation imclone income dollar million sell administrative development development restructure expense share expense total restructuring activity downsize streamline worldwide operation accelerate depreciation asset impairment shutdown cost pension curtailment settlement charge process standardization implementation cost gain sale leaseback property termination lease contract gain sale product line business total restructure litigation settlement insurance recovery product liability upfront licensing milestone payment acquire inprocess research development ar impairment loss sale debt repurchase gain sale imclone share total income taxis item decrease net earning continue operation nongaap financial measure nongaap financial measure include nongaap earning continue operation relate eps information adjust exclude certain cost expense gain loss specify item information intend enhance investor overall understanding past financial performance prospect future example nongaap earning ep information indication baseline performance item consider reflective ongoing result addition information primary indicator use basis evaluate performance allocate resource set incentive compensation target planning forecast future period information intend consider isolation substitute net earning dilute eps prepared accordance gaap item gaap measure exclude purpose determine adjusted earning adjust measure charge relate implementation pti gain loss purchase sale business product line investment discontinue operation restructure exit cost accelerate depreciation charge asset impairment charge recovery relate significant legal proceeding upfront license milestone payment inlicense product achieve regulatory approval immediately expense iprd charge prior special initiative funding bristolmyers squibb foundation significant tax event detail list item exclude nongaap earning continue operation specify item similar charge gain item recognize prior period reasonably possible reoccur future period table content reconciliation gaap nongaap follow year end december year end december specify specify dollar million share datum gaap item nongaap gaap item nongaap net earning continue operation attributable bms earning attributable unvested restricted share net earning continue operation attributable bms diluted eps calculation average common share outstandingdilute diluted ep continue operation attributable bms income taxis effective income tax rate earning continue operation income taxis effective income tax rate low statutory rate decision permanently reinvest earning certain manufacturing operation ireland puerto rico switzerland offshore federal research development tax credit favorable tax rate ireland puerto rico grant schedule expire prior increase effective tax rate primarily million tax charge recognize fourth quarter result additional taxable income earning foreign subsidiary previously consider permanently reinveste offshore additional information item financial statementsnote income taxis discontinue operation december complete splitoff remain interest mead johnson mean exchange offer bms shareholder august complete divestiture convatec business cidron healthcare limited affiliate nordic capital fund vii avista capital partner lp avista january complete divestiture bristolmyers squibb medical imaging medical imaging avista item financial statementsnote discontinue operation noncontrolle interest noncontrolle interest primarily relate partnership sanofi territory cover america relate plavix net sale item financial statementsnote alliance collaboration increase noncontrolle interest correspond increase net sale plavix net earning discontinue operation attributable noncontrolle interest primarily relate publicly own portion mead johnson prior complete divestiture splitoff summary noncontrolle interest follow year end december dollar million sanofi partnership noncontrolle interestpretax income taxis net earning continue operation attributable noncontrolle interestnet taxis net earning discontinue operation attributable noncontrolle interestnet taxis net earning attributable noncontrolle interestnet taxis table content financial position liquidity capital resource net cash position december follow dollar million cash cash equivalent marketable securitiescurrent marketable securitiesnoncurrent total cash cash equivalent marketable security shortterm borrowing include current portion longterm debt longterm debt total debt net cash position maintain significant level work capital approximately billion december billion december pay billion dividend reacquire million aggregate principal value outstanding debt million mean tender offer acquire zymogenetic million repurchase million common stock future period expect cash generate operation exist cash cash equivalent marketable security borrowing capital market sufficient cover cash need work capital capital expenditure strategic alliance acquisition milestone payment dividend pay common stock debt repurchase rely shortterm borrowing meet liquidity need cash cash equivalent marketable security hold outside approximately billion billion december respectively utilize fund nonus operation repatriate taxis previously provide cash repatriation subject restriction certain jurisdiction subject withholding taxis cash cash equivalent marketable security hold billion december represent approximately total balance cash cash equivalent marketable security hold billion december increase result internal restructuring certain legal entity diversify investment portfolio acquire noncurrent marketable security include purchase corporate debt security investment subject change fair value result interest rate fluctuation market factor impact result operation investment policy place limit investment time maturity investment institution policy require investment highly rate corporate financial institution item financial statementsnote cash cash equivalent marketable security continue monitor potential impact deteriorate economic condition certain european country discuss geographic area relate impact prescription trend pricing discount creditworthiness customer ability collect outstanding receivables country currently believe condition material impact liquidity cash flow financial flexibility billion year revolve credit facility syndicate lender mature december extendable consent lender facility contain customary term condition include financial covenant ratio consolidate net debt consolidated capital exceed end quarter compliance covenant inception facility borrowing outstanding facility december additional source liquidity sell trade account receivables principally nonus government hospital customer primarily japan italy portugal spain party receivables sell nonrecourse basis approximate million million respectively sale agreement allow recourse event uncollectibility retain interest underlie asset sell credit rating moodys investor service moodys longterm shortterm credit rating currently prime respectively longterm credit outlook remain stable outlook standard poor sp longterm shortterm credit rating currently respectively longterm credit rating remain stable outlook fitch rating fitch longterm shortterm credit rating currently f respectively longterm credit rating change august stable negative outlook credit rating consider investment grade longterm rating designate low default risk somewhat susceptible adverse effect change circumstance economic condition shortterm rating designate strong capacity timely repayment table content cash flow follow discussion cash flow activity december dollar million cash flow provide byused operating activity invest activity financing activity operate activity cash flow operating activity represent cash receipt cash disbursement relate activity invest activity financing activity operate cash flow derive adjust net earning noncontrolle interest noncash operating item depreciation amortization impairment charge stockbase compensation charge gain loss attribute invest financing activity gain loss sale product line business change operate asset liability reflect time difference receipt payment cash associate transaction recognize result operation net impact change operate asset liability aggregate net cash outflow million cash inflow million million item include impact change receivables inventory defer income account payable income taxis receivablepayable operating asset liability discuss detail continue maximize operate cash flow work capital initiative design improve work capital item directly affect change sale volume receivables inventory account payable improvement drive action include nonrecourse factoring nonus trade receivables revise contractual payment term customer vendor enhance collection process supply chain initiative design optimize inventory level progress area monitor period component annual incentive plan follow summarize certain work capital component express percentage trail month net sale trail trail december month december month dollar million net sale net sale net trade receivables inventory account payable total change operate asset liability aggregate net cash outflow million include cash outflow receivables million primarily attribute increase sale cash outflow operate asset liability million primarily relate pension funding excess current year expense million partially offset increase rebate sale return million primarily increase medicaid rebate effective january agency administrative delay payment manage care organization cash inflow account payable million primarily attribute time vendor alliance payment cash inflow inventory million primarily relate work inventory balance change operate asset liability aggregate net cash inflow million include cash inflow account payable million primarily attribute timing payment vendor alliance impact work capital initiative discuss cash inflow receivables million primarily attribute additional factoring nonus trade receivables japan spain cash inflow defer income million mainly milestone payment receive pfizer million astrazeneca million partially offset amortization table content cash outflow operate asset liability million primarily relate pension funding excess current year expense million payment otsuka amortize reduction net sale extension period million change operate asset aggregate net cash inflow million include cash inflow income tax payablereceivable million include impact receipt million tax refund include interest relate prior year foreign tax credit carryback claim cash inflow account payable million primarily attribute time vendor alliance payment cash inflow inventory million primarily attribute utilization inventory build prior year new product launch strategic build exist product launch include new indication abilify cash inflow defer income million primarily receipt upfront license milestone payment alliance partner cash outflow account receivables million attribute increase sale cash outflow operate asset liability million primarily net litigation relate payment million attribute settlement certain pricing sale litigation accrue prior period pension funding excess current year expense million increase noncurrent inventory million investing activity net cash investing activity billion include net purchase marketable security billion purchase zymogenetics inc million capital expenditure million net cash investing activity billion include acquisition medarex billion net cash acquire million net purchase marketable security billion capital expenditure million mead johnson cash include splitoff million proceed sale business investment include business asiapacific region million australia million proceed sale genmab celldex security million net cash provide investing activity billion include proceed divestiture convatec billion medical imaging million proceed tender share imclone billion proceed sale leaseback paris france facility million proceed sale business include mature brand business egypt million capital expenditure million include expenditure associate construction biologic facility deven massachusetts acquisition kosan million financing activity net cash financing activity billion include dividend payment billion debt repurchase mean tender offer million common stock repurchase million net proceed exercise stock option million net proceed termination interest rate swap agreement million table content net cash financing activity million include dividend payment billion repayment mead johnson revolving credit facility million early extinguishment certain debt security million net proceed issuance mead johnson note billion revolve credit facility million net proceed mead johnson ipo million net proceed termination interest rate swap agreement million net proceed exercise stock option million net cash financing activity billion include dividend payment billion redemption float rate convertible senior debenture billion repayment note august million yen note million repurchase note million net proceed issuance note million note billion net proceed termination interest rate swap agreement million net proceed stock option exercise million reflect exercise few stock option decrease average stock price compare prior period dividend declare common share december declare quarterly dividend common share expect pay dividend year share decrease total dividend despite share increase primarily attribute million share reduction mead johnson splitoff dividend decision quarterly basis board director table content contractual obligation payment period contractual obligation december follow obligation expire period dollar million total later year shortterm borrowing longterm debt interest longterm debta operating lease purchase obligation uncertain tax positionsb longterm liability totalc include estimate future interest payment shortterm longterm debt security include accrue interest payable recognize consolidated balance sheet consist primarily accrual interest shortterm longterm debt accrual periodic cash settlement derivative net counterparty b uncertainty relate timing reversal uncertain tax position shortterm uncertain tax benefit provide table item financial statementsnote income taxis detail c table exclude future contribution pension postretirement postemployment benefit plan require contribution contingent numerous factor include minimum regulatory funding requirement fund status plan uncertainty future obligation exclude table contribution international plan expect million item financial statementsnote pension postretirement postemployment liability detail addition commit approximately billion aggregate potential future research development milestone payment party inlicense development program early stage milestone define milestone achieve phase iii clinical trial comprise billion total commit late stage milestone define milestone achieve post phase iii clinical trial comprise billion total commit payment agreement generally payable achievement certain developmental regulatory milestone specific timing predict addition certain royalty obligation calculate percentage net sale agreement provide salesbased milestone aggregate approximately billion obligate pay alliance partner achievement certain sale level discussion contractual obligation item financial statementsnote pension postretirement postemployment liability note short term borrowing longterm debt note financial instrument note lease sec consent order previously disclose august enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter settlement reach consent copy attach exhibit quarterly report form q period end september term consent agree subject certain define exception limit sale product sell direct customer include wholesaler distributor hospital retail outlet pharmacie government purchaser base expect demand amount exceed approximately month inventory hand make timely public disclosure change practice agree consent certain measure implement include establish formal review certification process annual quarterly report file sec b establish business risk disclosure group c retain outside consultant comprehensively study help reengineer accounting financial reporting process publicly disclose sale incentive offer direct customer purpose induce purchase product excess expect demand e ensure budget process give appropriate weight input come adequately document process establish companywide policy limit sale direct customer purpose comply consent policy include adoption procedure monitor limit sale direct customer accordance term consent procedure include governance process escalate appropriate management level potential question concern compliance policy timely resolution question concern addition compliance policy monitor regular basis maintain inventory management agreement imas pharmaceutical wholesaler account nearly total gross sale biopharmaceutical product current term ima wholesaler customer provide weekly information respect month hand productlevel inventory outmovement product table content large wholesaler currently account approximately total gross sale biopharmaceutical product inventory information receive wholesaler internal information estimate month hand product level inventory wholesaler estimate month hand product inventory level biopharmaceutical businesss wholesaler customer large wholesaler extrapolate month hand calculate large wholesaler contrast biopharmaceutical business outside significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely accordingly rely variety method estimate month hand product level inventory business unit believe abovedescribe procedure provide reasonable basis ensure compliance consent recently issue accounting standard item financial statementsnote accounting policy discussion impact relate recently issue accounting standard critical accounting policy prepare financial statement conformity accounting principle generally accept preparation financial statement conformity generally accept accounting principle gaap require use estimate assumption affect report amount asset liability include disclosure contingent asset contingent liability date financial statement report amount revenue expense report period critical accounting policy important financial condition result operation require difficult subjective complex judgment management application result need estimate effect matter inherently uncertain new discount healthcare reform law medicare coverage gap manage medicaid expansion public health service b program require additional assumption lack historical claim experience addition new pharmaceutical company fee estimate subject external datum calculation base company relative share industry result uncertainty factor surround estimate judgment preparation consolidated financial statement actual result vary estimate accounting policy discuss audit committee board director revenue recognition accounting policy revenue recognition substantial impact report result rely certain estimate require difficult subjective complex judgment management recognize revenue title substantially risk reward ownership transfer customer generally occur date shipment net grosstonet sale adjustment discuss involve significant estimate judgment discussion revenue recognition item financial statementsnote accounting policiesrevenue recognition sale rebate return accrual grosstonet sale adjustment follow significant category grosstonet sale adjustment chargeback manage healthcare rebate contractual discount medicaid rebate cash discount sale return adjustment involve significant estimate judgment require use information external source net sale reconciliation gross sale net sale significant category grosstonet sale adjustment chargeback relate government program business participate program government entity significant department defense department veteran affair party include cover entity b drug pricing program pricing product extend wholesaler list price participate entity entity purchase product wholesaler low program price wholesaler charge difference acquisition cost low program price account chargeback reduce account receivable equal estimate chargeback claim attributable sale determine estimate chargeback primarily base historical experience program chargeback current contract price program consider chargeback payment level inventory distribution channel claim processing time lag adjust reduction account receivable periodically quarter reflect actual experience table content cash discount certain country offer cash discount generally approximate sale price incentive prompt payment account cash discount reduce account receivable discount consider payment performance adjust accrual reflect actual experience manage healthcare rebate contract discount offer rebate discount manage healthcare organization manage prescription drug program medicare advantage prescription drug plan cover medicare drug benefit addition commercial plan globally contract counterpartie hospital group purchasing organization begin rebate medicare program include discount company brandname drug patient fall medicare coverage gap addition accrue rebate department defense tricare retail pharmacy refund program account manage healthcare rebate contract discount establish accrual equal estimate manage healthcare rebate contractual discount attributable sale determine estimate manage healthcare rebate contractual discount accrual primarily base historical experience rebate discount current contract price consider sale performance product subject manage healthcare rebate contract discount level inventory distribution channel adjust accrual periodically quarter reflect actual experience medicaid rebate business participate state government medicaid program certain qualify federal state government program discount rebate provide participate state local government entity discount rebate provide program include medicaid rebate accrual consider medicaid rebate purpose discussion retroactive january minimum rebate medicaid drug sale increase medicaid rebate extend drug riskbase medicaid manage care plan begin march account medicaid rebate establish accrual equal estimate medicaid rebate claim attributable sale determine estimate medicaid rebate accrual primarily base historical experience medicaid rebate expansion prospective basis participation nonmandatory aspect qualify federal state government program legal interpretation applicable law relate medicaid qualify federal state government program new information change medicaid program regulation guideline impact rebate consider outstanding medicaid claim medicaid payment level inventory distribution channel adjust accrual periodically quarter reflect actual experience sale return account sale return establish accrual equal estimate sale recognize related product expect return return establish product determine estimate sale return accrual primarily base historical experience sale return consider factor impact sale return factor include level inventory distribution channel estimate shelf life product recall product discontinuance price change competitive product introduction generic product introduction competitive new product instance expect precipitous decline demand follow loss exclusivity consider factor adjust accrual periodically quarter reflect actual experience event product recall product discontinuance consider reason impact action adjust sale return accrual appropriate taking account historical experience estimate level inventory distribution channel product discontinuance estimate continue demand sale return accrual new product estimate primarily base historical sale return experience similar product line product similar therapeutic category limit circumstance new product extension exist line product historical experience product similar therapeutic category reliably estimate expect return new product defer recognition revenue right return long exist develop sufficient historical experience estimate sale return consider shelf life new product determine adjustment sale return accrual appropriate shelf life connection new product tend short shelf life establish product develop optimal manufacturing process new product lengthen shelf life addition high launch quantity manufacture advance launch date ensure sufficient supply exist satisfy market demand case assess reduce shelf life estimate level inventory distribution channel project demand determine adjustment sale return accrual appropriate table content pharmaceutical company fee pharma fee beginning pay annual nontaxdeductible fee federal government base allocation market share brand prior year sale certain government program include medicare medicaid department veterans affairs department defense tricare pharma fee finalize preliminary funding base information oneyear lag pharma fee calculate base market datum company industry participant company visibility fee classify financial reporting purpose operate expense adjustment addition grosstonet sale adjustment describe grosstonet sale adjustment example offer sale discount significantly nonus business offer consumer coupon rebate business addition number country outside include certain major european country provide rebate government entity generally account grosstonet sale adjustment establish accrual equal estimate adjustment attributable sale generally determine estimate accrual grosstonet sale adjustment primarily base historical experience performance commitment government entity relevant factor include estimate level inventory distribution channel adjust accrual periodically quarter reflect actual experience use information external source use information external source estimate grosstonet sale adjustment estimate inventory wholesaler base project prescription demandbase sale product historical inventory experience analysis thirdparty information include write oral information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum internal information inventory information receive wholesaler product recordkeeping process exclude inventory hold intermediary sell retailer hospital effective january change service provider prescription datum wk supplier market research audit datum pharmaceutical industry project prescription demandbase sale biopharmaceutical product prior prescription datum base nextgeneration prescription service version national prescription audit provide im continue practice combine retail mail prescription volume retailequivalent basis use methodology internal demand forecast use information external source identify prescription trend patient demand average selling price estimate subject inherent limitation estimate rely thirdparty information certain thirdparty information form estimate reflect limitation include lags date thirdparty information generate date receive thirdparty information retirement benefit pension plan postretirement benefit plan account actuarial valuation key assumption calculate cost pension benefit discount rate expect longterm rate return plan asset consultation actuary evaluate select key assumption calculate cost pension benefit salary growth retirement turnover healthcare trend mortality rate base expectation actual experience appropriate determine assumption remeasurement date include december year calculate liability information date pension expense follow year depend assumption pension expense vary range outcome material effect report earning project benefit obligation future cash fund actual result give year differ estimate economic factor determine discount rate use yield high quality corporate bond coincide cash flow plan estimate payout citigroup pension discount curve determine discount rate plan plan pension expense determine weighted average discount rate present value benefit obligation december plan determine discount rate discount rate determine plan pension expense reduce expense increase approximately million assumed discount rate determine project benefit obligation december reduce project benefit obligation increase approximately million table content determine expect longterm rate return plan asset estimate return individual asset class input external advisor consider longterm historical return include actual performance compare benchmark similar investment plan pension expense determine expect longterm rate return plan asset expect longterm rate return plan asset determine plan pension expense reduce expense increase million detailed discussion retirement benefit item financial statementsnote pension postretirement postemployment liability business combination consolidate financial statement reflect acquire business completion acquisition asset acquire liability assume recognize date acquisition respective fair value excess purchase price estimate fair value net asset acquire recognize goodwill determine fair value intangible asset include iprd typically use income method method start forecast expect future net cash flow risk adjust base estimate probability technical regulatory success cash flow adjust present value apply appropriate discount rate reflect risk factor associate cash flow stream significant estimate assumption inherent income method method include timing project future cash flow time project cost develop iprd commercially viable product discount rate select measure risk inherent future cash flow assessment asset life cycle competitive trend impact asset include consideration technical legal regulatory economic barrier entry expect change standard practice indication address asset specific intangible asset follow approach utilize iprd value market participant view value preexist relationship acquiree consider term respective collaboration arrangement include cost profit sharing split project unit account typically global view consider potential jurisdiction indication january acquire iprd project initially capitalize consider indefinitelived asset subject annual impairment review occurrence certain event compound reach commercialization asset amortize expect useful life prior january amount allocate acquire iprd expense date acquisition technology relate specific platform value base expect annual number antibodie achieve early candidate nomination status technology commercial product value utilize multiperiod excessearning method income approach premise value intangible asset equal present value aftertax cash flow solely attribute intangible asset license value utilize discount cash flow method utilize estimate future riskadjuste milestone royalty payment project earn respective product estimate economic term compound development significant delay obtain marketing approval inability bring respective product market result related intangible asset partially fully impair commercialize product inability meet sale forecast result related intangible asset partially fully impair determine useful life intangible asset base period expect contribute future cash flow pertinent matter associate asset environment operate consider include legal regulatory contractual provision effect obsolescence demand competition economic factor amortization period intangible asset typically follow iprd commercialization patent life respective product license term respective license arrangement technology estimate life technology table content zymogenetics inc acquisition october acquire zymogenetics inc aggregate purchase price million million net cash acquire item financial statementsnote acquisition estimate fair value identifiable intangible asset million include million iprd project million assign pegylatedinterferon lambda currently phase iib development treatment hepatitis c million assign phase ii product million license attribute product stage development ultimate realization iprd project depend successful regulatory approval receive market factor relevant typical biopharmaceutical product million technology associate recothrom whollyowne commercialize product develop market use topical hemostat control moderate bleed surgical procedure amortize year life project cash flow utilize valuation assume initial positive cash flow commence shortly receipt expect regulatory approval subject trial result thing estimate occur number year project cash flow discount actual cash flow attribute project likely different assume medarex inc acquisition september acquire remain outstanding share medarex own approximately billion item financial statementsnote acquisition estimate fair value identifiable intangible asset billion include billion iprd billion assign yervoy fully human antibody currently phase iii development treatment metastatic melanoma fda accept filing review biologic license application yervoy pretreate advanced melanoma state action date march ongoing yervoy phase ii study lung cancer phase iii study adjuvant melanoma hormonerefractory prostate cancer ultimate realization yervoys asset value depend successful regulatory approval receive market factor typical biopharmaceutical product remain iprd assign project phase ii development project stage development generate medarex technology develop licensing partner generate milestone payment royalty commercialization million technology attribute technology platform produce high affinity fully human antibody use broad range therapeutic area include immunology oncology develop technology amortize expect useful life year million license attribute separate license arrangement receive regulatory approval license amortize expect useful life year project cash flow assume initial positive cash flow commence shortly receipt expect regulatory approval subject trial result thing approve potentially early project cash flow discount actual cash flow attribute project likely different assumed impairment goodwill goodwill tested annually impairment twostep process step identify potential impairment second step measure impairment loss goodwill consider impaired carrying reporting unit goodwill exceed estimate fair value biopharmaceutical segment include separate reporting unit base geography aggregate impairment testing purpose base recent annual impairment test complete quarter fair value goodwill substantially excess relate carrying value discussion goodwill acquire inprocess research development intangible asset item financial statementsnote accounting policiesgoodwill acquire inprocess research development intangible asset indefinitelive intangible asset include iprd indefinitelive intangible asset subject amortization test impairment annually frequently event change circumstance indicate asset impair consider factor include stage development table content current legal regulatory environment competitive landscape consider industry success rate bring developmental compound market iprd impairment charge occur future period recognize million charge relate medarex project cease development longlive asset periodically evaluate current fact circumstance indicate carry value depreciable asset hold recoverable circumstance determine exist estimate undiscounted future cash flow produce longlived asset appropriate grouping asset compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique include discount value estimate future cash flow report asset dispose low carrying value estimate net realizable value estimate future cash flow base reasonable supportable assumption projection require judgment change key assumption business prospect change market condition result impairment charge impairment charge longlive asset million million million discussion impairment longlive asset item financial statementsnote accounting policiesimpairment longlive asset million asset impairment charge recognize connection writedown asset fair value cost sell manufacturing operation latina italy meet hold sale criterion additional million charge recognize operation sell item financial statementsnote restructure additional information manufacturing operation evaluate impairment result low sale forecast facility depreciate expect useful life net carrying value approximately million december anticipate undiscounted cash flow attribute facility exceed net carrying value significant result impairment recognize expect cash flow estimate base current sale forecast expectation subject change base near long term production volume margin generate facility potential alternative future use lead future impairment marketable security investment company marketable security classify available sale report fair value change fair value report accumulate comprehensive income decline fair value consider temporary charge earning fair value determine base observable market quote valuation model assessment counterparty credit worthiness credit default risk underlie security overall capital market liquidity determine security otherthantemporarily impair typically consider severity duration decline future prospect issuer ability intent hold security recovery decline fair value determine credit relate charge earning transfer fair value level recognize begin report period average cost method determine realize gain loss sale available sale security realize gain loss include incomeexpense level investment include frs ar utilize valuation model include base expect cash flow stream collateral value include assessment counterparty credit quality default risk underlie security discount rate overall capital market liquidity valuation subject uncertainty difficult predict utilize considerable judgment estimation factor impact valuation include change credit rating security underlie asset support security rate default underlie asset underlie collateral value discount rate counterparty risk ongoing strength quality market credit liquidity discussion current noncurrent marketable security frs ar item financial statementsnote fair value measurement note cash cash equivalent marketable security account own company ability exercise significant influence equity method accounting share net income loss equity investment include equity net income affiliate consolidated statement earning investment fair market value fall carry value assess decline temporary consider intent ability hold investment market price market price fluctuation investment publicly trade share inability investee sustain earning capacity impairment loss recognize incomeexpense decline market value deem temporary table content contingency normal course business subject contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability tax matter recognize accrual contingency probable liability incur loss reasonably estimate estimate subject uncertainty difficult predict actual result vary estimate discussion contingency item financial statementsnote accounting policiescontingencie note income taxis note legal proceeding contingency income taxis valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative judgment subject change adjustment defer tax valuation allowance earning period assessment net defer tax asset billion billion december respectively net valuation allowance billion billion december respectively recognize defer tax asset december relate federal net operating loss carryforward million federal research development tax credit carryforward million net operating loss carryforward expire vary amount begin research development tax credit carryforward expire vary amount begin realization carryforward dependent generating sufficient domesticsource taxable income prior expiration realization assure believe likely defer tax asset realize provide taxis undistribute earning foreign subsidiary expect reinveste permanently offshore company complete internal restructuring certain legal entity contribute million tax charge recognize fourth quarter possible tax authority assert additional material tax liability arise restructure assertion occur company vigorously challenge assertion believe prevail assurance result prior mead johnson splitoff follow transaction occur internal spinoff mead johnson share own ii conversion mead johnson class b share class share iii conversion mead johnson company limited liability company transaction splitoff mead johnson exchange offer qualify taxexempt transaction internal revenue code base private letter ruling receive internal revenue service relate conversion mead johnson class b share class share outside legal opinion rely certain assumption representation covenant mead johnson future conduct business matter effect tax treatment exchange example current tax law generally create presumption exchange taxable mead johnson shareholders engage transaction result great change stock ownership year period begin year exchange offer establish exchange offer plan series relate transaction effect change ownership internal spinoff exchange offer determine qualify tax exempt transaction subject tax exchange taxable sale market value addition negative basis excess loss account ela investment stock mead johnson prior transaction receive opinion outside legal counsel effect likely eliminate ela transaction taxable income respect ela tax law area complex possible internal spinoff exchange offer tax exempt internal revenue code irs assert additional taxable income period respect ela expose additional taxis occur base understand internal revenue code opinion outside legal counsel tax reserve million establish reduce gain disposal mead johnson include discontinued operation agree certain tax relate indemnity mead johnson set forth tax sharing agreement example mead johnson agree indemnify potential tax effect result breach certain representation discuss certain transaction relate acquisition mead johnson stock asset agree indemnify mead johnson certain taxis relate business prior completion ipo create restructure facilitate ipo table content establish liability possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know discussion income taxis item financial statementsnote accounting policiesincome taxis note income taxis special note forwardlooke statement annual report include document incorporate reference write oral statement time time contain certain forwardlooking statement meaning section security act section e securities exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base current expectation involve inherent risk uncertainty include factor delay divert change cause actual outcome differ materially current expectation statement likely relate thing goal plan projection financial position result operation cash flow market position product development product approval sale effort expense performance result current anticipate product outcome contingency legal proceeding financial result base current expectation involve inherent risk uncertainty include internal external factor delay divert change year include important factor cautionary statement include annual report particularly item risk factor believe cause actual result differ materially forwardlooke statement believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date undertake obligation release publicly revision forwardlooke statement result new information future event table content item quantitative qualitative disclosure market risk expose market risk change currency exchange rate interest rate result certain derivative financial instrument available costeffective basis hedge underlie economic exposure primary net foreign currency translation exposure euro japanese yen canadian dollar british pound australian dollar mexican peso chinese renminbi foreign currency forward contract manage exposure instrument generally qualify cash flow hedge accounting treatment manage consolidated basis efficiently net exposure advantage natural offset derivative instrument interest rate risk management strategy derivative instrument principally comprise fixedto float interest rate swap generally qualify fairvalue hedge accounting treatment addition financial instrument include derivative subject counterparty credit risk consider overall fair value measurement derivative financial instrument trading purpose foreign exchange risk significant portion revenue earning cash flow expose change foreign currency rate use foreign currency forward contract manage foreign exchange risk primarily arise certain intercompany transaction designate derivative instrument foreign currency cash flow hedge appropriate addition expose foreign exchange transaction risk arise nonfunctional currency denominate asset liability earning denominate nonus dollar currency order manage risk use foreign currency forward contract offset exposure certain asset liability earning denominate certain foreign currency foreign currency forward contract designate hedge change fair value derivative recognize earning incomeexpense occur estimate appreciation underlie currency hedge level dollar december variable hold constant decrease fair value foreign exchange forward contract hold december million realize effect earning remain life contract expose translation risk nonus dollardenominate net asset order manage risk use nonus dollar borrowing hedge foreign currency exposure net investment certain foreign affiliate nonus dollar borrowing designate hedge net investment effective portion foreign exchange gain loss hedge recognize foreign currency translation component accumulate oci additional information item financial statementsnote financial instrument interest rate risk use interest rate swap interest rate risk management strategy interest rate swap principally fixedtofloate rate swap designate fairvalue hedge swap intend provide appropriate balance fix float rate debt estimate increase basis point shortterm longterm interest rate decrease fair value interest rate swap million exclude effect counterparty credit risk realize affect earning remain life swap marketable security subject change fair value result interest rate fluctuation market factor policy invest highly rate institution place limit time maturity investment individual institution estimate increase basis point interest rate general decrease fair value debt security portfolio approximately million credit risk periodically sell nonus trade receivables mean reduce collectability risk sale agreement provide recourse event uncollectibility retain interest underlie asset sell monitor investment counterpartie objective minimize concentration credit risk investment policy place limit time maturity investment individual counterparty policy require investment primarily highly rate corporate financial government government support institution use derivative instrument expose credit risk fair value derivative instrument contract positive expose credit risk counterparty fails perform fair value derivative instrument contract negative counterparty expose credit risk fail perform obligation require post collateral derivative table content contract liability position require counterpartie post collateral derivative asset position seek minimize credit risk derivative instrument enter transaction reputable financial institution policy diversify derivative counterpartie mitigate overall risk counterparty default additional information item financial statementsnote fair value measurement note cash cash equivalent marketable security note shortterm borrowing longterm debt note financial instrument table content bristolmyer squibb company consolidate statement earning dollar share million share datum item financial statement supplementary datum year end december earning net sale cost product sell marketing sell administrative advertising product promotion research development acquire inprocess research development provision restructure litigation expense net equity net income affiliate gain sale imclone share incomeexpense total expense earning continue operation income taxis provision income taxis net earning continue operation discontinue operation earning net taxis gain disposal net taxis net earning discontinue operation net earning net earning attributable noncontrolle interest net earning attributable bristolmyer squibb company amount attributable bristolmyer squibb company net earning continue operation net earning discontinue operation net earning attributable bristolmyer squibb company earning common share continue operation attributable bristolmyer squibb company basic diluted earning common share attributable bristolmyer squibb company basic dilute dividend declare common share accompany note integral consolidated financial statement table content bristolmyers squibb company consolidate statement comprehensive income retain earning dollar millions year end december comprehensive income net earning comprehensive incomeloss foreign currency translation foreign currency translation reclassify net earning business divestiture foreign currency translation hedge net investment derivative qualify cash flow hedge net taxis derivative qualify cash flow hedge reclassify net earning net taxis derivative reclassify net earning business divestiture net taxis pension postretirement benefit net taxis pension postretirement benefit reclassify net earning net taxis pension postretirement benefit reclassify net earning business divestiture net taxis available sale security net taxis available sale security reclassify net earning net taxis total comprehensive incomeloss comprehensive income comprehensive income attributable noncontrolle interest comprehensive income attributable bristolmyer squibb company retain earning retain earning january net earning attributable bristolmyer squibb company cash dividend declare retain earning december accompany note integral consolidated financial statement table content bristolmyers squibb company consolidated balance sheet dollar million share share datum december asset current asset cash cash equivalent marketable security receivables inventory defer income taxis prepaid expense total current asset property plant equipment goodwill intangible asset defer income taxis marketable security asset total asset liability current liability shortterm borrowing account payable accrue expense defer income accrue rebate return foreign income taxis payable dividend payable total current liability pension postretirement postemployment liability defer income foreign income taxis payable liability longterm debt total liability commitment contingency note equity bristolmyers squibb company shareholder equity prefer stock convertible series par value share authorize million share issue outstanding liquidation value share common stock par value share authorize billion share billion issue capital excess par value stock accumulate comprehensive loss retain earning cost treasury stock million common share million total bristolmyer squibb company shareholder equity noncontrolle interest total equity total liability equity accompany note integral consolidated financial statement table content bristolmyers squibb company consolidate statement cash flow dollar million year end december cash flow operating activity net earning adjustment reconcile net earning net cash provide operating activity net earning attributable noncontrolle interest depreciation amortization defer income tax expense stockbase compensation expense acquire inprocess research development impairment charge gain related divestiture discontinue operation gain sale imclone share gain change operate asset liability receivable inventory account payable deferred income foreign income taxis payable net cash provide operating activity cash flow invest activity proceed sale maturity marketable security purchase marketable security addition property plant equipment capitalize software proceed sale business property plant equipment investment proceed divestiture discontinued operation mead johnson cash splitoff purchase business net cash acquire proceed sale imclone share proceed sale leaseback property net cash inprovide investing activity cash flow financing activity shortterm debt repayment longterm debt borrowing longterm debt repayment interest rate swap termination issuance common stock excess tax benefit sharebase arrangement common stock repurchase dividend pay proceed mead johnson initial public offer net cash financing activity effect exchange rate cash cash equivalent decreaseincrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral consolidated financial statement table content note accounting policy basis consolidation consolidate financial statement prepare conformity united states generally accept accounting principle gaap include account bristolmyer squibb company refer bristolmyer squibb bms company control majorityowned subsidiary intercompany balance transaction eliminate material subsequent event evaluate disclose report issuance date codevelopment cocommercialization license arrangement enter party therapeutic area term include upfront licensing contingent payment arrangement assess determine term economic control entity require consolidation entity entity consolidated control mean majority voting interest refer variable interest entity arrangement material variable interest entity include associated codevelopment cocommercialization license arrangement determine exist reclassification certain prior year amount reclassify conform current year presentation use estimate preparation financial statement require use management estimate assumption base complex judgment significant assumption employ estimate determine fair value intangible asset restructuring charge accrual sale rebate return accrual include relate health care reform legal contingency tax asset tax liability stockbase compensation expense pension postretirement benefit include actuarial assumption note pension postretirement postemployment liability fair value financial instrument direct observable market quote inventory obsolescence potential impairment longlive asset allowance bad debt estimate apply revenue recognition policy new discount healthcare reform law medicare coverage gap manage medicaid expansion public health service b program require additional assumption lack historical claim experience addition new pharmaceutical company fee estimate subject external datum calculation base company relative share industry result actual result differ estimate result revenue recognition revenue recognize title substantially risk reward ownership transfer customer generally time shipment certain sale nonus business recognize date receipt purchaser note alliance collaboration discussion revenue recognition relate alliance revenue reduce time recognition reflect expect return estimate base historical experience business trend provision time revenue recognition discount rebate estimate sale allowance base historical experience update change fact circumstance include impact new legislation healthcare reform appropriate provision recognize reduction revenue limit circumstance new product extension exist line product historical experience product similar therapeutic category exist revenue defer right return long exist sufficient historical experience estimate sale return develop sale rebate return accrual sale rebate return accrual establish relate revenue recognize result reduction sale establishment liability accrual recognize base estimate proportion recognize revenue result rebate return chargeback accrual relate government program cash discount establish similar manner recognize reduction account receivable table content income taxis provision income taxis determine asset liability approach accounting income taxis approach defer taxis represent future tax consequence expect occur report amount asset liability recover pay provision income taxis represent income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis asset liability adjust change tax rate tax law change enact valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment cash cash equivalent cash cash equivalent consist treasury security government agency security bank deposit time deposit money market fund cash equivalent primarily highly liquid investment original maturity month time purchase recognize cost approximate fair value cash cash equivalent maintain foreign currency million december subject currency rate risk marketable security investment company marketable security classify available sale date purchase report fair value december fair value determine base observable market quote valuation model assessment counterparty credit worthiness credit default risk underlie security overall capital market liquidity decline fair value consider temporary charge earning consider temporary report component accumulate comprehensive income oci shareholder equity decline fair value determine credit relate charge earning average cost method determine realize gain loss sale available sale security investment own company ability exercise significant influence maintain account equity method accounting share net income loss equity investment include equity net income affiliate consolidated statement earning equity investment review impairment assess decline market value investment carry value temporary making determination factor evaluate determine loss value recognize include consideration intent ability hold investment market price market price fluctuation investment publicly trade share inability investee sustain earning capacity justify carry investment impairment loss recognize expense decline market value deem temporary inventory valuation inventory state low average cost market property plant equipment depreciation expenditure addition renewal improvement capitalize cost depreciation generally compute straightline method base estimate useful life relate asset estimate useful life major class depreciable asset follow building year machinery equipment fixture year impairment longlive asset current fact circumstance periodically evaluate determine carry value depreciable asset hold recoverable circumstance exist estimate undiscounted future cash flow generate longlived asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique include discount table content value estimate future cash flow asset dispose report low carrying value estimate net realizable value capitalize software certain cost obtain internal use software significant system project capitalize amortize estimate useful life software cost obtain software project significant expense incur business combination acquire business include consolidated financial statement obtain control acquire asset acquire liability assume recognize date acquisition respective fair value excess purchase price estimate fair value net asset acquire recognize goodwill business combination enter january legal cost audit fee business valuation cost business acquisition cost expense incur goodwill acquire inprocess research development intangible asset goodwill test impairment annually twostep process step identify potential impairment second step measure impairment loss goodwill impaired carrying reporting unit goodwill exceed estimate fair value biopharmaceutical segment include separate reporting unit base geography aggregate impairment testing purpose annual goodwill impairment assessment complete quarter subsequently monitor potential impairment remain quarter indicate impairment goodwill fair value inprocess research development iprd acquire business combination determine base present value research project project cash flow income approach future cash flow predominately base net income forecast project consistent historical pricing margin expense level similar product revenue estimate base relevant market size growth factor expect industry trend individual project life cycle life research project underlie patent determine fair value research project expect revenue adjust technical risk completion result cash flow discount rate approximating company weightedaverage cost capital iprd acquire january initially capitalize consider indefinitelived asset subject annual impairment review occurrence certain event review require determination fair value respective intangible asset fair value intangible asset carry value impairment loss recognize difference compound reach commercialization asset amortize expect useful life prior january amount allocate acquire iprd expense date acquisition patentstrademark license technology amortize straightline basis estimate useful life consider impaired net carry value exceed estimate fair value restructure restructuring charge recognize result action streamline operation rationalize manufacture facility judgment estimate impact restructuring plan include future termination benefit exit cost incur action place actual result vary estimate product liability accrual product liability establish undiscounted basis probable liability incur liability reasonably estimate base exist information accrual adjust periodically assessment effort progress additional information available receivables relate insurance thirdparty recovery product liability recognize undiscounted basis probable recovery realize contingency loss contingency legal proceeding claim occur wide range matter include government investigation shareholder lawsuit product environmental liability tax matter accrual recognize probable liability incur loss reasonably estimate gain contingency recognize realize table content derivative financial instrument derivative financial instrument principally management interest rate foreign currency exposure hold issue trading purpose derivative instrument recognize fair value change derivative fair value recognize earning specific hedge criterion meet derivative designate fair value hedge change fair value derivative hedge item attributable hedge risk recognize earning derivative designate cash flow hedge effective portion change fair value derivative report accumulate comprehensive income oci subsequently recognize earning hedge item affect earning cash flow classify consistent underlying hedged item derivative designate assign hedge forecast transaction specific asset specific liability hedge asset liability sell extinguish forecast transaction hedge long probable occur gain loss immediately recognize designate hedge earning nonderivative instrument designate hedge net investment foreign affiliate nonderivative instrument mainly euro denominate longterm debt effective portion designate nonderivative instrument recognize foreign currency translation section oci ineffective portion recognize earning shipping handle cost shipping handling cost include marketing sell administrative expense million million million million million include discontinue operation advertising product promotion cost advertising product promotion cost expense incur foreign currency translation foreign subsidiary earning translate dollar average exchange rate net asset foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate recognize oci net asset subsidiary highly inflationary economy remeasure functional currency report currency remeasurement recognize earning research development research development cost expense incur strategic alliance party provide right develop manufacture market andor sell pharmaceutical product right own party certain research development payment alliance partner contingent achievement certain predetermine criterion milestone payment achieve prior regulatory approval product expense research development milestone payment connection regulatory approval capitalize amortize cost product sell remain useful life asset capitalize milestone payment test recoverability periodically event change circumstance indicate carrying amount recoverable research development recognize net reimbursement connection collaboration agreement upfront license milestone receipt obtain development defer amortize estimate life product income amortization period upfront license milestone receipt new materially modify arrangement january assess determine consider term arrangement recently issue accounting standard new accounting standard adopt january impact consolidate financial statement adoption item standard provide clarify criterion determine transferor surrender control transfer financial asset remove concept qualify specialpurpose entity table content require ongoing reassessment primary beneficiary variable interest entity eliminate quantitative approach previously require determine primary beneficiary provide guidance determine primary beneficiary entity power direct activity variable interest entity significantly impact entity economic performance obligation absorb loss right receive benefit event significant variable interest entity january new revenue recognition standard adopt apply new materially modify revenue arrangement upfront licensing fee contingent milestone relate research development deliverable guidance provide principle application guidance multiple deliverable exist arrangement separate consideration allocate eliminate residual method allocate revenue require allocation consideration receive bundle revenue arrangement separate deliverable introduce estimate selling price method value element vendorspecific objective evidence thirdparty evidence sell price available expand relate disclosure requirement adoption standard expect material impact consolidate financial statement begin annual nontaxdeductible fee pay federal government base allocation company market share brand prior year sale certain government program include medicare medicaid department veterans affairs department defense tricare fee classify operating expense note alliance collaboration sanofi company agreement sanofiaventis sanofi codevelopment cocommercialization avaproavalide irbesartanirbesartan hydrochlorothiazide angiotensin ii receptor antagonist indicate treatment hypertension diabetic nephropathy plavix clopidogrel bisulfate platelet aggregation inhibitor worldwide alliance operate framework geographic territory america principally canada puerto rico latin american countries australia europe asia accordingly territory partnership form manage central expense market research development royalty supply finish product individual country general country level agreement copromote partnership form party sell brand comarket party operate sell brand independently place agreement expire later respect plavix respect avaproavalide americas australia europe asia ii expiration patent exclusivity right applicable territory company act operating partner own majority control interest territory cover americas australia sanofis ownership interest territory company consolidate country partnership result territory reflect sanofis share result noncontrolle interest company recognize net sale territory comarkete country outside territory eg germany italy irbesartan spain greece discovery royalty owe sanofi include cost product sell cash flow operating activity partnership territory cover america australia include operating activity company consolidated statement cash flow distribution partnership profit sanofi sanofis fund ongoing partnership operation occur routine basis recognize operating activity sanofi act operating partner own majority control interest territory cover europe asia company ownership interest territory include asset company consolidate partnership entity territory account equity method reflect share result equity net income affiliate company routinely receive distribution profit provide fund ongoing operation partnership territory cover europe asia reflect cash provide operating activity company sanofi separate partnership govern copromotion irbesartan alliance company recognize income relate amortization defer income associate sanofis million payment company acquisition interest irbesartan license formation alliance defer income continue amortize expect expiration license income attribute certain supply activity development optout royalty sanofi reflect net income table content follow summarize financial information reflect consolidated financial statement year end december dollar million territory cover americas australia net sale discovery royalty expense noncontrolle interest pretax profit distribution sanofi territory cover europe asia equity net income affiliate profit distribution company net sale europe comarkete country income irbesartan license fee income supply activity development optout royalty december dollar million investment affiliate territory cover europe asia defer income irbesartan license fee follow summarize financial information interest partnership sanofi territory cover europe asia consolidated account equity method year end december dollar million net sale cost product sell gross profit marketing sell administrative advertising product promotion research development incomeexpense net income current asset current liability cost product sell include discovery royalty million million million pay directly sanofi expense share base applicable ownership percentage current asset current liability include approximately million billion billion relate receivablespayable attribute respective year net cash distribution company sanofi intercompany balance partnership territory remain current asset current liability consist thirdparty trade receivables inventory amount company sanofi purchase inventory royaltie expense reimbursement otsuka company worldwide commercialization agreement otsuka pharmaceutical co ltd otsuka codevelop copromote otsuka abilify aripiprazole treatment schizophrenia bipolar mania disorder major depressive disorder japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt term agreement company purchase product otsuka perform finish manufacture sale thirdparty customer company otsuka product currently copromote otsuka canada united kingdom uk germany france spain germany france spain product invoice thirdparty customer company behalf otsuka company recognize alliance revenue contractual share thirdparty net sale reduce start january company continue receive thirdparty net sale france germany spain expense reimbursement begin january company invoice thirdparty customer uk behalf otsuka company receive net sale expense reimbursement company recognize alliance revenue abilify ship risk reward ownership transfer thirdparty customer certain country company presently exclusive distributor product exclusive right sell abilify company recognize net sale relate cost product sell expense table content april company otsuka agree extend portion commercialization manufacturing agreement expect loss product exclusivity april term agreement company pay otsuka million amortize reduction net sale extension period unamortized balance include asset begin january share abilify net sale company recognize change reduce january period otsuka responsible expense relate commercialization abilify reimbursement net principally advertise product promotion sell general administrative expense begin january expect loss exclusivity april include expect month pediatric extension company receive follow percentage annual net sale share net sale billion billion billion billion billion billion billion billion billion excess billion period otsuka responsible expense relate commercialization abilify addition company otsuka announce enter oncology collaboration sprycel dasatinib ixempra ixabepilone include japan european union eu market oncology territory begin collaboration fee company pay otsuka annually follow percentage net sale sprycel ixempra oncology territory net sale million million million million million million billion excess billion period otsuka contribute million certain commercial operational expense relate oncology product ii commercial operational expense relate product territory excess million start otsuka right copromote sprycel company japan eu market extension oncology collaboration include changeofcontrol provision case acquisition company acquire company compete product abilify new company assume abilify agreement amend oncology collaboration exist today acquire company product compete abilify otsuka elect request acquire company choose div abilify compete product scenario abilify divest otsuka obligate acquire company right abilify agreement amend agreement provide event generic competitor abilify january company option terminate abilify april amendment agreement previously amend remain force company exercise option company receive payment otsuka accord predetermine schedule oncology collaboration terminate time ii oncology collaboration continue truncated period accord predetermine schedule eu agreement remain unchanged expire june country company exclusive right sell abilify agreement expire later th anniversary commercial sale country expiration applicable patent country addition million extension payment total milestone payment otsuka agreement december million million expensed iprd remain million capitalize intangible asset amortize cost product sell remain life agreement table content follow summarize financial information relate alliance reflect consolidated financial statement year end december dollar million abilify net sale include amortization extension payment oncology product collaboration fee otsukas reimbursement operating expense amortization expense extension payment amortization expense upfront license milestone payment december dollar million asset extension payment intangible asset upfront license milestone payment january company grant otsuka exclusive right japan develop commercialize onglyza company expect receive milestone payment base certain regulatory event salesbase payment follow regulatory approval onglyza japan retain right copromote onglyza otsuka japan otsuka responsible development cost japan lilly company epidermal growth factor receptor egfr commercialization agreement eli lilly company lilly lilly november acquisition imclone system incorporate imclone codevelopment promotion erbitux cetuximab necitumumab imcf expire erbitux september company codevelopment copromotion right product canada japan erbitux indicate use treatment patient metastatic colorectal cancer use treatment squamous cell carcinoma head neck egfr agreement respect erbitux sale north america lilly receive distribution fee base flat rate net sale north america plus reimbursement certain royalty pay lilly include cost product sell october company imclone amend codevelopment agreement merck kgaa merck provide cocommercialization erbitux japan right agreement expire lilly ability terminate agreement determine commercially unreasonable lilly continue erbitux receive marketing approval japan july use erbitux treat patient advance recurrent colorectal cancer company receive pretax profit merck sale erbitux japan share equally lilly company share profit commercialization japan include income company amortize million previously capitalize milestone payment account license acquisition remain term agreement amortization classify cost product sell execution initial commercialization agreement company acquire ownership interest imclone account equity method company sell share imclone approximately million recognize pretax gain million november january company lilly restructure egfr commercialization agreement describe company imclone relate necitumumab novel target cancer therapy currently phase iii development nonsmall cell lung cancer restructure company share cost develop potentially commercialize necitumumab canada japan lilly maintain exclusive right necitumumab market company fund development cost study fund global study company pay million lilly milestone payment approval canada company recognize sale receive profit bear loss necitumumab lilly provide selling effort party general equally participate commercialization effort japan company lilly share commercial cost profit evenly agreement relate necitumumab continue patent expiration party agree terminate terminate time company month advance notice month prior launch party uncured material breach party agree terminate lilly manufacture bulk requirement assume responsibility fillfinish necitumumab begin table content follow summarize financial information relate alliance reflect consolidated financial statement year end december dollar million net sale distribution fee royalty reimbursement amortization expense milestone payment equity net income affiliate income japan commercialization fee december dollar million intangible asset upfront license milestone payment gilead company gilead sciences inc gilead joint venture develop commercialize atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oncedaily single tablet threedrug regimen combine company sustiva efavirenz gileads truvada emtricitabine tenofovir disoproxil fumarate canada europe company account participation joint venture equity method accounting recognize share joint venture result equity net income affiliate consolidated statement earning canada european countries company record revenue bulk efavirenz component atripla sale product party customer revenue efavirenz component determine apply percentage atripla revenue approximate revenue sustiva brand limited number eu country company recognize revenue atripla product purchase gilead distribute party customer follow summarize financial information relate alliance reflect consolidated financial statement year end december dollar million net sale equity net loss affiliate astrazeneca company maintain worldwide codevelopment cocommercialization agreement astrazeneca plc astrazeneca worldwide exclude japan codevelopment cocommercialization onglyza saxagliptin dppiv inhibitor saxagliptin agreement second worldwide include japan codevelopment cocommercialization dapagliflozin sodiumglucose cotransporter sglt inhibitor sglt agreement compound study treatment diabete discover company kombiglyze codevelope astrazeneca saxagliptin agreement agreement company jointly develop clinical marketing strategy share commercialization expense profit loss equally global basis exclude case saxagliptin japan company manufacture product company cocommercialize dapagliflozin japan share profit loss equally agreement company option decline involvement cocommercialization give country instead receive royalty royalty percentage rate company optsout cocommercialization agreement tiere base net sale july fda approve onglyza adjunct diet exercise improve blood sugar glycemic control adult treatment type diabete mellitus august company astrazeneca launch onglyza october onglyza receive marketing authorization use eu treat adult type diabetes combination metformin sulfonylurea thiazolidinedione agent diet exercise provide adequate glycemic control december fda approve kombiglyze saxagliptin metformin combination therapy treatment type diabete adult company receive astrazeneca total million upfront licensing milestone payment relate saxagliptin agreement million upfront licensing payment relate sglt agreement december include million receive payment defer amortize useful life product income additional milestone payment expect receive company successful achievement development regulatory event salesbase milestone saxagliptin agreement company table content receive additional million remain development regulatory milestone saxagliptin meet additional million sale base milestone saxagliptin meet sglt agreement company receive additional million development regulatory milestone dapagliflozin meet additional million salesbased milestone dapagliflozin meet agreement company astrazeneca share development commercialization cost majority development cost initial development plan pay astrazeneca astrazeneca bear cost initial agree development plan dapagliflozin japan additional development cost share equally net reimbursement company development cost relate saxagliptin dapagliflozin net research development follow summarize financial information relate alliance reflect consolidated financial statement year end december dollar million net sale amortization income upfront license milestone payment research development reimbursement tofrom astrazeneca december dollar millions defer income upfront license milestone payment pfizer company pfizer inc pfizer maintain worldwide codevelopment cocommercialization agreement eliquis apixaban anticoagulant discover company study prevention treatment broad range venous arterial thrombotic condition company receive million upfront licensing payment addition company receive million milestone payment april commencement phase iii clinical trial prevention major adverse cardiovascular event acute coronary syndrome million milestone filing marketing authorization application eu payment defer amortize useful life product income pfizer fund development cost initial development plan effective january go forward company fund net reimbursement company eliquis development cost net research development company receive additional payment pfizer additional million base achieve development regulatory milestone company jointly develop clinical marketing strategy share commercialization expense profit loss equally global basis manufacture product arrangement follow summarize financial information relate alliance reflect consolidated financial statement year end december dollar million amortization income upfront license milestone payment research development reimbursement pfizer december dollar millions defer income upfront license milestone payment exelixis october company enter metabolic collaboration agreement exelixis inc license exelixis smallmolecule tgr agonist program include backup tgr agreement second collaborate discover optimize characterize smallmolecule ror antagonist ror agreement company pay exelixis initial payment million expense research development pay additional development approval milestone million tgr agreement million ror agreement exelixis eligible receive additional million salesbased milestone tgr ror program royaltie net sale product tgr ror program company receive exclusive worldwide license develop commercialize small molecule tgr agonist ror antagonist tgr agreement company sole responsibility research development manufacturing commercialization ror agreement company collaborate exelixis ror antagonist program preclinical transition point company sole responsibility research development manufacture commercialization result product table content december company exelixis enter global codevelopment cocommercialization arrangement xl metvegret inhibitor oral anticancer compound license xl utility ras raf mutant tumor development exelixis term arrangement company pay exelixis million execution agreement pay additional million expensed research development june company terminate development collaboration exelixis xl right return exelixis result million termination fee expense research development company pay exelixis development regulatory milestone million additional million salesbased milestone relate xl addition company exelixis history collaboration identify develop promote oncology target january company exelixis enter oncology collaboration license agreement exelixis purse development small molecule ind codevelopment copromotion term agreement pay exelixis million upfront licensing milestone payment date pursuant amendment agreement execute october exelixis optedout codevelopment xl company payment exelixis million expense research development result company receive exclusive worldwide license develop commercialize xl sole responsibility development manufacture commercialization compound successful pay exelixis development regulatory milestone million additional million salesbased milestone royaltie royalty percentage rate tiere base net sale december company hold equity investment exelixis represent outstanding share alder november company alder biopharmaceuticals inc alder enter global agreement development commercialization ald novel biologic complete phase iia development treatment rheumatoid arthritis term arrangement alder grant company worldwide exclusive right develop commercialize ald potential indication cancer alder retain right grant company option codevelop exclusive right cocommercialize outside united states company pay alder million upfront licensing payment expense research development addition company pay million developmentbase regulatory base milestone payment potential salesbased milestone certain circumstance exceed million royalty net sale company choose option pursue cancer indication company pay additional million developmentbased regulatorybase milestone payment aforementione salesbased milestone royalty net sale royalty percentage rate tiere base net sale note business segment information company operate biopharmaceutical segment engage discovery development licensing manufacturing marketing distribution sale innovative medicine help patient prevail disease global research development organization global supply chain organization utilize responsible development delivery product market product distribute sell regional organization serve united states europe latin america middle east africa japan asia pacific canada emerge market business support global corporate staff function segment information present consistent financial information regularly review chief operating decision maker purpose evaluate performance allocate resource set incentive compensation target planning forecast future period product sell principally wholesaler less extent directly distributor retailer hospital clinic government agency pharmacie gross sale large pharmaceutical wholesaler percentage total gross sale follow mckesson corporation cardinal health inc amerisourcebergen corporation table content select geographic area information follow property plant net sale equipment dollar millions united states europe japan asia pacific canada latin america middle east africa emerge market total net sale key product follow year end december dollar millions plavix avaproavalide abilify reyataz sustiva franchise total revenue baraclude erbitux sprycel ixempra orencia onglyzakombiglyze mature product total capital expenditure depreciation property plant equipment biopharmaceutical segment follow year end december dollar million capital expenditure depreciation segment income exclude impact significant item indicative current operating performance ongoing result earning attribute sanofi noncontrolle interest reconciliation earning continue operation income taxis follow year end december dollar million biopharmaceutical segment income reconcile item downsize streamline worldwide operation impairment loss sale manufacturing operation accelerate depreciation asset impairment shutdown cost process standardization implementation cost gain sale product line business asset litigation recoverycharge upfront license milestone payment acquire inprocess research development ar impairment loss sale gain sale imclone share bms foundation funding initiative noncontrolle interest earning continue operation income taxis table content note restructure productivity transformation initiative pti design fundamentally change way business run meet challenge change business environment advantage diverse opportunity marketplace transformation nextgeneration biopharmaceutical company continue addition pti strategic process design achieve culture continuous improvement enhance efficiency effectiveness competitiveness continue improve cost base implement follow pti restructuring charge recognize year end december dollar million employee termination benefit exit cost provision restructure net impairment loss sale manufacturing operation accelerate depreciation asset impairment shutdown cost pension curtailment settlement charge process standardization implementation cost total cost gain sale product line business asset net charge accelerate depreciation asset impairment charge shutdown cost include cost product sell primarily relate rationalization manufacturing network biopharmaceutical segment asset continue depreciate cease use date facility remain charge primarily attribute process standardization activity attribute pension plan curtailment charge recognize incurred restructuring charge include termination benefit workforce reduction manufacturing sell administrative research development personnel geographic region approximately follow table represent activity employee termination exit cost liability year end december dollar million liability begin year charge change estimate provision restructure net foreign currency translation charge discontinue operation spend mead johnson splitoff convatec divestiture liability end year connection continue optimization manufacturing network operation latina italy sell international chemical investor se ici result million loss loss consist million impairment charge record attribute writedown asset fair value cost sale asset meet hold sale criterion million work capital adjustment transaction relate fee million million subordinate promissory note payable installment receive consideration additional charge require pertain company obligation fund portion icis future restructuring cost million million transaction year supply agreement enter ici company nonexclusive supplier certain product ici year tolling manufacturing agreement extend additional year enter ici company supply certain raw material product process finished latina facility distribute company market table content note acquisition zymogenetics inc acquisition october bms acquire outstanding share common stock zymogenetics inc zymogenetics october aggregate purchase price approximately million acquisition relate cost million classified incomeexpense zymogenetic focus develop commercialize therapeutic proteinbase product treatment human disease company collaborate development pegylatedinterferon lambda novel interferon currently phase iib development treatment hepatitis c infection acquisition provide company right develop commercialize pegylatedinterferon lambda bring prove capability therapeutic protein revenue recothrom fda approve specialty surgical biologic goodwill generate acquisition primarily attribute ownership right pegylate interferon lambda goodwill iprd intangible asset value acquisition nondeductible tax purpose purchase price allocation follow dollar million purchase price cash identifiable net asset cash marketable security inventory current longterm asset inprocess research development intangible asset technology defer income taxis current longterm liability total identifiable net asset goodwill include million record long term asset inventory expect utilize excess year include million relate pegylatedinterferon lambda attribute recothrom amortize year result zymogenetic operation include accompany consolidated financial statement october pro forma supplemental financial information provide impact acquisition material operating result medarex inc acquisition september company acquire mean tender offer secondstep merger remain outstanding share stock equivalent medarex own total purchase price million acquisition cost million classified incomeexpense medarex focus discovery development commercialization fully human antibodybased therapeutic product address major unmet healthcare need area oncology inflammation autoimmune disorder infectious disease result acquisition right yervoy ipilimumab currently phase iii development receive increase biologics development pipeline create balanced portfolio small molecule biologic goodwill generate acquisition primarily attribute balanced portfolio associated biopharma model potential optimize exist yervoy program goodwill iprd intangible asset value acquisition nondeductible tax purpose table content purchase price allocation follow dollar million purchase price cash fair value company equity medarex hold prior acquisition total identifiable net asset cash marketable security current longterm asset inprocess research development intangible asset technology intangible asset license shortterm borrowing current longterm liability defer income taxis total identifiable net asset goodwill income approximately million recognize remeasurement fair value equity interest medarex hold acquisition date include ownership interest genmab million ownership celldex therapeutic inc million subsequently sell december loss million include approximately billion related yervoy amortize year amortize year result medarex operation include accompany consolidated financial statement august pro forma supplemental financial information provide impact acquisition material operating result kosan biosciences inc acquisition june company complete acquisition kosan biosciences inc kosan cancer therapeutic company library novel compound include hsp inhibitor cancer microtubule stabilizer additional potential neurodegenerative disease net purchase price approximately million transaction account purchase method accounting purchase price allocate acquiredinprocess research development million net asset million goodwill million note mead johnson nutrition company initial public offering february mead johnson complete initial public offering ipo sell million share class common stock share net proceed million deduct million underwriting discount commission offer expense allocate noncontrolle interest capital excess par value stock completion ipo million share mead johnson class common stock million share mead johnson class b common stock hold company represent interest mead johnson combine voting power outstanding common stock right holder share class common stock class b common stock identical regard voting conversion share class common stock entitle vote share share class b common stock entitle vote share convertible time election holder share class common stock class b common stock automatically convert share class common stock agreement relate separation mead johnson enter include separation agreement transitional service agreement tax matter agreement registration right agreement employee matter agreement table content note discontinued operation mead johnson nutrition company splitoff splitoff remain interest mead johnson complete december splitoff effect exchange offer previously hold million share mead johnson converting class b common stock class common stock million outstanding share company stock result pretax gain million million net taxis share receive connection exchange value closing price december reflect treasury stock gain exchange determine sum fair value share receive plus net deficit mead johnson attributable company taxis direct expense relate transaction include tax reserve million establish convatec disposition august divestiture convatec business cidron healthcare limited affiliate nordic capital fund vii avista capital partner lp avista complete gross purchase price million result pretax gain million million net taxis medical imaging disposition january divestiture bristolmyers squibb medical imaging medical imaging avista complete gross purchase price approximately million result pretax gain million aftertax loss million transitional relationship discontinue operation subsequent respective disposition cash flow income associate mead johnson convatec medical imaging business continued generate relate activity transitional nature result agreement intend facilitate orderly transfer business operation include service accounting customer service distribution manufacturing activity relate convatec medical imaging business complete december amend mead johnson agreement expire september income generate transitional activity include incomeexpense expect material future result operation cash flow table content follow summarize financial information relate mead johnson convatec medical imaging business segregate continue operation report discontinue operation date disposition year end december dollar million net sale mead johnson convatec medical imaging net sale earning income taxis mead johnson convatec medical imaging earning income taxis provision income taxis earning net taxis gain disposal mead johnson convatec medical imaging gain disposal provision income taxis gain disposal net taxis net earning discontinue operation net earning discontinue operation attributable noncontrolle interest net earning discontinue operation attributable bristolmyer squibb company table content note earning share year end december amount million share datum basic eps calculation income continue operation attributable bms earning attributable unvested restricted share income continue operation attributable bms common shareholder net earning discontinue operation attributable bms eps numerator basic eps denominator basic average common share outstanding ep basic continue operation discontinue operation net earning eps numerator diluted income continue operation attributable bms earning attributable unvested restricted share income continue operation attributable bms common shareholder net earning discontinue operation attributable bms eps numerator diluted eps denominator diluted average common share outstanding contingently convertible debt common stock equivalent incremental share attributable sharebased compensation plan average common share outstanding common share equivalent eps diluted continue operation discontinue operation net earning net earning discontinue operation eps calculation net earning discontinue operation attributable bms earning attributable unvested restricted share net earning discontinue operation attributable bms ep calculation antidilutive weightedaverage equivalent share stock incentive plan total antidilutive share table content note incomeexpense incomeexpense include year end december dollar million interest expense interest income impairment loss sale manufacturing operation lossgain debt repurchase auction rate security ar impairment net foreign exchange transaction gainslosse gain sale product line business asset acquisition relate item income alliance partner pension curtailment settlement charge incomeexpense note income taxis component earning continue operation income taxis categorize base location tax authority follow year end december dollar million nonus total provisionbenefit income taxis attributable continue operation consist year end december dollar millions current nonus total current defer nonus total defer total provision effective tax rate reconciliation effective tax rate statutory federal income tax rate earning income taxis dollar million earning continue operation income tax statutory rate tax effect foreign subsidiary earning previously consider permanently reinveste offshore foreign tax effect certain operation ireland puerto rico switzerland state local taxis net valuation allowance federal state foreign contingent tax matter acquire inprocess research development expense federal research development tax credit impairment financial instrument foreign table content increase effective tax rate million charge recognize fourth quarter result primarily additional taxable income earning foreign subsidiary previously consider permanently reinveste offshore million charge completion tax return million benefit completion tax return unfavorable earning mix high low tax jurisdiction partially offset certain favorable discrete tax adjustment million compare million benefit primarily result effective settlement international uncertain tax position outofperiod tax adjustment million relate previously unrecognized net defer tax asset primarily attribute deferred profit financial reporting purpose relate certain alliance december material current prior period decrease effective tax rate primarily high pretax income include gain sale imclone share unfavorable earning mix high tax jurisdiction unfavorable tax impact relate iprd ar impairment charge additional million benefit completion tax return partially offset million benefit relate final settlement audit internal revenue service irs defer taxis valuation allowance component current noncurrent defer income tax assetsliabilitie follow december dollar million foreign net operating loss carryforward milestone payment license fee defer income federal net operating loss carryforward pension postretirement benefit state net operating loss credit carryforward intercompany profit inventory item federal research development tax credit carryforward foreign defer tax asset sharebase compensation legal settlement depreciation repatriation foreign earning acquire intangible asset tax deductible goodwill federal foreign tax credit carryforward valuation allowance defer tax asset recognize deferred income taxis current deferred income taxis noncurrent foreign income taxis payable current liability noncurrent total valuation allowance defer tax asset establish likely defer tax asset realize december valuation allowance million establish follow item million foreign net operating loss table content tax credit carryforward million state defer tax asset include net operating loss tax credit carryforward million federal net operating loss carryforward change valuation allowance follow year end december dollar million balance beginning year provision valuation allowance release valuation allowanceother comprehensive income goodwill balance end year federal net operating loss carryforward acquire result acquisition zymogenetic medarex kosan biosciences inc kosan adnexus subject limitation section internal revenue code net operating loss carryforward expire vary amount begin research development tax credit carryforward expire vary amount begin realization research development tax credit carryforward dependent generating sufficient domesticsource taxable income prior expiration realization assure management believe likely defer tax asset realize income tax payment million million million income tax payment net million cash refund relate foreign tax credit carryback claim current tax benefit realize exercise stock option credit capital excess par value stock million million december taxis provide approximately billion undistributed earning foreign subsidiary undistribute earning invest expect permanently invest offshore future earning repatriate earning determine remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provide company favorable tax rate ireland puerto rico grant schedule expire prior company complete internal restructuring certain legal entity contribute million charge recognize fourth quarter possible tax authority assert additional material tax liability arise restructure assertion occur company vigorously challenge assertion believe prevail assurance result business conduct country world subject tax numerous jurisdiction result significant number tax return file subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report require year resolve liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know effect change estimate related contingent tax liability include effective tax rate reconciliation reconciliation begin end gross unrecognized tax benefit follow year end december dollar million balance begin year gross addition tax position relate current year gross reduction tax position relate current year gross addition tax position relate prior year gross reduction tax position relate prior year settlement reduction tax position relate lapse statute cumulative translation adjustment balance end year uncertain tax benefit reduce deferred tax asset extent uncertainty directly relate asset recognize current non current foreign income taxis payable unrecognized tax benefit recognize table content impact effective tax rate million million million december respectively gross addition tax position relate current year year end december include million tax reserve relate transfer international unit mead johnson prior ipo splitoff transaction recognize discontinued operation gross reduction tax position relate prior year year end december include million liability relate mead johnson accrue interest penalty unrecognize tax benefit classify current noncurrent foreign income taxis payable accrue interest relate unrecognized tax benefit million million million december respectively accrue penalty relate unrecognized tax benefit million million million december respectively interest penalty relate unrecognized tax benefit classify income tax expense expensebenefit relate interest unrecognized tax benefit expense million benefit million million expensebenefit relate penalty unrecognize tax benefit expense million benefit million million company currently examination number tax authority include major tax jurisdiction list table propose adjustment tax issue transfer price certain tax credit deductibility certain expense company estimate reasonably possible total unrecognized tax benefit december decrease range approximately million million month result settlement certain tax audits event expect change unrecognized tax benefit primarily settlement related involve payment additional taxis adjustment certain defer taxis andor recognition tax benefit company anticipate reasonably possible new issue raise tax authority require increase balance unrecognized tax benefit estimate increase reasonably time company believe adequately provide open tax year tax jurisdiction income tax return file federal jurisdiction state foreign jurisdiction exception company subject federal state local nonus income tax examination tax authority follow summary major tax jurisdiction tax authority assert additional taxis base tax year currently audit subsequent year likely audit canada france germany italy mexico table content note fair value measurement fair value financial asset liability classify follow category level quote price unadjuste active market accessible measurement date identical asset liability fair value hierarchy give high priority level input level observable price base input quote active market corroborate market datum level unobservable input little market datum available fair value hierarchy give low priority level input december december quote quote price price active significant significant active significant significant market unobservable market unobservable identical observable identical observable asset input input asset input input dollar million level level level total level level level total available sale treasury bill government agency security equity security prime money market fund corporate debt security commercial paper fdic insure debt security treasury money market fund government agency money market fund auction rate security float rate security frs total available sale asset derivative interest rate swap derivative foreign currency forward derivative total derivative asset total asset fair value derivative foreign currency forward derivative interest rate swap derivative natural gas contract total derivative liability total liability fair value majority ar private placement security longterm nominal maturity rate standard poor primarily represent interest insurance securitization valuation model utilize rely exclusively level input lack observable market quote ars portfolio input base expect cash flow stream collateral value include assessment counterparty credit quality default risk underlie security discount rate overall capital market liquidity fair value ar determine internally develop valuation base indicative bid receive underlying asset security evidence fair value table content frs longterm debt security coupon reset periodically benchmark interest rate million principal par frs receive know report default frs current lack active market frs general lack transparency underlie asset qualitative analysis rely value frs include discussion broker fund manager default risk underlie security overall capital market liquidity level input decline fair value report temporary loss comprehensive income intention sell investment likely investment require sell recovery amortize cost basis financial asset liability utilize level level input direct indirect observable price quote utilize include libor euribor yield curves foreign exchange forward price nymex future price common stock price quote summary valuation technique level level financial asset liabilitie treasury bill government agency securitie government agency money market fund value quote market price observable pricing source report date equity security value quote stock price new york stock exchange national association security dealer automate quotation system report date prime money market fund net asset value share corporate debt security commercial paper value quote market price observable pricing source report date fdic insure debt security value quote market price observable pricing source report date treasury money market fund value quote market price observable pricing source report date interest rate swap derivative asset liability value libor euribor yield curve credit valuation adjustment report date counterpartie contract highlyrate financial institution experience significant downgrade valuation fluctuate considerably periodtoperiod volatility underlie interest rate drive market condition duration swap addition credit valuation adjustment volatility significant impact valuation interest rate swap change counterparty credit rating credit default swap spread foreign currency forward derivative asset liability value quote forward foreign exchange price report date counterpartie contract highlyrate financial institution experience significant downgrade valuation fluctuate considerably periodtoperiod volatility underlie foreign currency majority foreign currency forward derivative mature year counterparty credit risk consider significant table content note cash cash equivalent marketable security cash cash equivalent million december million december consist prime money market fund government agency security treasury security cash equivalent primarily consist highly liquid investment original maturity month time purchase record cost approximate fair value follow table summarize current noncurrent marketable security account available sale debt security equity security december december unrealize unrealized unrealized unrealized gain loss gain loss amortize accumulate accumulate amortize accumulate accumulate dollar million cost basis oci oci fair value cost basis oci oci fair value current marketable security certificate deposit corporate debt security commercial paper fdic insure debt security government agency security total current noncurrent marketable security corporate debt security treasury bill government agency security fdic insure debt security auction rate security float rate security total noncurrent asset equity security frs unrealized loss position month december follow table summarize activity financial asset utilize level fair value measurement noncurrent current noncurrent dollar million frs ar total frs frs ar total fair value january sale settlement unrealize gainslosse fair value december december million noncurrent available sale corporate debt security government agency securitie treasury bill fdic insure debt security float rate security mature year million corporate debt security mature year auction rate security mature year table content note receivables receivable include december dollar million trade receivable allowance net trade receivables alliance partner receivables prepaid refundable income taxis miscellaneous receivables receivables receivables net deferred income relate alliance partner recognition income result alliance partner receivables defer income reduce million million december respectively additional information alliance partner note alliance collaboration nonus receivables sell nonrecourse basis million million respectively aggregate receivable pharmaceutical wholesaler represent total trade receivables december respectively second quarter government greece announce intend convert certain past receivables government run hospital non interest bear note pay year period december notes process issue receivables million million include longterm asset million charge attribute imputed discount expect noninterest bearing note expect collection period recognize incomeexpense change allowance follow year end december dollar million balance begin year provision bad debt chargeback discount bad debt writtenoffpayment chargeback discount discontinue operation balance end year note inventory inventory include december dollar million finish good work process raw packaging material inventory inventory expect remain onhand year million million december respectively include non current asset addition million inventory currently sell food drug administration fda approves manufacturing process change inventory noncurrent asset include capitalize cost relate production product program phase iii development subject final fda approval million million december respectively status regulatory approval process probability future sale consider assess recoverability cost table content note property plant equipment property plant equipment include december dollar million land building machinery equipment fixture construction progress gross property plant equipment accumulate depreciation property plant equipment depreciation expense million million million million million include discontinue operation capitalize interest million million million note goodwill intangible asset change carry goodwill segment follow dollar million biopharmaceutical total balance january medarex acquisition mead johnson splitoff distribution balance december zymogenetic acquisition balance december intangible asset include december december gross net gross net estimate carry accumulate carrying carry accumulate carry dollar million useful life amortization amortization license year technology year capitalize software year total finitelive intangible asset inprocess research development note total intangible asset change intangible asset follow dollar million intangible asset carry january capitalize software addition zymogenetics acquisition medarex acquisition mead johnson splitoff sale convatec amortization license technology amortization capitalize software impairment charge intangible asset carry december amortization expense include discontinue operation million million table content expect future amortization expense december finitelive intangible asset million million million million million million note accrue expense accrue expense include december dollar million employee compensation benefit royaltie accrue research development restructuringcurrent pension postretirement benefit accrue litigation total accrue expense note sale rebate return accrual reduction trade receivables list accrue rebate return liability follow december dollar million chargeback relate government program cash discount reduction trade receivables manage healthcare rebate contract discount medicaid rebate sale return adjustment accrue rebate return note deferred income defer income include december dollar millions upfront license milestone receipt atripla defer revenue gain saleleaseback transaction total defer income current portion noncurrent portion upfront license milestone receipt amortize expect life product note alliance collaboration information pertain revenue recognition transaction alliance collaboration defer gain saleleaseback transaction relate sale leaseback transaction amortize remain lease term relate facility million million million note lease information pertain gain saleleaseback transaction table content note equity change common share treasury stock capital excess par value stock follow cost capital excess common share treasury treasury par value dollar share million issue stock stock stock balance january employee stock compensation plan balance december mead johnson ipo adjustment mead johnson net asset transfer mead johnson splitoff employee stock compensation plan balance december stock repurchase program employee stock compensation plan balance december accumulate balance relate component comprehensive incomeloss oci net taxis follow derivative pension accumulate foreign qualifying currency effective postretirement available comprehensive dollar million translation hedge benefit sale security incomeloss balance january comprehensive incomeloss balance december comprehensive incomeloss balance december comprehensive incomeloss balance december reconciliation noncontrolle interest follow dollar millions balance january mead johnson ipo adjustment mead johnson net asset transfer mead johnson splitoff net earning attributable noncontrolle interest comprehensive income attributable noncontrolle interest distribution balance december noncontrolle interest primarily relate partnership sanofi territory cover america net sale plavix net earning attributable noncontrolle interest present net taxis million million million consolidated statement earning correspond increase provision income taxis distribution partnership profit sanofi sanofis fund ongoing partnership operation occur routine basis include operating activity consolidate statement cash flow activity include pretax income distribution relate partnership net earning noncontrolle interest include discontinue operation million million treasury stock recognize cost reacquire share treasury share acquire mead johnson splitoff recognize fair value stock splitoff date share issue treasury recognize utilize firstin firstout method board director authorize repurchase billion common stock repurchase open market private transaction include repurchase plan establish accordance rule b securities exchange act amend stock repurchase program expiration date expect place year suspend discontinued time company repurchase million share average price approximately share aggregate cost million include million transaction fee table content note pension postretirement postemployment liability company certain subsidiary sponsor define benefit pension plan define contribution plan termination indemnity plan regular fulltime employee principal define benefit pension plan bristolmyers squibb retirement income plan cover employee represent approximately consolidated pension plan asset obligation fund policy contribute amount fund past service liability plan benefit base primarily participant year credit service final average compensation plan asset consist principally equity fixedincome securities comprehensive medical group life benefit provide substantially retiree elect participate comprehensive medical group life plan medical plan contributory contribution adjust periodically vary date retirement life insurance plan noncontributory plan asset consist principally equity fixedincome security similar plan exist employee certain country outside net periodic benefit cost define benefit pension postretirement benefit plan include pension benefit benefit dollar million service cost benefit earn year interest cost project benefit obligation expect return plan asset amortization prior service costbenefit amortization net actuarial loss net periodic benefit cost curtailment settlement special termination benefit total net periodic benefit cost continue operation discontinue operation total net periodic benefit cost retirement income plan plan amend june amendment eliminate credit future benefit relate service effective december salary increase continue consider additional fiveyear period determine benefit obligation relate prior service plan amendment account curtailment result applicable plan asset obligation remeasure remeasurement result million reduction accumulate oci million net taxis correspond decrease unfunded status plan curtailment update plan asset valuation change discount rate curtailment charge million recognize incomeexpense second quarter remain unrecognize prior service cost addition participant reclassify inactive benefit plan purpose actuarial gain loss amortize expect weightedaverage remain life plan participant year connection plan amendment contribution principal define contribution plan puerto rico increase effective january net impact action expect reduce future retiree benefit cost future cost continue subject market condition factor include actual expect plan asset performance interest rate fluctuation lumpsum benefit payment certain plan asset relate obligation transfer retirement income plan plan new plan sponsor mead johnson active mead johnson participant result million reduction accumulate oci million net taxis quarter correspond decrease unfunded status plan update plan asset valuation change discount rate net actuarial loss prior service cost expect amortize accumulate oci net periodic benefit cost dollar million pension benefit benefit amortization net actuarial loss amortization prior service costbenefit table content change define benefit postretirement benefit plan obligation asset fund status amount recognize consolidated balance sheet follow pension benefit benefit dollar million benefit obligation begin year service costbenefit earn year interest cost plan participant contribution curtailment settlement actuarial lossesgain transfer mead johnson retiree drug subsidy benefit pay special termination benefit exchange rate gainslosse benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution plan participant contribution settlement transfer mead johnson retiree drug subsidy benefit pay exchange rate lossesgain fair value plan asset end year fund status assetsliabilitie recognize asset accrue expense pension postretirement liability accrue benefit cost fund status recognize accumulate comprehensive loss net actuarial loss net obligation adoption prior service costbenefit total table include activity relate mead johnson pension postretirement plan separation activity certain define benefit pension postretirement plan asset liability transfer separate mead johnson sponsor define benefit pension postretirement plan final transfer occur december relate plan asset liability transfer participant allocate base assumption set forth plan transfer agreement accumulate benefit obligation define benefit pension plan million million december respectively additional information relate pension plan follow dollar million pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset table content actuarial assumption weightedaverage assumption determine benefit obligation december follow pension benefit benefit discount rate rate compensation increase weightedaverage actuarial assumption determine net periodic benefit cost year end december follow pension benefit benefit discount rate expect longterm return plan asset rate compensation increase yield high quality corporate bond match duration benefit obligation determine discount rate citigroup pension discount curve develop discount rate plan factor consider develop expect return plan asset include longterm historical return input external advisor individual asset class return forecast develop base market condition example priceearning level yield longterm growth expectation expect longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualize return pension plan follow year year year expect return plan asset determine expect rate return calculate value asset refer marketrelated value fair value plan asset exceed marketrelate value million december marketrelated value exceed fair value plan asset million december change primarily drive asset gain offset recognition significant loss incur plan asset difference assume actual return amortize marketrelated value straightline basis threeyear period gain loss result change actuarial assumption change discount rate difference assume actual experience difference actual assume return plan asset gain loss difference amortize market relate value amortize extent exceed high marketrelated value project benefit obligation respective plan result approximately million related pension benefit expect amortized majority remain actuarial loss amortize life expectancy plan participant plan expect remain service period plan assume healthcare cost trend rate december follow healthcare cost trend rate assume year rate cost trend rate assume decline ultimate trend rate year rate reach ultimate trend rate assume healthcare cost trend rate effect amount report healthcare plan onepercentagepoint change assume healthcare cost trend rate follow effect percentage percentage dollar million point increase point decrease effect total service interest cost effect postretirement benefit obligation table content plan asset fair value pension postretirement plan asset asset category december follow december december dollar million level level level total level level level total equity fund equity security fix income fund venture capital limited partnership government mortgage back security corporate debt security shortterm investment fund treasury agency security insurance contract collateralize mortgage obligation bond event drive hedge fund asset back security state municipal bond real estate cash cash equivalent total plan asset fair value fair value determine base observable market quote valuation model assessment counterparty credit worthiness credit default risk underlie security overall capital market liquidity transfer fair value level recognize begin report period investment valuation policy investment class follow equity fund security classify level include publicly trade equity trade national security exchange value report sale price reporting date security classify level value net asset value share hold year end base fair value underlie investment level equity fund value estimate fair value estimate fair value base fair value underlie investment value cost plus minus accumulate earning loss approximate fair value equity security security classify level include publicly trade equity trade national security exchange value report sale price reporting date publicly trade equity trade overthecounter market value report bid price reporting date fix income fund security classify level include publicly trade equity trade national security exchange value report sale price reporting date security classify level value net asset value share hold year end base fair value underlie investment venture capital limit partnership interest classify level carry estimate fair value estimate fair value base fair value underlie investment value cost plus minus accumulate earning loss approximate fair value government mortgage back security security classify level value quote market price broker dealer quotation transparent pricing source report date corporate debt security security classify level value quote market price observable pricing source report date value base comparable security similar yield credit rating security classify level value estimate bid broker party vendor source utilize expect cash flow stream datum include counterparty credit quality default risk discount rate overall capital market liquidity shortterm investment fund security classify level value net asset value share hold year end base fair value underlie investment short term investment primarily invest short term money market instrument table content treasury agency security security classify level value quote market price observable pricing source report date security classify level value quote market price broker dealer quotation transparent pricing source report date insurance contract interest classify level carry contract value approximate estimate fair value estimate fair value base fair value underlie investment insurance company insurance contract hold certain nonus pension plan collateralize mortgage obligation bond security classify level value quote market price observable pricing source report date value base comparable security similar yield credit rating purpose underlie loan security classify level value estimate bid broker thirdparty vendor source utilize expect cash flow stream datum include counterparty credit quality default risk discount rate overall capital market liquidity event drive hedge fund security classify level value net asset value share hold year end base fair value underlie investment event drive hedge fund primarily invest long short relative country position strategy include global fix income global currency global equity commodity emerge market debt inflationindexe bond asset back security security classify level value quote market price observable pricing source report date value base comparable security similar yield credit rating purpose underlie loan security classify level value estimate bid broker thirdparty vendor source utilize expect cash flow stream datum include counterparty credit quality default risk discount rate overall capital market liquidity state municipal bond security classify level value quote market price broker dealer quotation transparent pricing source report date real estate interest classify level value quote market price observable pricing source report date value base comparable investment interest classify level value net asset value share hold year end base fair value underlie investment cash cash equivalent security classify level highly liquid investment original maturity month time purchase recognize cost approximate fair value pende trade sale purchase include cash cash equivalent final settlement follow summarize activity financial asset utilize level fair value measurement collateralize corporate mortgage asset venture capital equity debt obligation back real limited insurance dollar million fund security bond security estate partnership contract total fair value january purchase sale issuance settlement net realize lossesgain unrealized gainslosse fair value december purchase sale issuance settlement net realize lossesgain unrealized gain fair value december investment strategy emphasize equity order achieve higher expect return low expense require cash contribution longterm target asset allocation public equity international private equity fix income maintain pension plan cash contribution benefit payment rebalance target necessary investment diversify major asset category approximately table content pension plan equity investment actively manage venture capital limited partnership typically value month lag bristolmyers squibb company common stock represent plan asset december contribution contribution pension plan million million include million mead johnson million contribution pension plan expect approximate million million contribute january contribution international pension plan million million million contribution international plan expect range million million estimate future benefit payment benefit pension medicare dollar millions benefit gross subsidy net year saving plan principal define contribution plan bristolmyer squibb saving investment program contribution base employee contribution level company match qualified define contribution plan amend allow increase matching additional company contribution effective expense relate plan million million million post employment benefit plan postemployment liability longterm disability benefit million million december respectively expense relate benefit million million million termination indemnity plan statutory termination obligation europe recognize undiscounted basis assume employee termination measurement date liability recognize obligation million december million december note employee stock benefit plan employee stock plan shareholder approve stock award incentive plan plan plan replace stock incentive plan plan expire plan provide million new share common stock reserve delivery participant plus share remain available new grant plan share recapture outstanding award plan share actually deliver participant connection award restriction lapse reduce number share reserve share tender prior year pay purchase price option share previously utilize satisfy withholding tax obligation exercise continue available reserve share common stock reserve issuance pursuant stock plan option conversion prefer stock million million december respectively share available grant active plan million million december respectively adjust combination plan share stock option exercise share unit vest issue treasury stock table content plan plan executive officer key employee grant option purchase common stock market price date option grant option generally exercisable installment year fourth anniversary grant date maximum term year additionally plan provide grant stock appreciation right grantee surrender exercisable right receive common stock andor cash measure excess market price common stock option exercise price plan plan provide grant common stock key employee subject restriction continuous employment restriction expire year period date grant compensation expense recognize restrict period restrict stock unit grant instead restrict stock stock unit right receive stock end specify vest period voting right begin market share unit grant certain executive plan vest market share unit condition continuous employment vest date payout factor equal payout factor share price vest date divide share price award date maximum share price payout factor calculate average closing price grant vest date trading day immediately precede grant vest date vest occur year year plan plan incorporate longterm performance award award year cycle deliver form target number performance share unit number share ultimately issue calculate base actual performance compare earning target performance criterion establish begin performance period award annual goal maximum payout threshold target meet performance period payment plan annual period stockbase compensation expense follow year end december dollar million stock option restrict stock market share unit longterm performance award total stockbase compensation expense continue operation discontinue operation total stockbase compensation expense defer tax benefit relate stockbase compensation expense alternative method determine pool excess tax benefit elect stock option stock option activity follow share common stock issue weightedaverage share million plan exercise price share balance january exercise expire forfeit balance december december unrecognized compensation cost relate stock option million expect recognize weightedaverage period year begin company stop grant stock option form compensation grant additional restrict stock unit market share unit additional information relate stock option grant exercise plan plan summarize follow year end december amount million share datum stock option grant weightedaverage grant date fair value share total intrinsic value stock option exercise cash proceed exercise stock option table content follow table summarize information concern stock compensation plan currently outstanding exercisable option number security issue weightedaverage exercise exercise outstanding option price outstanding share million right option right plan category equity compensation plan approve shareholder equity compensation plan approve shareholder plan terminate share long grant follow table summarize significant range outstanding exercisable option december amount million share datum option outstanding option exercisable weighted weight average weighted average weight remain average aggregate remain average aggregate contractual exercise intrinsic contractual exercise intrinsic number life price value number life price value range exercise price outstanding year share million exercisable year share million vest expect vest aggregate intrinsic value precede table represent total pretax intrinsic value base close stock price december million inthemoney option exercisable december million outstanding option exercisable weightedaverage exercise price december fair value stock option estimate grant date blackschole option pricing model stock option service condition model apply multiple input variable determine probability satisfy market condition option service market condition follow weightedaverage assumption valuation expect volatility riskfree interest rate dividend yield expect life yrs yrs expect volatility assumption require blackschole model derive calculate year historical volatility weighting equally derive imply volatility blend historical imply volatility approach expect volatility believe representative future stock price trend historical volatility riskfree interest rate assumption base treasury yield curve effect grant date dividend yield assumption base historical expect dividend payout expect life stock option represent weightedaverage period stock option remain outstanding derive output latticebinomial model expect life impact underlying assumption calibration model model assume employee exercise behavior function option remain vested life extent option inthemoney model estimate probability exercise function variable base historical exercise cancellation prior option grant expense base award ultimately expect vest recognize vest period forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate table content restrict stock award restrict stock unit weightedaverage share thousand number share grantdate fair value nonveste share january grant vested forfeited nonveste share december expect vest restrict stock award restrict stock unit vest ratably year period december unrecognized compensation cost relate nonveste restrict stock million expect recognize weightedaverage period year fair value nonveste share restrict stock award unit determine base closing trading price company common stock grant date total fair value vest share million million million respectively million share grant weighted average grant date fair value million share grant weighted average grant date fair value market share unit weightedaverage share thousand number share grantdate fair value nonveste share january grant vested forfeited nonveste share december expect vest market share unit vest ratably year period base share price performance december unrecognized compensation cost relate nonveste market share unit million expect recognize weightedaverage period year fair value market share unit estimate date grant model apply multiple input variable determine probability satisfy market condition model use follow input variable expect volatility riskfree interest rate dividend yield expect volatility base year historical volatility level company common stock current imply volatility fouryear riskfree interest rate derive federal reserve base market share unit contractual term expect dividend yield base historical dividend payment fair value market share unit amortize vest period award longterm performance awards longterm performance share unit determine base achievement annual performance goal vest end year period fair value performance award base closing trading price common stock grant date fair value performance share unit grant discount participate dividend fair value performance share unit grant discount risk free interest rate date grant participate dividend performance share unit grant million million million weight average grant date fair value respectively assume payout share unit outstanding million december million december million share issue december unrecognized compensation cost relate performance share unit plan million expect recognize weightedaverage period year total fair value vest share million million million respectively table content note shortterm borrowing longterm debt shortterm borrowing include december dollar millions bank draft principal value yen note convertible senior debenture demand note payable mead johnson total medarex acquisition medarexs outstanding convertible senior note assume note adjust right receive cash time principal outstanding equivalent share time prior maturity substantially redeem longterm debt include december dollar million principal value note euro note euro note note note note debenture debenture debenture othermature subtotal adjustment principal value fair value interest rate swap unamortize basis adjustment swap termination unamortized bond discount total include debt float rate convertible senior debenture redeem holder par september fundamental change ownership occur debenture callable par time company debenture conversion price equal conversion rate share principal subject certain antidilutive adjustment maximum conversion rate share principal debenture pay interest quarterly annual rate equal month libor reset quarterly minus yield zero february mead johnson company borrower mead johnson guarantor indirect majorityowne subsidiary enter year syndicate revolve credit facility agreement fourth quarter mead johnson borrow million revolve credit facility issue note total billion proceed repay certain intercompany debt prior splitoff table content million aggregate principal value debt repurchase tender offer million notional interest rate swap relate debt repurchase terminate follow table summarize activity swap include principal repurchase loss termination basis adjustment gain dollar million value price repurchase proceed terminate swap loss debenture note total million aggregate principal value debt repurchase million notional interest rate swap relate debt repurchase terminate follow table summarize activity swap include principal repurchase loss termination basis adjustment gain dollar million value price repurchase proceed terminate swap loss debenture debenture note total million aggregate principal value debt repurchase million notional interest rate swap relate debt repurchase terminate follow table summarize activity swap include principal repurchase gain termination basis adjustment gain dollar million value price repurchase proceed terminate swap loss note debenture debenture note total discussion interest rate swap note financial instrument interest payment net amount related interest rate swap million million million principal value longterm debt obligation million december million remain million later fair value longterm debt million million december respectively estimate base quote market price similar debt instrument fair value shortterm borrowing approximate carry value short maturity debt instrument billion year revolve credit facility syndicate lender mature december maintain facility extendable consent lender contain customary term condition include financial covenant ratio consolidate net debt consolidated capital exceed end quarter company compliance covenant inception facility borrowing outstanding facility december december million financial guarantee provide form standby letter credit performance bond standby letter credit insurance company support thirdparty liability program performance bond issue support range ongoing operating activity include sale product hospital foreign ministry health bond custom duty value add tax guarantee relate miscellaneous legal action significant majority outstanding financial guarantee expire year expect fund table content note financial instrument financial instrument include cash cash equivalent marketable security receivables account payable debt instrument derivative short term maturity carrying receivables account payable approximate fair value exposure market risk change currency exchange rate interest rate result certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument qualify cash flow net investment fair value hedge meet certain criterion include effectiveness offset hedge exposure change fair value derivative qualify hedge accounting recognize earning occur financial instrument include derivative subject counterparty credit risk consider overall fair value measurement derivative financial instrument trading purpose foreign currency forward contract manage cash flow exposure primary net foreign currency exposure hedge euro japanese yen canadian dollar british pound australian dollar mexican peso fixedtofloate interest rate swap interest rate risk management strategy swap qualify fairvalue hedge accounting treatment certain net asset change foreign exchange volatility hedge nonus dollar borrowing qualify net investment hedge derivative financial instrument present certain market counterparty risk concentration counterparty risk mitigate limiting amount individual counterparty bank worldwide standard poor moodys longterm debt rating high addition conventional derivative financial instrument utilize consolidated financial statement materially impact counterpartie fail perform accord term agreement currently collateral form securitization require furnish counterpartie derivative financial instrument follow summarize fair value outstanding derivative december december december december balance sheet fair fair balance sheet fair fair dollar million location notional value notional value location notional value notional value derivative designate hedge instrument interest rate contract asset accrue expense foreign currency forward contract asset accrue expense hedge net investment longterm debt natural gas contract accrue expense total derivative notional value natural gas contract million decatherm december qualifying hedge cash flow hedge foreign currency forward contract foreign currency forward contract utilize hedge forecast intercompany transaction certain foreign currency contract designate foreign currency cash flow hedge appropriate notional fair value amount contract million million net liability million million net liability december respectively majority contract qualify hedge probable forecast cash flow effective portion change fair value temporarily report accumulate oci recognize earning hedge item affect earning follow table summarize significant outstanding foreign currency forward contract december fair value contract base yearend currency rate view relation fair value underlie hedged transaction overall reduction exposure adverse fluctuation foreign currency exchange rate weightedaverage notional fair value dollar million currency rate strike price assetliability maturity foreign currency forwards euro euro japanese yen japanese yen table content defer loss foreign currency forward contract qualify cash flow hedge accounting million million net taxis december expect reclassify earning month effectiveness assess inception hedge quarterly basis assessment determine derivative designate qualifying hedge continue highly effective offset change cash flow hedge item ineffective portion change fair value include current period earning impact hedge ineffectiveness earning significant cash flow hedge accounting discontinue forecast transaction long probable occur originally forecast date day hedge long effective discontinued foreign exchange hedge report incomeexpense significant interest rate contract terminate swap qualify cash flow hedge recognize accumulate oci amortize earning remain life debt hedge debt remain outstanding impact oci earning foreign currency forward contract natural gas contract forward start swap qualified cash flow hedge follow foreign currency forward natural gas forward start contract contract swap total impact dollar million net carrying january cash flow hedge defer oci cash flow hedge reclassify cost product soldinter expense effective portion change defer taxis cash flow hedge reclassify net earning business divestiture net carrying december hedge net investment nonus dollar borrowing primarily million note million note billion total hedge foreign currency exposure net investment certain foreign affiliate borrowing designate hedge net investment effective portion foreign exchange gain loss recognize foreign currency translation cta component accumulate oci december million million note dedesignate impact oci earning nonderivative debt designate hedge net investment follow net investment hedge dollar million net carrying january change spot value nonderivative debt designate hedge gainloss recognize incomeexpense net overhedged portion net carrying december fair value hedge interest rate contract derivative instrument interest rate risk management strategy principally fixedtofloate interest rate swap designate fairvalue hedge total notional amount fair value outstanding interest rate swap million million net asset million million net asset december respectively swap underlie debt benchmark risk hedge recognize fair value swap intend create appropriate balance fix float rate debt basis adjustment debt qualify fair value hedge relationship amortize earning adjustment interest expense remain life debt underlie swap terminate prior maturity table content fixedtofloate interest rate swap execute convert million debenture million debenture million note fix rate debt variable rate debt fixedtofloate interest rate swap execute convert million note note fix rate debt variable rate debt swap qualify fair value hedge debt instrument fixedtofloate interest rate swap agreement million notional million notional terminate generating proceed million million notional fixedtofloate interest rate swap agreement terminate proceed million million notional fixedtofloate interest rate swap agreement terminate proceed million proceed swap termination accrue interest defer amortize interest expense remain life underlie debt additionally company terminate certain interest rate swap agreement connection repurchase certain debt obligation result net proceed million million million gain loss attributable transaction immediately recognize incomeexpense discussion company debt repurchase note shortterm borrowing longterm debt follow summarize interest rate swap outstanding december notional underlie variable rate year fair dollar million debt receive transaction maturity value swap associate note month libor note month libor note month libor million note month eur euribor million note month eur euribor debenture month libor note month libor note month libor debenture month libor total interest rate swap impact interest expense interest rate swap qualify fair value hedge follow dollar million recognize reduction interest expense amortization basis adjustment swap termination recognize reduction interest expense total nonqualifye foreign currency forward contract foreign currency forward contract utilize hedge foreign currencydenominate monetary asset liability primary objective contract protect dollar value foreign currencydenominate monetary asset liability effect volatility foreign exchange rate occur prior receipt settlement dollar contract designate hedge adjust fair value incomeexpense occur substantially offset change fair value underlie foreign currency denominate monetary asset liability notional fair value amount contract significant december furthermore foreign currency forward contract offset exposure certain asset liability earning denominate certain foreign currency contract designate hedge adjust fair value incomeexpense occur december company hold foreign exchange contract contract mature month impact earning nonqualifye foreign currency forward contract significant year end december table content note lease minimum rental commitment noncancelable operating lease primarily real estate motor vehicle effect december follow year end december dollar million later year total minimum rental commitment operate lease expense million million million million million include discontinue operation sublease income material year end december saleleaseback administrative facility paris france complete million million result pretax gain million gain defer reduce future lease cost lease period note legal proceeding contingency company certain subsidiary involve lawsuit claim government investigation legal proceeding arise ordinary course business relate product liability patent commercial consumer environmental security matter company recognize accrual contingency probable liability incur loss reasonably estimate litigation expense net include million insurance reimbursement prior litigation offset additional reserve certain average wholesale price awp litigation million security litigation settlement million relate awp litigation net revise estimate previously accrue amount cash payment relate significant litigation million million million significant matter describe company believe substantial defense matter assurance increase scope pende matter future lawsuit claim government investigation legal proceeding material note company unable assess outcome respective litigation able provide estimate range potential loss furthermore failure enforce patent right likely result substantial decrease respective product sale generic competition intellectual property plavix litigation plavix currently company large product rank net sale plavix patent subject number challenge include litigation apotex inc apotex corp apotex describe significant market product company product partner sanofi company intend vigorously pursue enforcement patent right plavix plavix litigation patent infringement litigation apotex relate matter previously disclose company territory partnership alliance sanofi plaintiff pende patent infringement lawsuit institute united states district court southern district new york district court entitle sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership v apotex suit base patent patent composition matter patent disclose claim thing hydrogen sulfate salt clopidogrel medicine available company plavix previously report district court uphold validity enforceability patent maintain main patent protection plavix november district court rule apotexs generic clopidogrel bisulfate product infringe patent permanently enjoin apotex engage activity infringe patent include market generic product patent expire table content apotex appeal district court decision december united states court appeal federal circuit circuit court affirm district court rule sustain validity patent apotex file petition circuit court rehear en banc march circuit court deny apotexs petition case remand district court proceeding relate damage july apotex file petition writ certiorari supreme court request supreme court review circuit court decision november supreme court deny petition decline review circuit court decision december company file motion district court summary judgment damage january apotex file motion seek stay ongoing damage proceeding pende outcome reexamination plavix patent patent trademark office pto describe april district court deny apotexs motion stay proceeding october district court grant company summary judgment motion award million damage plus cost interest apotex appeal damage award validity patent claim clopidogrel bisulfate finally judicially determine favor company possible time determine damage award uphold appeal previously disclose company territory partnership alliance sanofi plaintiff additional patent infringement lawsuit dr reddys laboratories inc dr reddys laboratories ltd dr reddys teva pharmaceuticals usa inc teva cobalt pharmaceuticals inc cobalt watson pharmaceuticals inc watson laboratories inc watson sun pharmaceuticals sun lawsuit dr reddys teva cobalt relate patent dr reddys sign consent judgment favor sanofi bms concede validity infringement patent previously report patent infringement action teva cobalt stay pende resolution apotex litigation party action agree bind outcome litigation apotex consequently july district court enter judgment cobalt teva permanently enjoin cobalt teva engage activity infringe patent patent expire cobalt teva file appeal july circuit court issue mandate teva appeal bind teva decision apotex litigation august cobalt consent entry judgment appeal agree bind circuit court decision apotex litigation lawsuit watson file october base patent patent disclose claim particular crystalline polymorph form hydrogen sulfate salt clopidogrel market plavix december court permit watson pursue declaratory judgment counterclaim respect patent january court approve party stipulation stay case pende outcome trial apotex matter bms watson enter stipulation dismiss case april pharmastar file request inter part reexamination patent pto pto grant request july july pto vacate reexamination proceeding lawsuit sun file july base infringement patent patent respect patent sun agree bind outcome apotex litigation dr reddys teva cobalt watson sun file anda fda respect dr reddys teva cobalt watson exclusivity period statutory stay periods hatchwaxman act expire accordingly final approval fda provide company authorization distribute generic clopidogrel bisulfate product subject legal remedy company apply include injunctive relief damage june apotex file request ex parte reexamination patent pto august pto agree reexamine patent december pto issue nonfinal office action reject claim cover plavix include claim previously uphold litigation apotex refer pto issue ex parte reexamination certificate withdraw rejection nonfinal office action confirm patentability claim patent apotex file second request ex parte reexamination patent june pto deny apotexs request reexamine patent additionally november apotex file lawsuit new jersey superior court entitle apotex inc et al v sanofiaventis et al seek payment million plus interest relate breakup march propose settlement agreement party file crossmotion summary judgment pende january apotex file lawsuit florida state court broward county allege breach contract relate party propose settlement agreement table content plavix litigation international plavix australia previously disclose sanofi notify august genrx proprietary limited genrx obtain regulatory approval application clopidogrel bisulfate mg tablets australia genrx subsidiary apotex change apotex august apotex file application federal court australia seek revocation sanofis australian patent case nsd sanofi file counterclaims infringement seek injunction september australian court grant sanofis injunction subsidiary company subsequently add party proceeding february second company spirit pharmaceuticals pty ltd file revocation suit patent case consolidate apotex case trial occur april august federal court australia hold claim patent cover clopidogrel bisulfate hydrochloride hydrobromide taurocholate salt valid federal court hold process claim pharmaceutical composition claim claim direct clopidogrel pharmaceutically acceptable salt invalid view decision possible generic company develop seek registration australia alternate salt form clopidogrel bisulfate hydrochloride hydrobromide taurocholate company sanofi file notice appeal court federal court australia court appeal hold invalidity claim cover clopidogrel pharmaceutically acceptable salt process claim pharmaceutical composition claim stay federal court rule apotex file notice appeal appeal hold validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claim hearing appeal occur february september federal court australia hold claim patent invalid november company sanofi apply high court australia high court special leave appeal judgment court march high court deny company sanofis request hear appeal court decision case remand federal court proceeding relate damage expect damage material company plavix eu previously disclose yes pharmaceutical development service gmbh yes pharmaceutical file application marketing authorization germany alternate salt form clopidogrel application rely datum study originally conduct sanofi bms plavix subject datum protection eu sanofi bms file action yes pharmaceutical partner administrative court cologne object marketing authorization matter currently pende specific marketing authorization withdraw market plavix canada apotex inc april apotex file impeachment action sanofi federal court canada allege sanofis canadian patent patent invalid patent cover clopidogrel bisulfate patent issue prohibition action canada previously disclose canadian federal court ottawa reject apotexs challenge patent hold asserted claim novel obvious infringe grant sanofis application order prohibition minister health apotex preclude approval apotexs abbreviate new drug submission patent expire decision affirm appeal federal court appeal supreme court canada june sanofi file defense impeachment action file suit apotex infringement patent trial expect occur intellectual property litigation abilify previously disclose otsuka file patent infringement action teva barr pharmaceuticals inc barr sandoz inc sandoz synthon laboratories inc synthon sun pharmaceutical sun zydus pharmaceuticals usa inc zydus apotex relate patent patent cover aripiprazole expire april include additional sixmonth pediatric exclusivity period aripiprazole comarketed company otsuka abilify nonjury trial district court district new jersey nj district court tevabarr apotex complete august november nj district court uphold validity enforceability patent maintain main patent protection abilify april nj district court rule defendant generic aripiprazole product infringe patent permanently enjoin engage activity infringe patent include market generic product patent include sixmonth pediatric extension expire sandoz synthon sun zydus bind nj district court decision december tevabarr apotex appeal decision court appeal federal circuit table content possible time determine outcome appeal nj district court decision otsuka prevail appeal generic competition likely result substantial decrease sale abilify material adverse effect result operation cash flow material financial condition atripla april teva file anda manufacture market generic version atripla atripla single tablet threedrug regimen combine company sustiva gilead truvada time company patent right cover sustivas composition matter method use challenge teva send gilead paragraph iv certification letter challenge orange book list patent atripla atripla product joint venture company gilead gilead file patent infringement action teva district court southern district new york sdny january company receive notice teva amend anda challenge additional orange book list patent atripla march company merck sharp dohme corp file patent infringement action teva sdny relate patent claim crystalline polymorph form efavirenz march gilead file patent infringement action teva sdny relate orange book list patent atripla discovery matter ongoing possible time reasonably assess outcome lawsuit impact company reyataz teva file anda manufacture market generic version reyataz dosage form mg company receive paragraph iv certification letter teva challenge orange book list patent reyataz december company novartis pharmaceutical corporation novartis file patent infringement lawsuit district court district delaware delaware district court teva infringement list patent cover reyataz trigger automatic month stay approval tevas anda subsequent patent infringement lawsuit file discovery matter ongoing possible time reasonably assess outcome lawsuit impact company baraclude august teva file anda manufacture market generic version baraclude company receive paragraph iv certification letter teva challenge orange book list patent baraclude september company file patent infringement lawsuit delaware district court teva infringement list patent covering baraclude trigger automatic month stay approval tevas anda possible time reasonably assess outcome lawsuit impact company sprycel september apotex file anda manufacture market generic version sprycel company receive paragraph iv certification letter apotex challenge orange book list patent sprycel include composition matter patent november company file patent infringement lawsuit district court district new jersey apotex infringement orange book list patent cover sprycel trigger automatic month stay approval apotexs anda possible time reasonably assess outcome lawsuit impact company general commercial litigation clayworth litigation previously disclose company number pharmaceutical manufacturer name defendant action file california state superior court oakland james clayworth et al v bristolmyers squibb company et al allege defendant conspire fix price pharmaceutical agree charge drug charge outside particularly canada assert claim california cartwright act unfair competition law plaintiff sought treble monetary damage injunctive relief relief december court grant company manufacturer motion summary judgment base passon defense judgment enter favor defendant july judgment favor defendant affirm california court appeals july california supreme court reverse court appeal judgment matter remand superior court proceeding defendant motion summary judgment ground remain pende motion deny trial schedule early summer possible time reasonably assess outcome lawsuit impact company event plaintiff successful appeal table content antitrust litigation previously disclose lawsuit comprise individual suit purport class action file company district court southern district ohio western division plaintiff include pharmacy chain individually assignee certain wholesaler health welfare benefit plansfund individual resident state lawsuit allege thing purport settlement apotex patent infringement litigation violate sherman act relate law plaintiff seek thing permanent injunctive relief bar apotex settlement andor monetary damage putative class action file behalf direct purchaser consolidate caption plavix direct purchaser antitrust litigation putative class action file behalf indirect purchaser consolidate caption plavix indirect purchaser antitrust litigation amend complaint file october defendant file consolidated motion dismiss december district court grant defendant motion dismiss direct purchaser claim appeal take dismissal january district court grant defendant motion dismiss respect indirect purchaser claim possible time reasonably assess outcome lawsuit impact company pricing sale promotional practice litigation investigation abilify state attorney general investigation march company receive letter delaware attorney general office advise multistate coalition investigate certain abilify marketing practice violate respective state consumer protection statute possible time reasonably assess outcome investigation potential impact company awp litigation previously disclose company number pharmaceutical manufacturer defendant number private class action suit bring attorney general state action plaintiff allege defendant cause average wholesale price awps product inflate injure government program entity person reimburse prescription drug base awps company defendant state attorney general suit pende state court country begin august company defendant trial commonwealth court pennsylvania commonwealth court bring commonwealth pennsylvania september jury issue verdict company find company liable fraudulent negligent misrepresentation commonwealth court judge issue decision pennsylvania consumer protection claim jury find company liable million enjoin company contribute provision inflate awps company move vacate decision commonwealth move judgment notwithstanding verdict alternative new trial motion currently pende commonwealth court previously report set class action consolidate district court district massachusetts awp mdl august district court grant preliminary approval propose settlement awp mdl plaintiff claim company million plus half cost class notice maximum payment million final approval hearing schedule occur march california b litigation previously disclose august county santa clara file purport class action company numerous pharmaceutical manufacturer behalf putative class city county california cover entity purchase drug pursuant b drug discount program b entity allege manufacturer provide proper discount b entity district court northern district california district court deny plaintiff motion prejudice certify class september supreme court grant certiorari issue b entity standing sue district court previously dismiss case find b entity stand court appeal ninth circuit reverse district court district court stay case pende decision supreme court possible time reasonably assess outcome lawsuit potential impact company table content product liability litigation company party product liability lawsuit previously disclose addition lawsuit company face unfiled claim involve product plavix previously disclose company certain affiliate sanofi defendant number individual lawsuit claim personal injury allegedly sustain plavix appear united states district court district new jersey nj district court december company defendant action nj district court execute tolling agreement respect unfiled claim potential additional plaintiff possible time reasonably assess outcome lawsuit potential impact company hormone replacement therapy company number defendant masstort litigation plaintiff allege thing hormone therapy product include hormone therapy product manufacture company estrace estradiol delestrogen ovcon cause breast cancer stroke blood clot cardiac injury woman defendant aware risk fail warn consumer december company defendant lawsuit file behalf plaintiff federal state court company enter separate settlement principle resolve claim approximately plaintiff company hormone therapy product sell company january august environmental proceeding previously report company party environmental proceeding matter responsible state federal foreign law include comprehensive environmental response compensation liability act cercla certain cost investigate andor remediate contamination result past industrial activity company current site waste disposal reprocess facility operate thirdpartie cercla matter respect cercla matter company responsible state federal foreign law company typically estimate potential cost base information obtain environmental protection agency counterpart state foreign agency andor study prepare independent consultant include total estimate cost site expect costshare potentially responsible party company accrue liability probable reasonably estimable company estimate share future cost site million december represent sum good estimate good estimate reasonably estimate minimal probable range cost take account potential recovery party new brunswick facility environmental personal injury lawsuit previously disclose lawsuit file company superior court middlesex county nj behalf current resident new brunswick nj live live adjacent company new brunswick facility complaint allege personal injury property damage result allege soil groundwater contamination property stem historical operation new brunswick facility october new jersey supreme court grant mass tort status case transfer new jersey superior court atlantic county centralize case management purpose company intend defend vigorously litigation possible time reasonably assess outcome lawsuit potential impact company north brunswick township board education previously disclose october company contact counsel represent north brunswick nj board education boe site waste material er squibb son disposed fill material contain industrial waste heavy metal excess residential standard discover expansion project north brunswick township high school number neighbor residential property adjacent public park area january new jersey department environmental protection njdep send company table content information request letter possible waste disposal site company respond march boe township current owner school property park conduct jointly finance soil remediation work ground water investigation work work plan approve njdep ask company contribute cost company actively monitor cleanup project include cost date school board township assert claim company instead company local entity negotiate agreement attempt resolve matter informal mean avoid litigation central component agreement provision company interim funding help defray cleanup cost assure work interrupt company transmit interim funding payment december november party commence mediation late effort successful party move bind allocation process addition september township boe file suit party allege contribute waste material site proceeding sec germany investigation previously disclose october sec notify company conduct informal inquiry activity certain company german pharmaceutical subsidiary employee andor agent october sec inform company inquiry formal sec inquiry encompass matter investigation german prosecutor munich germany resolve company understand inquiry concern potential violation foreign corrupt practice act company cooperate sec medarex shareholder litigation july company medarex announce signing merger agreement provide acquisition medarex company tender offer share cash follow announcement certain medarex shareholder file similar lawsuit state federal court relate transaction medarex member medarexs board director company follow consolidation state court action august party enter memorandum understand mou pursuant party reach agreement principle settle state federal action pursuant agreement mou thing medarex certain supplemental disclosure tender offer period party agree present superior court new jersey mercer county nj superior court stipulation settlement documentation require order obtain approval court settlement dismissal action term set forth mou july propose settlement approve nj superior court objector settlement file motion reconsideration ask court reconsider approval settlement deny december january objector file notice appeal king pharmaceuticals inc november king pharmaceuticals inc king affiliate entity file suit zymogenetics inc zymogenetics wholly own subsidiary company note acquisition united states district court eastern district tennessee king allege zymogenetic engage unfair competition false advertising trademark infringement relate claim federal law tennessee state law king seek form relief include damage injunctive relief precluding company make certain representation king product company recothrom product king file motion district court seek temporary restraining order preliminary injunctive relief december judge deny king motion preliminary injunction lawsuit continue trial case currently schedule fourth quarter possible time reasonably assess outcome lawsuit potential impact company table content note select quarterly financial datum unaudite dollar million share datum quarter second quarter quarter fourth quarter year net sale gross margin net earning continue operation net earning continue operation attributable noncontrolle interest net earning continue operation attributable bms net earning discontinue operation attributable bms net earning attributable bms eps attributable bms basic net earning continue operation net earning discontinue operation net earning common share dilute net earning continue operation net earning discontinue operation net earning common share dividend declare common share cash cash equivalent marketable security dollar million share datum quarter second quarter quarter fourth quarter year net sale gross margin net earning continue operation net earning continue operation attributable noncontrolle interest net earning continue operation attributable bms net earningsloss discontinue operation attributable bms net earning attributable bms eps attributable bms basic net earning continue operation net earningsloss discontinue operation net earning common share dilute net earning continue operation net earningsloss discontinue operation net earning common share dividend declare common share cash cash equivalent marketable security earning share quarter add amount year period compute discrete basis marketable security include current noncurrent asset table content follow specify item affect comparability result dollar million quarter second quarter quarter fourth quarter year restructuring activity downsize streamline worldwide operation impairment loss sale manufacturing operation accelerate depreciation asset impairment shutdown cost pension curtailment settlement charge process standardization implementation cost total restructuring litigation charge net upfront licensing milestone payment iprd impairment acquisition relate item product liability charge total income taxis item outofperiod tax adjustment specify tax charge decrease net earning continue operation dollar million quarter second quarter quarter fourth quarter year restructuring activity downsize streamline worldwide operation accelerate depreciation asset impairment shutdown cost pension curtailment settlement charge process standardization implementation cost gain sale product line business asset total restructure litigation charge bms foundation funding initiative loss sale investment upfront license milestone payment acquisition relate item debt repurchase swap termination product liability chargesinsurance recovery total income taxis item decrease net earning continue operation table content report independent register public accounting firm board director stockholder bristolmyers squibb company audit accompany consolidated balance sheet bristolmyer squibb company subsidiary company december relate consolidated statement earning comprehensive income retain earning cash flow year period end december financial statement responsibility company management responsibility express opinion financial statement base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidate financial statement present fairly material respect financial position bristolmyer squibb company subsidiary december result operation cash flow year period end december conformity accounting principle generally accept united states america discuss note consolidated financial statement company adopt accounting standard relate business combination effective business combination enter january audit accordance standard public company accounting oversight board united states company internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion company internal control financial reporting deloitte touche llp parsippany new jersey february table content item change disagreement accountant account financial disclosure item control procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure control procedure term define exchange act rule ae base evaluation management conclude december disclosure control procedure effective management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include report issue report effectiveness company internal control financial reporting december include change internal control financial reporting change companys internal control financial reporting quarter end december materially affect reasonably likely materially affect company internal control financial reporting item b information table content report independent register public accounting firm board director stockholder bristolmyers squibb company audit internal control financial reporting bristolmyer squibb company subsidiary company december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design supervision company principal executive principal financial officer person perform similar function effect company board director management personnel provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting include possibility collusion improper management override control material misstatement error fraud prevented detect timely basis projection evaluation effectiveness internal control financial reporting future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission audit accordance standard public company accounting oversight board united states consolidated financial statement company year end december report date february express unqualified opinion financial statement deloitte touche llp parsippany new jersey february table content iii item director executive officer registrant reference proxy statement file march respect director registrant incorporate reference hereof response information require item b information require item respect executive officer registrant include ia reliance general instruction g instruction item b regulation sk item executive compensation reference proxy statement file march respect executive compensation incorporate reference hereof response information require item item security ownership certain beneficial owner management relate stockholder matter reference proxy statement file march respect security ownership certain beneficial owner management incorporate reference hereof response information require item item certain relationship relate transaction reference proxy statement file march respect certain relationship relate transaction incorporate reference hereof response information require item item auditor fee reference proxy statement file march respect auditor fee incorporate reference hereof response information require item table content iv item